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Distinct Patterns of Ccr5 Versus Alternative Coreceptor Dependence in
Non-Natural Host Versus Natural Host Simmian Immunodeficiency
Virus Infection
Abstract
Natural host sooty mangabeys infected with simian immunodeficiency viruses (SIV) exhibit high plasma viral
loads without widespread CD4+ T cell loss. By contrast, non-natural host rhesus macaques experimentally
infected with related SIV exhibit high viral loads but display subsequent CD4+ T cell loss and progression to
AIDS, analogous to the effects of HIV-1 infection in humans. Several mechanisms have been proposed to
explain these discrepant outcomes, including infection of distinct target cells in vivo. Cell targeting is
substantially determined at the level of viral entry. Prior work demonstrated that sooty mangabey infection
occurs in the absence of functional coreceptor CCR5, implicating alternative SIV entry pathways in this
natural host. In this thesis, I identified host-dependent patterns of SIV coreceptor use that distinguish viral
entry in sooty mangabeys from viral entry in rhesus macaques. I cloned and characterized a panel of putative
sooty mangabey coreceptors. Transfected target cells expressing species-specific CD4 and coreceptors
identified sooty mangabey CCR5, CXCR6, and GPR15 as functional coreceptors of SIV in vitro. While rhesus
macaque CCR5 and GPR15 also supported robust SIV infection in vitro, rhesus macaque CXCR6 was a
remarkably poor coreceptor of SIV. Using CCR5 antagonist Maraviroc to block CCR5-mediated infection in
primary peripheral blood mononuclear cells (PBMCs), I determined that SIV were highly CCR5-dependent
in rhesus macaque PBMCs, whereas SIV were partially CCR5-independent in sooty mangabey PBMCs,
implicating alternative coreceptors in infection of the natural host primary cells. A chemokine ligand of
CXCR6, CXCL16, partially attenuated SIV infection of sooty mangabey PBMCs, indicating that sooty
mangabey CXCR6 was indeed an alternative coreceptor of some SIV in primary sooty mangabey cells.
Collectively, these data define coreceptor use as a host determinant distinguishing sooty mangabey SIV
infection from rhesus macaque SIV infection in primary cells. Because CD4+ T cells from sooty mangabeys
express exceedingly low levels of CCR5 relative to CD4+ T cells from rhesus macaques, the expression
patterns of CXCR6 and other alterative coreceptor(s) in sooty mangabey CD4+ cell subsets may classify host
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DISTINCT PATTERNS OF CCR5 VERSUS ALTERNATIVE CORECEPTOR DEPENDENCE IN 
NON-NATURAL HOST VERSUS NATURAL HOST SIMMIAN IMMUNODEFICIENCY VIRUS 
INFECTION 
Sarah T.C. Elliott 
Ronald G. Collman, M.D. 
Natural host sooty mangabeys infected with simian immunodeficiency viruses (SIV) exhibit high 
plasma viral loads without widespread CD4+ T cell loss.  By contrast, non-natural host rhesus 
macaques experimentally infected with related SIV exhibit high viral loads but display subsequent 
CD4+ T cell loss and progression to AIDS, analogous to the effects of HIV-1 infection in humans.  
Several mechanisms have been proposed to explain these discrepant outcomes, including 
infection of distinct target cells in vivo.  Cell targeting is substantially determined at the level of 
viral entry.  Prior work demonstrated that sooty mangabey infection occurs in the absence of 
functional coreceptor CCR5, implicating alternative SIV entry pathways in this natural host.  In 
this thesis, I identified host-dependent patterns of SIV coreceptor use that distinguish viral entry in 
sooty mangabeys from viral entry in rhesus macaques.  I cloned and characterized a panel of 
putative sooty mangabey coreceptors.  Transfected target cells expressing species-specific CD4 
and coreceptors identified sooty mangabey CCR5, CXCR6, and GPR15 as functional coreceptors 
of SIV in vitro.  While rhesus macaque CCR5 and GPR15 also supported robust SIV infection in 
vitro, rhesus macaque CXCR6 was a remarkably poor coreceptor of SIV.  Using CCR5 antagonist 
Maraviroc to block CCR5-mediated infection in primary peripheral blood mononuclear cells 
(PBMCs), I determined that SIV were highly CCR5-dependent in rhesus macaque PBMCs, 
whereas SIV were partially CCR5-independent in sooty mangabey PBMCs, implicating alternative 
coreceptors in infection of the natural host primary cells.  A chemokine ligand of CXCR6, 
CXCL16, partially attenuated SIV infection of sooty mangabey PBMCs, indicating that sooty 
mangabey CXCR6 was indeed an alternative coreceptor of some SIV in primary sooty mangabey 
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cells.  Collectively, these data define coreceptor use as a host determinant distinguishing sooty 
mangabey SIV infection from rhesus macaque SIV infection in primary cells.  Because CD4+ T 
cells from sooty mangabeys express exceedingly low levels of CCR5 relative to CD4+ T cells from 
rhesus macaques, the expression patterns of CXCR6 and other alterative coreceptor(s) in sooty 
mangabey CD4+ cell subsets may classify host target cells that maintain high levels of SIV 
replication without leading to loss of CD4+ T cell homeostasis.  
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Despite major advances in therapy, the disease burden of human immunodeficiency type 1 (HIV-
1) remains high.  In 2013, 2.1 million people became newly infected with HIV-1 and there were 
approximately 35 million people living with HIV-1.  The impacts of HIV-1 are especially critical in 
developing nations where up to 70% of new infections occur.  In 2013, 11.7 million patients were 
receiving antiretroviral therapy in low- and middle-income countries, representing only 36% of 
people living with HIV in these regions (1).  There remains a strong need for inexpensive and 
accessible therapies, new ways to modulate pathogenesis, a preventative HIV-1 vaccine, and/or 
a cure for HIV-1.  Despite the ability of modern combination antiretroviral therapy (ART) to control 
HIV-1 viral loads and substantially lower the rate of progression to AIDS (acquired 
immunodeficiency syndrome), viral rebound inevitably occurs in patients on long-term ART with 
undetectable peripheral plasma viral loads when therapy is discontinued.  Identifying and 
targeting persistent reservoirs of HIV-1 remains a major hurdle to treating and curing HIV-1 
infection. 
   
Efforts to further understand HIV-1 pathogenesis are also needed.  Importantly, not all CD4+ T 
cell loss following HIV-1 infection is a result of direct viral infection and killing (4, 33, 44, 45, 108).  
Chronic immune activation caused by HIV-1 infection is one of the major drivers of CD4+ T cell 
loss and progression to AIDS.  Chronic immune activation is a broad term encompassing many 
observed consequences in HIV-1 infection arising from the host pro-inflammatory immune 
response to the virus, the immune-modulatory functions of viral proteins, the immune response to 
opportunistic pathogens, the loss of gastrointestinal mucosal integrity and subsequent microbial 
translocation, the altered balance of critical CD4+ T cell subsets, and the increased homeostatic 
proliferation of CD4+ T cells (83).  Some measures of immune activation correlate better with 
progression to AIDS than HIV-1 plasma viral loads (108).  Furthermore, even patients with 
controlled viremia on successful ART experience chronic immune activation and consequent 
increased morbidity and mortality (93), highlighting the need for a better understanding of 
mechanisms leading to this activation.  Given the multifactorial nature of chronic immune 
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activation, the relative contributions of each mechanism of chronic immune aviation to CD4+ T cell 
loss and progression to AIDS remain largely undefined.   
 
Strikingly, natural SIV (simian immunodeficiency virus) infection in nonhuman primate sooty 
mangabeys (Cercocebus atys) leads to ongoing viral replication without chronic immune 
activation or disease progression to AIDS.  It is critical to understand how SIV infection and 
replication can occur in these primates without resulting in chronic immune activation.  My goal 
for this thesis was to define SIV viral entry coreceptors in sooty mangabeys and to compare these 
to SIV viral entry coreceptors in rhesus macaques, primate hosts that progress to AIDS following 
infection with SIV.  The identification of sooty mangabey target cells that express functional 
coreceptors of SIV may inform cellular reservoirs of viral infection in sooty mangabeys that 
maintain SIV replication without leading to chronic immune activation, loss of immune 
homeostasis, and disease progression in these natural hosts. 
 
Origins of HIV and SIV 
HIV-1 is responsible for the current worldwide AIDS epidemic.  Multiple cross-species 
transmissions of SIV from nonhuman primates gave rise to HIV-1 (34, 103).  Specifically, a cross-
species transmission of SIV from chimpanzees (Pan troglodytes troglodytes, SIVcpz) resulted in 
HIV-1 Group M (Figure 1.1), by far the most prevalent HIV-1 globally.  Recent studies 
demonstrate that SIVcpz is pathogenic in chimpanzee hosts (55).  SIVcpz originated from cross-
species transmission and recombination of viruses from red-capped mangabeys (Cercocebus 
torquatus, SIVrcm) and greater spot-nosed monkeys (Cercopithecus nictitans, SIVgsn) (5, 24, 
36).  In contrast to HIV-1 and SIVcpz, SIVrcm and SIVgsn infections are presumed to be non-
pathogenic in their cognate hosts. 
 
My research determined the viral entry characteristics of SIVsmm, a virus found in nonhuman 
primate sooty mangabeys.  SIVsmm infection does not lead to AIDS or death over the typical 
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lifetime of its sooty mangabey host (94) (Figure 1.2).  Sooty mangabey SIVsmm is of special 
interest because direct cross-species transmissions of SIVsmm to humans gave rise to HIV-2, 
another pathogenic HIV in humans (21, 51, 65) (Figure 1.1).  Crucially, cross-species 
transmission of SIVsmm into Asian nonhuman primate rhesus macaques (Macaca mulatta) leads 
to simian AIDS (72).  Multiple passages of SIVsmm in rhesus macaques gave rise to SIVmac, a 
group of viruses used in rhesus macaque challenge studies as models for vaccine development, 
new treatments, and AIDS pathogenesis (50).  It is critical to define how SIVsmm can replicate in 
sooty mangabeys without leading to AIDS, whereas the same virus or very closely related viruses 
cause AIDS in rhesus macaques (107). 
 
Natural and Non-Natural Hosts of SIV 
Sooty mangabeys are referred to as natural hosts of SIV. SIV is endemic in these natural 
hosts.  SIV-infected natural hosts typically exhibit high viral loads without a consequent loss of 
CD4+ T cells or progression to AIDS (94, 104).	  (Table 1.1).  Rhesus macaques are referred to as 
non-natural hosts of SIV.  SIV infections of non-natural host macaques are experimental and 
generally lead to high viral loads, widespread CD4+ T cell loss, and rapid progression to AIDS 
(104).  We hypothesize that discrepancies in viral entry and consequent cell subset tropism are 
mechanisms whereby SIV infection of non-natural host rhesus macaques leads to widespread 
CD4+ T cell loss while SIV infection of natural host sooty mangabeys does not. 
 
Non-natural host infections, most commonly SIVmac 239 and SIVmac 251 infection of macaques, 
are used to model HIV-1 infection and pathogenesis in humans.  The outcomes in HIV-1-infected 
humans are much like those in SIVmac-infected rhesus macaques.  Without ART intervention, 
HIV-1 infection typically leads to high viral loads, loss of peripheral CD4+ T cells, and progression 
to AIDS.  It should be noted that disease progression in HIV-1-infected humans is much slower 
(8-10 years from infection to AIDS) than disease progression in SIVmac 239- or SIVmac 251-




Peripheral HIV and SIV plasma viral loads typically spike in the first weeks of the acute phase of 
infection and then settle to a set point viral load during the chronic phase of infection (Figure 1.3).  
Viral loads reach a high set point in SIV-infected natural host sooty mangabeys as well as non-
natural host rhesus macaques.  Immune control of SIVsmm viral replication is not responsible for 
the lack of pathogenesis in sooty mangabeys; ongoing SIVsmm infection and replication clearly 
occur in these animals.  This distinguishes natural host sooty mangabeys from HIV-1 elite 
controllers, infected patients that do not progress to AIDS even in the absence of therapy, who 
display frequently undetectable set point plasma viral loads (105). 
 
Peripheral CD4+ T cell counts are a measure of disease progression, and AIDS can be clinically 
defined by a drop in CD4+ T cells below a threshold at which patients become increasingly 
susceptible to opportunistic infections.  In natural host SIV infections, CD4+ T cells generally 
decline transiently during the acute phase of infection and reach a relatively stable set point CD4+ 
T cell count during the chronic phase of infection (Figure 1.3B).  By contrast, HIV-1 infection in 
humans and SIV infection in non-natural hosts results in an acute drop in CD4+ T cell counts, 
transient recovery to an unstable set point, and a steady decline over time with progression to 
AIDS (Figure 1.3A).  In this study, I defined SIV entry in natural host sooty mangabeys and non-
natural host rhesus macaques.  An understanding of viral entry and tropism may determine how 
SIVsmm infection and replication in natural host sooty mangabeys fail to induce widespread 
CD4+ T cell loss, while closely-related SIVmac infection and replication in rhesus macaques lead 
to rapid peripheral CD4+ T cell loss. 
 
Chronic Immune Activation 
Chronic immune activation drives CD4+ T cell loss and progression to AIDS following 
human HIV-1 infection and non-natural host SIV infection.  Viremia alone is clearly not sufficient 
to induce AIDS as demonstrated by the lack of disease progression in SIV-infected natural hosts, 
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as well as the lack of disease progression in rare HIV-1 long-term non-progressors with high viral 
loads.  Many mechanisms leading to chronic immune activation have been proposed, but the 
casual relationship between infection and immune activation remains largely undefined.  The 
importance of studying these mechanisms is highlighted by the observation that successfully 
ART-treated patients with undetectable HIV-1 viremia exhibit higher levels of T cell activation than 
uninfected people, and that this residual immune activation is associated with increased morbidity 
and mortality even in patients receiving effective ART (99).  Therapies targeting the inflammatory 
aspects of HIV-1 infection may limit progression to AIDS and HIV-1-associated morbidity in 
patients on ART. 
 
In HIV-1 infection, chronic immune activation, measured by HLA-DR, CD38, CD69, and other 
molecules on CD4+ and CD8+ T cells, is a correlate of pathogenesis and mortality; the level of T 
cell activation is often more predictive of disease progression than viral load or CD4+ T cell count 
(26, 37, 38, 108, 112).  Pro-inflammatory cytokines (including IFNγ, IL-2, and TNF) are found at 
high levels in plasma during the chronic stage of pathogenic HIV-1 infection.  Microbial 
translocation across the gastrointestinal barrier, evidenced in part by increased plasma levels of 
bacterial and fungal products such as peptidoglycan, lipopolysaccharide (LPS), and flagellin, 
leads to innate immune activation and further release of pro-inflammatory cytokines.  There is 
also marked lymph node hyperplasia in chronically HIV-1 infected patients, including infiltration of 
CD8+ T cells, macrophages, and other immune cells (92).  Like HIV-1-infected humans, SIV-
infected non-natural hosts also display signs of chronic immune activation.  SIVmac-infected 
rhesus macaques exhibit high levels of activation markers on T cells, cell turnover, microbial 
translocation, chronic innate immune responses, and lymph node pathology (12, 13, 16, 28, 53, 
74, 106). 
 
In contrast to human HIV-1 and non-natural host SIV infection, chronic immune activation is 
absent in SIV infection of sooty mangabeys and other natural hosts.  While the immune response 
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is high in the acute phase of sooty mangabey SIVsmm infection, it resolves to baseline levels 
during the chronic phase of infection (Figure 1.3B).  A number of factors underlie discrepancies 
between SIVsmm natural host sooty mangabey infection and SIVmac non-natural host rhesus 
macaque infection (summarized in Table 1.1).  Sooty mangabeys show no increase in the 
percentage of CD4+ T cells expressing activation markers CD25 or HLA-DR as well as no 
significant increase in bystander cell turnover or apoptosis post-infection (74, 106).  The innate 
immune response during the chronic phase of SIV infection in natural hosts is tempered relative 
to the response in non-natural hosts; for example, chronic type I interferon-stimulated gene 
expression is lower in SIVsmm-infected sooty mangabeys than in SIVmac-infected non-natural 
host rhesus macaques (12, 53).  The magnitude and breadth of adaptive SIV-specific T cell 
responses (including production of inflammatory cytokines IFNγ, IL-2, and TNF) are lower in 
chronically SIVsmm-infected sooty mangabeys than in chronically HIV-1-infected humans (28).  
Studying differences between SIV infection in pathogenic and non-pathogenic hosts can lead to 
further identification of the mechanisms underlying chronic immune activation. 
 
Critical Cell Subsets 
The loss of critical CD4+ T cell subsets likely contributes to chronic immune activation, 
CD4+ T cell loss, and progression to AIDS in pathogenic hosts whereas protection of critical CD4+ 
T cell subsets may protect natural hosts from disease progression.  Short-lived, activated CD4+ T 
cells support the majority of viral replication in both natural and non-natural hosts (42, 58).  These 
cells are primarily terminally differentiated effector cells from the gastrointestinal mucosa-
associated lymphoid tissue (GALT), the predominant tissue site of viral replication in both natural 
and non-natural hosts (48, 87).  HIV and SIV infection also occur in additional CD4+ T cell 
subsets and tissue sites.  Natural host sooty mangabeys exhibit protection of specific and likely 
critical CD4+ T cell subsets relative to non-natural hosts and humans.  These protected cell 
subsets include sooty mangabey CD4+ T-helper 17 (Th17) cells, T central memory cells (Tcm), 




Some studies maintain that chronic immune activation in infected humans and non-natural hosts 
is largely supported by microbial translocation from the gastrointestinal tract (15, 31).  
Maintenance of the sooty mangabey gastrointestinal immune milieu likely provides a barrier to 
microbial translocation and chronic immune activation in these natural hosts.  GALT CD4+ T cells 
are rapidly depleted upon acute HIV-1 infection of humans, SIVmac infection of rhesus 
macaques, and SIVsmm infection of sooty mangabeys (16, 71).  However, sooty mangabeys 
maintain GALT CD4+ T cells during the chronic phase of infection whereas human and rhesus 
macaque GALT CD4+ T cells are further depleted (Figure 1.3) (87).  As a subset of GALT cells, 
Th17 cells support the physical and immunological barrier to microbial translocation by 
maintaining antibacterial defenses and intestinal epithelial architecture.  Crucially, humans and 
rhesus macaques exhibit a loss of critical gastrointestinal Th17 cells post-infection whereas sooty 
mangabeys do not (14, 19).   
 
Chronic immune activation is also marked by lymph node pathology in humans and non-natural 
hosts.  By contrast, SIV infection of natural hosts does not lead to lymph node pathology or 
immune cell infiltration (27, 106).  Viral replication is low in lymph nodes of natural hosts relative 
to lymph nodes of non-natural hosts and humans (7, 18, 25, 40, 75).  Critical CD4+ Tcm cells 
reside in the lymph node and maintain T cell homeostasis by replenishing short-lived CD4+ 
effector T cells lost to infection (17).  CD4+ Tcm cells are a large reservoir of HIV-1 in humans 
and are progressively depleted in SIV-infected rhesus macaques (13, 23, 63, 80, 88).  Infection 
and depletion of Tcm leads to homeostatic proliferation and the location within the lymph node, a 
compartment where many immune responses are initiated, may contribute to widespread immune 
activation.  Importantly, CD4+ Tcm from sooty mangabeys are protected from infection, high rates 
of turnover, and depletion relative to CD4+ Tcm from humans and rhesus macaques (18, 73, 82).  
Another subset of lymphoid T cells, CD4+ Tfh cells, reside in the lymph node germinal center and 
support survival and activation of B cells.  CD4+ Tfh cells are infected at high frequencies in 
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chronic human HIV-1 and non-natural host SIV infection relative to natural host SIV infection (18, 
70, 120).  The relative protection of Tfh cells may also protect sooty mangabeys from chronic 
immune activation. 
 
For this study, I defined host-dependent viral entry pathways in sooty mangabeys and rhesus 
macaques that likely underlie the differential infection and depletion of critical cell subsets such as 
CD4+ Th17, Tcm and Tfh.  Identification of these entry pathways may define additional critical cell 
subsets and mechanisms leading to chronic immune activation and disease progression. 
HIV and SIV Virology 
 HIV and SIV are lentiviruses from the family Retroviridae.  Each virion is enveloped by a 
lipid membrane and associated matrix, inside of which is a capsid containing two copies of single-
stranded RNA genome.  The surface of the virion lipid membrane contains trimers of Envelope 
(Env) protein, each monomer of which is composed of gp120 and gp41 subunits.  HIV and SIV 
Env trimers initiate viral entry by binding to receptor CD4 on the surface of T cells, macrophages, 
monocytes, dendritic cells, and other target cells (Figure 1.4).  This induces a conformational 
change in gp120 that allows binding to the coreceptor, a cell-surface 7-transmembrane 
chemokine receptor.  Binding to this chemokine receptor induces further conformational changes 
exposing the gp41 fusion subunit of Env, initiating fusion and entry into the target cell.   
The expression of CD4 and functional coreceptor initially define HIV and SIV cellular tropism.  
The vast majority of HIV-1 transmitter/founder Env and early primary isolates are CCR5-tropic 
(32, 122).  In up to half of untreated HIV-1 infections (dependent on the subtype), the virus 
evolves the ability to infect cells via CXCR4 leading to the emergence of dual CCR5/CXCR4-
tropic and singly CXCR4-tropic primary isolates (113).  Importantly, most SIV do not use CXCR4 
(29, 77, 101).  Previous dogma held that, like HIV-1, most SIVsmm and SIVmac viruses utilize 
coreceptor CCR5.  However, in this study, I identified non-CCR5, non-CXR4, alternative 
coreceptors of SIV that support SIV infection in vitro and ex vivo.  These alternative coreceptors 




Post-fusion and entry, the viral capsid is shed and the viral reverse transcriptase converts viral 
RNA into DNA.  HIV and SIV reverse transcriptase enzymes make frequent nucleotide mis-
incorporations and can facilitate recombination of the two RNA genomes in each capsid.  These 
frequent errors allow HIV and SIV to quickly evolve resistance to antiretroviral drugs, restriction 
factors, and the host immune response.  Following reverse transcription, viral DNA integrates into 
the host cell genome and early viral gene transcription is driven off viral long terminal repeats 
(LTR) by host cell proteins. 
  
The viral genomes of HIV-1 and SIVsmm/SIVmac are very similar (Figure 1.5).  Both carry critical 
gag, pol, and env genes that encode the matrix and capsid, the reverse transcriptase and 
integrase, and the surface envelope glycoproteins, respectively.  Early viral products Tat and Rev 
facilitate transcription and nuclear export of viral mRNA into the cytoplasm, respectively.  Viral 
product Nef supports cell activation and immune evasion.  HIV-1 Vpr mediates nuclear import of 
the HIV-1 pre-integration complex and facilitates infection of non-dividing cells. 
  
Following viral fusion and entry initially dictated by the expression of CD4 and coreceptor, 
multiple host cell mechanisms can further restrict which cells are ultimately infected with and 
produce HIV or SIV.  Cytoplasmic TRIM5 (tripartite-motif-containing protein 5) proteins mediate 
early post-entry restriction by interacting with viral capsid and blocking un-coating (102, 110).  
Cytoplasmic host restriction factor SAMHD1 (SAM domain-and HD-domain-containing protein 1) 
hydrolyzes dNTPs and thereby decreases the rate of reverse transcription in cells with naturally 
low levels of dNTPs, such as myeloid cells and dendritic cells (6, 41, 91).  The SIV protein Vpx 
overcomes this restriction by targeting SAMHD1 for proteasomal degradation (52, 62).  Notably, 
there is no Vpx protein in HIV-1 to counteract SAMHD1.  Host cell membrane protein tetherin 
(also known as BST2) acts late in infection to anchor mature virions to the cell surface and 
prevent viral release (79).  Most SIV counteract nonhuman primate tetherin with viral Nef protein, 
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whereas HIV-1 and HIV-2 overcome human tetherin restriction with Vpu and Env, respectively 
(54, 100).  The restriction factor APOBEC3 (apolipoprotein B-editing catalytic subunit-like 3) is 
incorporated into nascent virions and induces guanine to adenine hyper-mutations in the proviral 
DNA genome during reverse transcription (49, 68).  HIV and SIV Vif proteins counteract 
APOBEC3 restriction (22). 
 
Notably, these host restriction factors can inhibit cross-species transmission of HIV and SIV.  For 
example, rhesus macaque Trim5 restricts HIV-1, thus HIV-1 does not infect rhesus macaques 
(109).  The HIV-1 Vif protein easily counteracts human APOBEC3 but not other primate 
APOBEC3 (69, 117), also presenting a barrier to HIV-1 infection of nonhuman primates.  SIV Vif 
proteins counteract APOBEC3 from multiple species, including other nonhuman primates and 
humans. 
 
Coreceptors and Cellular Tropism 
HIV and SIV cellular tropism is initially dictated by the expression of CD4 and functional 
coreceptors on the surface of host cells.  Coreceptor expression can clearly delineate subsets of 
human CD4+ cells that are targeted by HIV-1.  CCR5 is expressed at high levels on human 
peripheral CD4+ memory T cells and expression levels generally increase in response to immune 
activation (81, 97, 119).  CCR5 is also found at high levels on human CD4+ T cells in the 
gastrointestinal mucosa, which likely explains the rapid depletion of gastrointestinal CD4+ T cells 
in acute infection (46, 115).  Human peripheral naïve CD4+ T cells do not express CCR5 and are 
therefore not directly targeted in early HIV-1 infection.  CXCR4, the coreceptor of some late-stage 
HIV-1, is expressed on these CD4+ naïve T cells as well as memory T cells.  The acquisition of 
CXCR4 use by HIV-1 is associated with accelerated peripheral CD4+ T cell loss and progression 
to AIDS as HIV-1 acquires the ability to infect CD4+ T naïve cells (10, 11).  It is not clear what 
portion of this accelerated CD4+ T cell loss is mediated by direct infection of CD4+ T naïve cells 
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versus indirect consequences on immune activation.  Nevertheless, this is a clear example of 
how viral coreceptor use impacts the outcome of infection. 
 
Like HIV-1, most SIV utilize coreceptor CCR5 in vitro.  However, SIV do not typically evolve the 
ability to use CXCR4 (29, 77, 101).  SIV-uninfected natural hosts, such as sooty mangabeys, 
display exceedingly low levels of CCR5 expression on peripheral, lymph node, and mucosal 
CD4+ T cells relative to uninfected non-natural hosts and humans (86).  The broadly low 
expression of CCR5 in sooty mangabey CD4+ T cells first led us to ask if coreceptors aside from 
CCR5 support robust SIVsmm replication made evident by high plasma viral loads in sooty 
mangabeys.  Such alternative coreceptors may define distinct SIV tropism in sooty mangabeys. 
Limited CCR5 and alternative coreceptor expression on critical CD4+ cell subsets in the natural 
host may protect sooty mangabeys from CD4+ T cell loss, chronic immune activation, and 
disease progression.  For example, exceedingly low CCR5 expression on critical CD4+ Tcm cells 
in sooty mangabeys relative to CD4+ Tcm in rhesus macaques was associated with 10-fold lower 
levels of viral DNA in sooty mangabey CD4+ Tcm relative to rhesus macaque CD4+ Tcm (73, 80, 
82).  These CD4+ Tcm cells are critical to maintaining CD4+ T cell homeostasis and the relative 
lack of SIVsmm infection of this subset has been hypothesized to protect sooty mangabeys from 
widespread CD4+ T cell loss. Ultimately, both the CD4+ cell subsets that are targeted and those 
that are preserved likely play an important role in immune homeostasis versus widespread CD4+ 
T cell loss and disease progression (13, 46, 47, 80, 105).  
 
Alternative Coreceptors of SIV 
Interestingly, multiple primate host species carry truncated dysfunctional alleles of CCR5 
(CCR5 Δ) that are not expressed at the cell surface and/or do not support HIV or SIV infection.  A 
32 base pair deletion in human CCR5 abrogates cell surface expression and coreceptor function.  
Approximately 21% of Caucasian North Americans carry a CCR5Δ32/Δ32 genotype, though the 
prevalence of this genotype is much less common in African-Americans, Asian-Americans, 
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Hispanic North Americans, and Native North Americans (123).  Humans with this CCR5Δ32/Δ32 
genotype are highly resistant to infection and those with a heterozygous CCR5wt/Δ32 genotype 
display slower progression to AIDS (9, 67, 98).  African primate red-capped mangabeys have an 
exceptionally high allelic frequency of CCR5Δ24 in the wild (CCR5 Δ24 allelic frequency 76-86.6%, 
CCR5Δ24/Δ24 genotype 62-73% of surveyed animals from Nigeria and Gabon) (8, 20).  Our lab 
previously identified a CCR5Δ2 allele in natural host sooty mangabeys (CCR5Δ2 allelic frequency 
26% in captive sooty mangabeys at the Yerkes National Primate Research Center YNPRC) (96).  
Both this allele and a previously described sooty mangabey CCR5Δ24 allele (85) (CCR5Δ24 allelic 
frequency 3% in captive sooty mangabeys at the YNPRC) are not expressed at the cell surface 
and do not support SIVsmm infection.  The discovery of sooty mangabey CCR5Δ2 most 
importantly led to the discovery of captive CCR5-null sooty mangabeys with CCR5Δ2/Δ24 and 
CCR5Δ2/Δ2 genotypes (CCR5 Δ/Δ genotype 8% of captive sooty mangabeys).  Notably, no CCR5Δ 
allele has been observed in non-natural host rhesus macaques (118).  The co-evolution and 
prevalence of CCR5Δ alleles in African nonhuman primate species lend support to the hypothesis 
that endemic SIV infections in natural hosts are partially to entirely CCR5-independent. 
  
Crucially, our lab previously discovered that robust SIVsmm infection and replication occur in 
sooty mangabeys with a CCR5Δ/Δ genotype (96) (Figure 1.6).  There is no significant difference in 
the prevalence of SIVsmm infection between sooty mangabey CCR5 genotypes (96).  Robust 
SIVsmm plasma viral loads greater than 104 RNA copies per mL are observed in sooty 
mangabeys lacking functional CCR5.  Although these levels are slightly lower (by 0.5 log10 RNA 
copies per mL) in animals with a CCR5Δ/Δ genotype than in animals with a CCR5wt/wt genotype 
(96), this robust infection of CCR5 Δ/Δ sooty mangabeys demonstrates that SIVsmm can use 
alternative, non-CCR5 coreceptors for initial infection of and replication within natural host sooty 
mangabeys.  We previously observed that transfected cells expressing human CD4 with human 
CCR5, CXCR6, GPR1, and GPR15 support SIVsmm Env-mediated infection (96).  However, 
species-specific amino acid differences between primate coreceptor molecules may affect 
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coreceptor function (89).  Thus, in this thesis, I extended these findings to a larger set of SIVsmm 
Env to determine which coreceptors of sooty mangabey origin support diverse SIVsmm Env-
mediated infection.  I also defined the species-specific alternative coreceptor use of SIVsmm Env 
from a very intriguing set of SIVsmm viruses that induce widespread CD4+ T cell loss in sooty 
mangabeys (76, 77). 
 
Other natural hosts are infected with SIV that have unique receptor and alternative coreceptor 
use patterns. Natural host red-capped mangabey SIVrcm primarily uses alternative coreceptor 
human CCR2 but not CCR5.  This SIVrcm CCR5-independence is consistent with the high allelic 
frequency of CCR5Δ alleles and the high prevalence of CCR5Δ/Δ genotypes amongst red-capped 
mangabeys (20).  When SIVrcm is passaged in macaque cells, SIVrcm gains the ability to use 
CCR4, not CCR5 (35).  SIVrcm also enters cells expressing human CXCR6 in vitro (8, 20).  
SIVagm from natural host African green monkeys (Chlorocebus) utilize human alternative 
coreceptors CXCR6 and GPR15, in addition to human CCR5, to infect cell lines in vitro (39, 59, 
60). 
 
While SIV from non-natural host rhesus macaques were found to use alternative receptors in 
vitro, the role of these coreceptors in infection of rhesus macaques in vivo is not entirely clear.  
SIVmac 239 uses rhesus macaque CCR5 and GPR15 in vitro, but GPR15 appears to play a 
negligible role in vivo (56, 90, 121).  A mutant SIVmac 239 Env that lacks the ability to use 
GPR15 (but still uses CCR5 in vitro) replicated in rhesus macaques and induced AIDS in vivo 
comparable to parental SIVmac 239 (90), revealing that GPR15 may not contribute to substantial 
infection or disease progression in rhesus macaques.  Plasma viral loads decreased when rhesus 
macaques chronically infected with SIVmac 251 were treated with CCR5 antagonist CMPD167 in 
vivo (114), indicating that CCR5 supports some viral replication in rhesus macaques.  A limited 
number of experiments also demonstrate the importance of CCR5 in rhesus macaque peripheral 
blood mononuclear cell (PBMC) infections; CCR5 antagonist Maraviroc blocked the majority of 
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SIVmac 239 infection and replication in rhesus macaque PBMCs (78) and high concentrations of 
CCR5 antagonist TAK-779 blocked all SIVmac 239 and SIVmac 251 infection and replication in 
rhesus macaque PBMCs (121).  These findings indicate that CCR5 is likely the primary 
coreceptor of SIVmac in rhesus macaque PBMCs. 
 
No one has reported a comprehensive analysis of SIVsmm/SIVmac coreceptors from both sooty 
mangabeys and rhesus macaques or a systematic study of SIVsmm/SIVmac CCR5 and 
alternative coreceptor use in primary cells ex vivo. 
 
Simian Immunodeficiency Viruses in This Study 
 To date, serological evidence of SIV infection in the wild has been observed in over 40 
nonhuman primate species (57, 103).  All naturally occurring SIV discovered to date were found 
in African primate species, though fully exhaustive surveys of Asian and American primates have 
not been performed (103).  The estimated prevalence of naturally occurring SIV in African primate 
hosts varies widely by species, ranging from 1% to over 50% (2).  Some natural host SIV 
infections are well studied in captivity and are known not to induce AIDS, including SIVsmm 
infection of sooty mangabeys and SIVagm infection of African green monkeys (specifically the 
subspecies Chlorocebus sabeaus and Chlorocebus pygerythrus).  Other SIV infections in African 
primates, for example SIVgsn in greater spot-nosed monkeys and SIVrcm in red-capped 
mangabeys, are not often studied in captivity and are only presumed to be widely non-pathogenic 
in their cognate hosts. 
 
The origin and naming conventions of SIV used in this study can be confounding.  In this thesis, I 
examined nonpathogenic SIVsmm from natural host sooty mangabeys that were naturally 
infected.  I also examined pathogenic SIV that are commonly used to experimentally infect non-




There are at least nine clades of SIVsmm circulating in captive sooty mangabeys in the United 
States.  These clades represent a magnitude of diversity close to that of the HIV-1 Group M 
subtypes (3, 65) (Figure 1.7).  Each of these clades likely arose from independent introductions 
of infected animals from Sierra Leone and Côte d’Ivoire.  I investigated SIVsmm Env from sooty 
mangabeys infected with SIVsmm Clade 1, the most prevalent SIVsmm at the Yerkes National 
Primate Research Center.  I found that SIVsmm Env from Clade 1, 2, 3, and 5 exhibited the same 
pattern of sooty mangabey CCR5 and alternative coreceptor use in vitro (Chapter 2).  Therefore, 
subsequent in vitro studies were performed using Clade 1 Env alone.  I also used a primary 
isolates from Clade 6 (SIVsmm D215) and a primary isolate from an unknown clade (SIVsmm 
M935) to infect primary sooty mangabey PBMCs (Chapter 3).   
 
Rhesus macaque SIVmac viruses were generated via cross-species transmissions and multiple 
passages of SIVsmm in rhesus macaques (50) (Figure 1.8).  In this study, I examined SIVmac 
239 and SIVmac 251, a related infectious provirus and viral swarm frequently used to 
experimentally challenge rhesus macaques.  SIVmac 239 and SIVmac 251 are most closely 
related to Clade 8 SIVsmm (3) (Figure 1.7).  I also examined the rhesus macaque virus SIVsmm 
E660.  Importantly, SIVsmm E660 was derived separately from the two SIVmac mentioned above 
and is more closely related to SIVsmm Clade 1 (3).  SIVsmm E660 was derived via multiple in 
vivo passages and the virus induces pathogenesis in non-natural host rhesus macaques.  The 
nomenclature is misleading; this SIVsmm E660 virus in rhesus macaques is not to be confused 
with non-pathogenic primary SIVsmm viruses in sooty mangabeys. 
 
Goals of This Thesis 
 I tested the hypothesis that natural host SIVsmm/sooty mangabey infection and non-
natural host SIVmac/rhesus macaque infection are sustained by different coreceptor-mediated 
entry pathways.  Specifically, I proposed that SIVsmm infection and replication in sooty 
mangabey cells is largely mediated by alternative (non-CCR5) coreceptors, making SIVsmm 
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partially CCR5-independent.  I also proposed that SIVmac infection and replication in rhesus 
macaque cells is mediated primarily by CCR5, making SIVmac largely CCR5-dependent. 
   
To address these hypotheses, I first examined a panel of putative alternative coreceptors cloned 
from sooty mangabeys and defined sooty mangabey CXCR6 as a robust alternative coreceptor of 
a diverse array of SIVsmm Env in vitro (Chapter 2).  Sooty mangabey GPR15 and GPR1 also 
supported moderate to low levels of SIVsmm infection in vitro.  Next, I analyzed approaches to 
block viral entry and demonstrated that small-molecule CCR5 antagonist Maraviroc and 
recombinant human chemokine CXCL16 are specific inhibitors of CCR5-mediated and CXCR6-
mediated SIV infection, respectively (Chapter 3).  Ultimately, I demonstrated that even through 
SIVmac uses alternative coreceptors in vitro, SIVmac infection and replication in primary rhesus 
macaque PBMCs ex vivo is largely CCR5-dependent (Chapter 4).  By contrast, I found that 
SIVsmm infection and replication in sooty mangabey PBMCs ex vivo is partially CCR5-
independent.  I also provided the first direct evidence that alternative coreceptor CXCR6 supports 
some SIVsmm replication in primary sooty mangabey PBMCs. 
 
These discoveries lend support to SIVmac infection of rhesus macaques as a model of CCR5-
tropic HIV-1 infection.  Crucially, given the ubiquitously low expression of CCR5 on sooty 
mangabey CD4+ T cells, the expression of functional alternative coreceptors of SIV in these hosts 
may delineate target cell subsets that support natural host SIV infections without leading to an 






Figure 1.1.  The natural host origins of HIV-1 Group M and SIVmac.  Solid arrows represent 
cross-species transmissions that occurred between nonhuman primates in the wild, or incidentally 
between humans and nonhuman primates.  Broken arrow represents SIVsmm cross-species 
transmission to rhesus macaques in captivity and the experimental derivations of SIVmac in 
rhesus macaques.  Non-pathogenic natural host sooty mangabeys and other presumed natural 
hosts of SIV are on the left (black); pathogenic non-natural hosts of SIV and human hosts of HIV 





Figure 1.2.  Lack of SIVsmm-associated mortality in infected natural host sooty 
mangabeys.  Kaplan-Meier survival curves of SIVsmm-infected (N=167, red) and uninfected 
(N=62, blue) sooty mangabeys from the Yerkes National Primate Research Center.  The 
proportion of surviving animals is shown in relation to the animals’ age in years.  Mortality rates 
do not differ significantly between groups (p=0.55).  Figure from Keele, B., et al.  Nature, 2009. 




Figure 1.3.  Characteristics of HIV and SIV infection in natural and non-natural hosts.  
Variation in plasma viral loads (black), peripheral CD4+ T cell counts (blue), immune activation 
(green), and gastrointestinal mucosa-associated lymphoid tissue (MALT) CD4+ T cells (red) 
during the course of A) human and non-natural host infections and B) natural host infections.  
The relative changes in each parameter are represented for the acute, chronic, and (in A) AIDS 
stages of infection.  SMs, sooty mangabeys; AGMs, African green monkeys.  Figure from 






Figure 1.4.  HIV and SIV entry.  HIV Env trimer subunit gp120 (or SIV Env trimer subunit gp140) 
binds to receptor CD4 on the surface of target cells, initiating a conformational change and 
subsequent binding to a 7-transmembrane coreceptor (represented here as CCR5).  Coreceptor 
binding induces further conformational changes, exposing the gp41 subunit and initiating 6-helix 
bundle formation, fusion, and ultimately viral entry.  Adapted from Kumar, V., et al.  Robbins 





Figure 1.5.  DNA structure of HIV-1 and SIVsmm/SIVmac.  A schematic representation of HIV-
1 and SIVsmm/SIVmac viral DNA genomes.  LTR, long terminal repeats.  Adapted from 
Hatziioannou, T., and Evans, D.  Nature Reviews Microbiology, 2012. (50). Reprinted by 





Figure 1.6.  SIVsmm infection and replication in the absence of functional CCR5 in vivo.  
Plasma viral loads (log10 RNA copies per mL; mean ± SEM) were collected in three surveys of 
infected sooty mangabeys between 2004 and 2009.  Viral loads are plotted by CCR5 genotype: 
CCR5wt/wt (n = 60), CCR5wt/Δ (n = 49), and CCR5Δ/Δ (n = 7).  The difference in viral loads between 
CCR5wt/wt and CCR5Δ/Δ sooty mangabeys is statistically significant (p<0.05; Dunn's multiple 
comparison test) whereas other comparisons do not reach statistical significance.  Adapted from 






Figure 1.7.  SIVsmm and SIVmac Env phylogeny.  Neighbor-joining phylogeny of 405 base 
pair env predicted amino acid sequences.  The scale represents 0.01 amino acid substitutions 
per site.  Strain nomenclature includes the primate center of origin (YNPRC, TNPRC, CNPRC, 
NIRC), the collection year, and the animal identification number.  Reference laboratory SIVsmm 
strains, laboratory SIVmac strains, and strains from sooty mangabeys living in the wild are shown 
in black.  HIV-2 strains (Subtypes A, B, C, D, H, D) are shown in gray.  SIVsmm strains (Clades 
1-9) identified from captive sooty mangabeys are in color.  Adapted from Apetrei, C., et al.  





Figure 1.8.  The separate origins of SIVsmm E660 versus SIVmac 251 and SIVmac 239.  
Rhesus macaque challenge viruses SIVmac 251, SIVmac 239, and SIVsmm E660 were derived 
via multiple passages of SIVsmm in rhesus macaques.  Large red arrows identify SIVsmm E660, 
SIVmac 251, and SIVmac 239.  Ca, Cercocebus atys sooty mangabey (gray).  Mm, Macaca 
mulatta rhesus macaque (blue).  Green boxes represent viral isolates and yellow boxes represent 
infectious molecular clones.  Solid arrows represent direct transmission events and broken 
arrows represent multiple cloning steps.  CNPRC, California National Primate Research Center.  
Adapted from Hatziioannou, T., and Evans, D.  Nature Reviews Microbiology, 2012. (50).  




Table 1.1.  Characteristics of rhesus macaque and sooty mangabey SIV infections. 
For comprehensive reviews pertaining to this figure, see (105, 107).   
 a RNA copies per mL, Mean ± SEM plasma viral loads: days 35-77 of SIVmac 239 infection in 
Indian Rhesus Macaques (50, 66). b RNA copies per mL, Mean ± SEM plasma viral loads: three 
surveys of chronically SIVsmm-infected CCR5wt/wt sooty mangabeys (95). c In rare instances, 
SIVsmm infection is associated with peripheral CD4+ T cell loss.  These include animals infected 
by an atypical SIVsmm with CXCR4 tropism (30, 76, 77), and aging SIVsmm-infected sooty 
mangabeys with declining CD4+ T cell counts (64, 111). d Time between SIV infection and AIDS.  
Note the typical lifespan of a captive sooty mangabey is 14-18 years (64).  e (74, 106). f CCR5 
expression is low on CD4+ T cells from the periphery, lymph node, and GALT of sooty 
mangabeys (86). g Central memory T cells (Tcm) (82). h CD4+ T-helper 17 cell (Th17) (14, 19). i 
Gut mucosal associated lymphoid tissue (GALT) (43, 71). j (87). k Lymph node pathology includes 
collagen deposition and/or an increased number of effector-type T cells (16, 106). l (28). m An 
acute increase in Type I IFN genes in natural and non-natural hosts returns to baseline in natural 
hosts but remains high in non-natural hosts (12, 53). n The frequency of double-negative (DN) 
CD4-CD8- T cells is higher in uninfected sooty mangabeys (and other natural hosts) than in 
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ϕ Pathogenic rhesus macaque viruses used in this study included SIVmac 239, SIVmac 251, and 
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CLONING AND ANALYSIS OF SOOTY MANGABEY ALTERNATIVE CORECEPTORS 
THAT SUPPORT SIMIAN IMMUNODEFICIENCY VIRUS SIVsmm ENTRY 
INDEPENDENTLY OF CCR5 
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Natural host sooty mangabeys infected with SIVsmm do not develop AIDS despite high viremia.  
Sooty mangabeys and other natural hosts express very low levels of CCR5 on CD4+ T cells and 
SIVsmm infection and robust replication occur in vivo in sooty mangabeys genetically lacking 
functional CCR5, indicating use of additional entry pathways.  SIVsmm use several alternative 
coreceptors of human origin in vitro, but it is not known which molecules of sooty mangabey 
origin support infection.  We cloned a panel of putative coreceptors from sooty mangabeys and 
tested their ability to mediate infection, in conjunction with smCD4, by pseudotypes carrying Envs 
from multiple SIVsmm subtypes.  Sooty mangabey smCXCR6 supported efficient infection by all 
SIVsmm pseudotypes with infection levels comparable to smCCR5; smGPR15 enabled infection 
by all pseudotypes at modest levels.  smGPR1 and smAPJ supported low and variable infection 
whereas smCCR2b, smCCR3, smCCR4, smCCR8, and smCXCR4 were not used by most 
pseudotypes.  Infection was similar with both known alleles of smCD4.  In contrast to typical 
SIVsmm, SIVsmm from rare infected sooty mangabeys with profound CD4+ T cell loss used 
smCXCR4, smCXCR6 and smCCR5 efficiently and also exhibited robust infection through 
smCCR3, smCCR8, smGPR1, smGPR15, and smAPJ.  Alternative coreceptors of typical 
SIVsmm, particularly smCXCR6 and smGPR15, may support virus replication in sooty 
mangabeys that display restricted CCR5 expression as well as sooty mangabeys genetically 
lacking CCR5.  Defining expression of these molecules on sooty mangabey CD4+ subsets may 
delineate distinct natural host target cell populations capable of supporting SIVsmm replication 





HIV-1 infection of humans and SIVmac infection of non-natural host rhesus macaques result in 
high viral loads, peripheral CD4+ T cell loss and progression to AIDS.  By contrast, SIVsmm 
infection of natural host sooty mangabeys rarely leads to peripheral CD4+ T cell loss or disease 
despite viral loads comparable to those measured in non-natural hosts.   Identifying mechanisms 
responsible for the different outcomes of infection between natural hosts and non-natural simian 
or human hosts has become a central focus of efforts to understand AIDS pathogenesis.  
Although many models of natural host infection exist, SIVsmm is unique as direct cross-species 
transmission of SIVsmm from sooty mangabeys to humans and rhesus macaques gave rise to 
pathogenic HIV-2 and SIVmac (2, 31).  Similarly, experimental transmission of SIVsmm from 
infected sooty mangabey hosts results in AIDS in non-natural host rhesus macaques (43).  While 
the factors regulating pathogenic versus nonpathogenic outcomes of infection are complex and 
not fully understood (9), comparison of infected sooty mangabeys with rhesus macaques recently 
revealed differential targeting of CD4+ T cell subsets (51).  Thus, an understanding of SIVsmm 
cellular tropism may identify cells in natural host sooty mangabeys that maintain viral replication 
without leading to CD4+ T cell depletion or AIDS.   
 
Classically, SIVsmm was thought to exclusively use the entry coreceptor CCR5 in vivo.  Highly 
restricted expression of CCR5 on CD4+ T cells is characteristic of SIV natural hosts, including 
sooty mangabeys, compared with non-natural host species (52, 53) and may contribute to distinct 
cellular targeting in vivo (51).  However, SIVsmm use of non-CCR5 coreceptors in vivo was 
revealed recently by the identification of common CCR5 deletion alleles among sooty mangabeys 
(CCR5∆2 and CCR5∆24) that abrogate CCR5 cell surface expression and entry coreceptor function 
(58).  A substantial minority of captive sooty mangabeys in US primate centers possess 
homozygous null (CCR5∆/∆) genotypes, but the absence of functional CCR5 expression does not 
restrict SIVsmm replication in vivo as CCR5∆/∆ animals are susceptible to natural as well as 
experimental infection and exhibit high viral loads (58).  These findings indicate that SIVsmm 
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infection, replication and cell targeting occur in vivo through alternative pathways in addition to 
CCR5.  
  
A number of 7-transmbrane receptors (7TMR) of human origin were shown to function as 
alternative coreceptors of HIV and SIV in vitro.  SIVsmm can enter target cells through human 
CXCR6, GPR1 and GPR15 in addition to CCR5 (11, 50, 58).  Natural host red-capped 
mangabeys, the majority of which carry a CCR5∆/∆ genotype, are naturally infected with SIVrcm 
that enter cells through human CCR2b but not CCR5 (4, 12, 74).  Experimental transmission of 
SIVrcm to pigtailed macaques resulted in expanded SIVrcm in vitro tropism for human CCR4 
(27).  Additional human 7TMR molecules that support entry or infection by subsets of HIV-1 or 
SIV include APJ, CCR3 and CCR8 (13, 14, 19, 50, 60, 64).  Although CXCR4 is a common 
coreceptor in late stages of HIV-1 infection, SIVsmm, like other SIV strains, does not use CXCR4 
except in rare cases (16, 46, 50, 62).  
  
Notably, the majority of alternative coreceptor studies to date employed 7TMR molecules of 
human origin and rarely utilized homologous species-derived molecules.  Species-specific amino 
acid differences in 7TMRs may markedly affect coreceptor function (55).  Therefore, in order to 
define the sooty mangabey molecules that mediate SIVsmm infection and that might be involved 
in CCR5-independent cell targeting and replication in vivo, we cloned sooty mangabey smAPJ, 
smCCR2b, smCCR3, smCCR4, smCCR8, smCXCR4, smCXCR6, smGPR1 and smGPR15.  
Because sooty mangabeys have two distinct alleles of CD4 that differ in their putative gp120 
binding regions (10, 24, 25), we utilized both smCD4 alleles in conjunction with sooty mangabey 
7TMRs for functional coreceptor analysis.  Finally, we compared coreceptor use by a variety of 
SIVsmm pseudotypes.  While infected sooty mangabeys do not progress to AIDS, SIVsmm exists 
in at least nine viral genetic lineages (2) and sooty mangabeys at the Yerkes National Primate 
Research Center (YNPRC) infected with subtype 5 SIVsmm generally display lower peripheral 
CD4+ T cell counts than uninfected sooty mangabeys or those infected with subtype 1, 2 or 3 
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SIVsmm (1).  In addition, a small number of infected sooty mangabeys developed rapid profound 
CD4+ T cell loss and were found to harbor SIVsmm variants with expanded use of human 
coreceptors in fusion assays, including CXCR4 (45, 46).  SIVsmm use of sooty mangabey 
coreceptors has not been described in these animals.  Thus, we assessed sooty mangabey-





Cloning sooty mangabey receptor molecules 
Full-length 7TMRs were cloned from sooty mangabey genomic DNA (APJ, CCR3, CCR8, 
CXCR6, GPR1, GPR15) or sooty mangabey cDNA (CCR2b, CCR4, CXCR4) from animals 
housed at the Yerkes National Primate Research Center (YNPRC).  Primers were designed to 
anneal outside the 7TMR open reading frame 5’ start codons and 3’ stop codons based on 
primers previously used to clone receptors from rhesus macaques (22, 42) or sequences 
matched to human and rhesus macaque mRNA published in GenBank.  Genomic DNA was 
extracted from unfractionated sooty mangabey PBMC.  cDNA was obtained from sooty 
mangabey CD4+ T cells stimulated for 120 hours with Concanavalin-A/IL-2 and subjected to 
mRNA purification (RNEasy Mini Kit; Qiagen, Valencia, CA) and reverse transcription 
(SuperScript First-Strand Synthesis System for RT-PCR; Invitrogen, Carlsbad, CA, USA).  The 50 
uL PCR reactions contained 200 ng genomic DNA or 0.1 uL cDNA, 1 unit high-fidelity Phusion 
polymerase in HF buffer (Finnzyme, Thermo Scientific, Waltham, MA), primers (0.5 mM), and 
dNTPs (0.2 mM).  Thermocycling conditions were: initial denaturation 98 °C for 45 seconds, 
followed by 30 cycles of 98 °C for 10 seconds, annealing for 30 seconds, 72 °C for 1.5 minutes, 
and a final extension at 72 °C for 10 minutes.  Annealing temperatures were 53 °C (CCR2b), 60 
°C (GPR1), 62 °C (CCR4, CXCR4), 64 °C (APJ, CCR3) and 72 °C (CCR8, CXCR6, GPR15).  
PCR products were column purified (QIAquick PCR Purification; Qiagen).  CCR8, CXCR6, 
GPR15 were then cloned into the expression plasmid pcDNA3.1+ (Invitrogen) using dual 
restriction digests with HindIII, BamHI and XhoI (22).  APJ, CCR2b, CCR4, CXCR4 and GPR1 
were TA-cloned using a pcDNA3.1 Directional TOPO Expression Kit (Invitrogen).  Clones were 
screened by restriction analysis and nucleotide sequencing.  Sequences of the sooty mangabey 
CCR2b, CCR3, CCR4, CCR8, CXCR4, GPR1, GPR15 and APJ clones were submitted to 
GenBank (Accession numbers: CCR2b, JN701018; CCR3, JN701013; CCR4, JN701019; CCR8, 
JN701014; CXCR4, JN701020; GPR1, JN701016; GPR15, JN701017; APJ, JN701012).  Cloning 
of wild-type smCCR5 from SM genomic DNA has been previously described (58).  SM CD4 
45	  
	  
alleles (smCD4 2.1 and smCD4 4.3) were PCR amplified from cDNA by T. Vanderford and 
TOPO-cloned into pcDNA3.1 (Invitrogen).  Individual clones were screened and verified by 
sequence analysis.  Because our smCXCR4 clone differed from a previously published 
smCXCR4 sequence (11) at two predicted amino acids (residues 32 and 171), the relevant region 
was PCR-amplified and sequenced from genomic DNA of ten additional sooty mangabeys using 
primers within the CXCR4 gene (forward 5’-AGT GAA TGT CCA TTC CTT TG-3’; reverse 5’-GAC 
AAT ACC AGG CAG GAT AA-3’).  Nucleotide and amino acid alignments were performed using 
the ClustalW algorithm in MacVector 12.0 (Cary, NC, USA).  7TMR membrane topology 
predictions were made using TMpred (http://www.ch.embnet.org/software/TMPRED_form.html).  
 
SIVsmm envelope clones and pseudotyped viruses 
SIVsmm env genes were cloned by C. Derdeyn and B. Li (Emory University) from virions isolated 
from plasma of infected sooty mangabeys employing single genome amplification (SGA) methods 
previously described (38, 39, 61).  Briefly, viral RNA was purified from plasma using the QIAamp 
Viral RNA purification kit (Qiagen) and cDNA was prepared using Superscript III (Invitrogen) and 
the primer SM-ER1 (5’- CTA TCA CTG TAA TAA ATC CCT TCC AGT CCC-3’).  First round PCR 
amplification was performed on endpoint diluted cDNA using primers H2SM-EF1 (5’- CCC TTG 
AAG GMG CMR GAG AGC TCA TTA-3’) and SM-ER1 (5’-ATA AAA TGA GAC ATG TCT ATT 
GCC AAT TTG-3’), followed by a second round of amplification using primers H2SM-EF2 (5’– 
CAC CTA AAA ART GYT GCT AYC ATT GCC AG-3’) and SM-ER2 (5’ -ATA AAA TGA GAC ATG 
TCT ATT GCC AAT TTG-3’).  PCR amplicons were cloned into the pcDNA3.1V5HisTOPO-TA 
expression vector (Invitrogen), and transformed colonies that contained an insert were identified 
by PCR screening.  SIVsmm Env-mediated infection was assessed using luciferase-expressing 
viral pseudotypes as previously described (58).  Pseudotyped virions were generated in 293T 
cells by co-transfecting pNL-Luc- E-R+ plasmid encoding an NL4-3-based env-deleted luciferase-
expressing HIV-1 viral backbone (15) along with plasmids carrying SIVsmm env genes.  
Pseudotypes lacking Env (pNL-Luc- E-R+ co-transfected with empty pcDNA3.1+) served as a 
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negative control and virions carrying VSV-G served as a positive control.  Cells were transfected 
overnight using Fugene (Promega; Madison, WI, USA) and washed the following day to remove 
DNA and transfection reagent.  Supernatants were collected 3 days post-transfection and stored 
at -80C in 5% sucrose to enhance stability.  Prior to use in infection assays, pseudotype stocks 
were treated with DNase (50 units/mL x 15 min).  Pseudotype virion stocks were quantified by 
HIV-1 Gag p24 antigen content as measured by ELISA (PerkinElmer, Waltham, MA, USA) and by 
infectivity based on luciferase output (RLU) measured in U87 cells stably expressing human CD4 
and CCR5 (5). 
 
Infection and coreceptor function analyses 
Coreceptor function was evaluated by infection of 293T cells transfected with CD4 and 7TMR 
molecules of interest as described (58).  Target cells were co-transfected with plasmids encoding 
CD4 and 7TMR plasmids using Fugene, washed the next day to remove transfection reagent and 
re-plated at 2×104 cells/well in 96 well plates.  CD4 and 7TMR expression was confirmed by flow 
cytometry (CCR2b, CCR4) and/or viral infection with promiscuous CD4-low SIVsmm.  The next 
day, cells were infected with pseudotype virus using equal amounts of each virus based on 
luciferase activity (RLU) measured in U87/CD4/CCR5 cells or based on p24 Gag antigen content.  
Infections were carried out by spin inoculation (1200×g for 2 hours at 25C).  Three days later, 
cells were lysed (0.5% Triton-X 100 in PBS) and luciferase was quantified by adding an equal 
volume of luciferase substrate (Luciferase Assay System; Promega) and measuring activity on 
either a MLX Microplate Luminometer (Dynex Technologies, Chantilly, VA) or a Luminoskan 
Ascent Microplate Luminometer (Thermo Scientific).  For infections in which blocking of 
endogenous human CXCR4 expressed by 293T cells was necessary, cells were treated for 1 
hour pre-infection with 20µM AMD3100 (Sigma-Aldrich, St. Louis, MO, USA), which was also 





All animal experimentation was conducted following guidelines established by the Animal Welfare 
Act and the NIH for housing and care of laboratory animals and performed in accordance with 
Institutional regulations after review and approval by the Institutional Animal Care and Use 
Committees (IACUC) at the Yerkes National Primate Research Center (YNPRC) and the 
Washington National Primate Research Center (WaNPRC).  Studies were also reviewed and 





Cloning and sequence analysis of sooty mangabey 7-transmembrane receptors 
We amplified the full open reading frames of smAPJ, smCCR2b, smCCR3, smCCR4, 
smCCR8, smCXCR4, smCXCR6, smGPR1, and smGPR15 using primers upstream and 
downstream of the coding regions.  Primers we designed to match both human and rhesus 
macaque genomic and mRNA sequences in order to maximize likely homology to sooty 
mangabey sequences (22).  Sooty mangabey genomic DNA was used for cloning 7TMRs that 
lack introns in the open reading frame: smAPJ, smCCR3, smCCR8, smCXCR6, smGPR1, and 
smGPR15.  Complimentary cDNA from sooty mangabey CD4+ PBMCs was used for cloning of 
smCCR2b, smCCR4 and smCXCR4, molecules which contain introns within the open reading 
frames.  Amplified receptors were cloned into mammalian expression plasmids for sequencing 
and functional studies.   
 
We aligned the predicted amino acid sequences of these sooty mangabey 7TMR molecules to 
sequences of human and rhesus macaque molecules.  Sooty mangabey molecules showed 
greater than 91% identity to human and greater than 98% identity to rhesus macaque sequences 
(Table 2.1).  While the domains of these 7TMR molecules that might interact with Env to facilitate 
entry have not been mapped, studies with human CCR5 and CXCR4 show that all extracellular 
regions may contribute to entry with the N-terminal domain (NTD) and extracellular loop 2 (ECL2) 
as the most critical (20).  Thus, we aligned the predicted extracellular regions between human 
and sooty mangabey 7TMR molecules (Figure 2.1).  7TMR molecules CCR4 and GPR1 were 
highly conserved between sooty mangabeys, rhesus macaques, and human within extracellular 
domains and differ by only two extracellular residues between sooty mangabey and human.  
CXCR6, CCR3, and CCR8 were particularly divergent between the species in extracellular 




Sequences were not described previously for smAPJ, smCCR2b, smCCR3, smCCR4, smGPR1 
and smGPR15, but smCXCR6 and smCXCR4 have been reported (11, 55).  Our clones matched 
the published smCXCR6 sequence, but differed at two predicted amino acids from the previously 
published smCXCR4 sequence (E32 instead of K in the NTD, and D171 instead of E in 
transmembrane domain 4).  These alleles differed in a region critical to CXCR4 antagonist 
AMD3100 binding (59).  To confirm that our smCXCR4 clone was not an artifact of PCR 
amplification or a unique sequence limited to one animal, we sequenced CXCR4 genes from ten 
additional sooty mangabeys.  Genomic sequencing revealed E32/D171 in all ten sooty 
mangabeys, indicating that the allele of smCXCR4 we cloned was neither an artifact nor rare 
among sooty mangabeys in the YNPRC colony.  
 
Both sooty mangabey CD4 alleles mediate SIVsmm pseudotype infection through smCCR5 
but not smCXCR4 
Studies of SIV Env-mediated infection in vitro were traditionally performed using human 
CD4 and coreceptors.  Sooty mangabeys are known to carry two distinct alleles of CD4, smCD4 
2.1 and smCD4 4.3, whose putative gp120 interaction domains differ from both human huCD4 
and from each other (24, 36).  Thus, we determined whether both alleles of smCD4 support 
SIVsmm infection through smCCR5, and whether they differ from huCD4 in this respect.  The two 
smCD4 alleles were independently cloned from cDNA and found to match the sequences 
previously reported (24). 
 
We tested function of the two smCD4 alleles in conjunction with smCCR5.  Virions were 
generated using a pNL-Luc- E-R+  HIV-1 viral backbone lacking Env and carrying luciferase in 
place of Nef.  This backbone was pseudotyped with subtype 1 SIVsmm Envs cloned by single 
genome amplification (SGA) from infected SM with CCR5-wild-type (CCR5wt/wt ) or CCR5-
deficient (CCR5∆/∆ ) genotypes (FFv and FNp, respectively) as previously described (58).  Target 
293T cells were transfected with huCD4, smCD4 2.1, and smCD4 4.3, with or without smCCR5, 
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then infected with pseudotype virions.  Luciferase output was measured as an indication of entry 
and infection.  Flow cytometry confirmed that huCD4, smCD4 2.1, and smCD4 4.3 were 
expressed at similar levels on the cell surface (data not shown).  Virions lacking Env served as a 
negative control and VSV-G pseudotypes served as a positive control (Figure 2.2 and data not 
shown). 
 
Both smCD4 2.1 and smCD4 4.3 enabled SIVsmm infection when transfected with smCCR5 
(Figure 2.2).  While modest quantitative differences were seen within individual experiments, 
there was no consistent difference in efficiency between smCD4 2.1, smCD4 4.3, and huCD4 
over repeated experiments.  CD4-independent SIV Env were described previously (26, 56, 73).  
In our experiments, target cells expressing smCCR5 in the absence of CD4 did not permit 
SIVsmm pseudotype infection, confirming that SIVsmm Env-mediated infection does not occur 
through smCCR5 independent of CD4.  Thus, despite sequence differences, both smCD4 
molecules support efficient SIVsmm pseudotype infection in conjunction with smCCR5.   
These results also showed that 293T cells expressing CD4 alone were unable to support infection 
by these pseudotypes.  Because 293T cells express endogenous human CXCR4 (17), the lack of 
infection following transfection of huCD4, smCD4 2.1 or smCD4 4.3 alone demonstrates that 
human CXCR4 is not a coreceptor for these SIVsmm.  Furthermore, given the breadth of human 
alternative coreceptors used by many SIV strains, lack of infection in CD4-transfected cells 
establishes 293T as a suitable cell line for our further coreceptor assays of SIVsmm.  
 
Multiple studies show that most naturally-occurring SIV, including SIVsmm, do not use human 
CXCR4.  One study reported that SIVsmm did not enter cells through a previously described but 
distinct allele of smCXCR4 (11).  Therefore, we asked if SIVsmm could utilize the smCXCR4 we 
cloned in conjunction with species-matched CD4 (Figure 2.3).  Neither the SIVsmm Envs derived 
from infected CCR5wt/wt nor those from CCR5Δ/Δ SM were capable of infecting cells through 
smCXCR4, regardless of which smCD4 allele was used.  A similar lack of infection through 
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smCXCR4 was also seen using an extended panel of additional SIVsmm pseudotypes 
(discussed further below, see Figure 2.5).  Efficient infection through smCXCR4 was seen with 
virions carrying the dual CCR5- and CXCR4-tropic HIV-1 89.6 Env (data not shown), confirming 
smCXCR4 expression and functionality.  These results confirm SIVsmm does not typically use 
smCXCR4, in contrast to HIV-1 infection where acquisition of CXCR4-tropism is relatively 
common.  
 
Alternative coreceptors from sooty mangabey support subtype 1 SIVsmm pseudotype 
infection 
Small differences in alternative coreceptor sequences between species can markedly 
alter coreceptor function (55), suggesting that prior studies using human 7TMR molecules may 
not necessarily reflect SIVsmm coreceptor use in natural host sooty mangabey infection.  
Therefore, we determined the capacity of eight additional 7TMR molecules cloned from sooty 
mangabey to mediate SIVsmm infection in conjunction with both smCD4 alleles.  These 
coreceptors included smCXCR6, smGPR15, and smGPR1, since we previously showed that 
SIVsmm frequently use human CXCR6, GPR15 and GPR1 (58); smCCR2b and smCCR4, since 
the human homologs of these receptors support infection by SIVrcm derived from natural host 
red-capped mangabey or following passage into pigtail macaques (4, 12, 27, 74); and smAPJ, 
smCCR3, and smCCR8, since the human molecules are used by limited subsets of HIV or SIV 
(13, 14, 19, 50, 60, 64). 
 
Alternative coreceptor smCXCR6 acted as a robust entry pathway for SIVsmm in conjunction with 
either smCD4 4.3 or smCD4 2.1, yielding infection levels generally comparable to smCCR5 
(Figure 2.4).  smGPR15 also supported infection, although to a lesser extent than smCXCR6 or 
smCCR5.  These results are similar to those seen previously using transfected human CXCR6 
and GPR15 (58).  smGPR1 and smAPJ supported low levels of infection as luciferase output is 
above the background in mock transfected cells for most Envs but well below output levels in 
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cells expressing smCCR5, smCXCR6, or smGPR15.  Surprisingly, neither smCCR2b nor 
smCCR4 supported infection by SIVsmm Env pseudotypes, even though these 7TMR support 
SIVrcm infection.  smCCR3 and smCCR8 also failed to mediate infection by these SIVsmm.  
smCD4 2.1 and smCD4 4.3 supported similar levels of infection (Figure 2.4A and Figure 2.4B 
respectively), whereas none of the alternative coreceptors enabled infection in the absence of 
CD4 (data not shown).  Similar coreceptor-mediated entry patterns were seen between Envs from 
CCR5-deficient and CCR5-wild-type sooty mangabeys, consistent with the notion that SIVsmm 
alternative coreceptor use is not a feature exclusive to virus from CCR5 Δ/Δ sooty mangabeys.  
 
Multiple subtypes of SIVsmm show similar alternative coreceptor use in vitro 
SIVsmm circulating in U.S. primate centers cluster in several genetic subtypes (2).  
Infected sooty mangabeys generally do not display CD4+ T cell loss, but, collectively, animals at 
YNPRC infected with subtype 5 SIVsmm display lower peripheral CD4+ T cell counts relative to 
sooty mangabeys infected with other subtypes (1).  Therefore, we asked if coreceptor use 
patterns differ among SIVsmm subtypes and, in particular, whether subtype 5 SIVsmm exhibit a 
distinct pattern that might lead to expanded tropism and consequent CD4+ T cell loss.  
Pseudotyped virions were generated with SGA-derived Envs from sooty mangabeys infected with 
SIVsmm subtype 5, as well as subtypes 2 and 3, and tested for infection of 293T cells transfected 
with sooty mangabey-derived coreceptors and smCD4.  Since we previously observed no 
difference in infection between the two smCD4 alleles, we utilized smCD4 4.3 to test this 
extended panel of SIVsmm Envs. 
 
 SIVsmm subtypes 2, 3, and 5 exhibited alternative coreceptor use patterns comparable 
to those observed for subtype 1 SIVsmm (Figure 2.5), with robust infection through smCXCR6 
and smCCR5.  These Envs displayed modest use of smGPR15 and levels of infection through 
smGPR1 and smAPJ that were variable and generally marginal.  Subtype 2, 3, and 5 Envs did 
not enter cells expressing smCXCR4 in conjunction with smCD4.  Notably, the subtype 5 
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SIVsmm did not display expanded alternative coreceptor use relative to other subtypes of 
SIVsmm examined, suggesting that factors other than distinct coreceptor use patterns underlie 
the relatively lower CD4+ T cell counts with this SIVsmm lineage. 
 
Rare SIVsmm that induce rapid CD4+ T cell loss in sooty mangabeys exhibit expanded 
sooty mangabey coreceptor use  
In contrast to the majority of infected animals, rare SIVsmm were described that give rise 
to profound rapid CD4+ T cell loss in infected sooty mangabey hosts (46).  Previous studies 
employing cell-cell fusion assays and coreceptors of human origin showed these SIVsmm 
isolates display expanded tropism for several coreceptors, including CXCR4 (45, 46).  Therefore, 
we determined if the expanded use of human coreceptors previously described also reflects 
expanded use of sooty mangabey-derived 7TMR molecules, and whether these coreceptors can 
support infection as well as cell-cell fusion.  We tested infection by pseudotyped virions carrying 
SGA-derived Env isolated from three of these very low-CD4 sooty mangabeys (FJv, FPy and 
FTv) and compared to infection with Env from one animal with Clade 1 typical non-progressive 
infection (FFv). 
 
Because 293T cells express low levels of endogenous human huCXCR4 (17), we first determined 
if transfection of smCD4 alone enabled infection.  Indeed, smCD4 alone enabled infection by 
pseudotypes carrying Envs from the CD4-low animals FJv, FPy and FTv (Figure 2.6).  This 
pattern differs from that seen with typical Clade 1 to Clade 5 SIVsmm (see Figure 2.3, Figure 2.4, 
Figure 2.5) where there is no infection in 293T cells expressing CD4 alone.  Pre-treatment with 
the CXCR4 antagonist AMD3100 completely abrogated SIVsmm FJv, FPy and FTv infection in 
293T cells transfected with smCD4 alone, confirming that infection is mediated by endogenous 
human CXCR4 on 293T cells.  Additionally, because AMD3100 completely blocks background 




Transfection of 293T cells with smCD4 and smCXCR4 together resulted in markedly increased 
levels of infection compared to cells transfected with smCD4 alone (Figure 2.6).  Thus, sooty 
mangabey-derived smCXCR4 supports robust infection by these low-CD4 SIVsmm pseudotypes.  
AMD3100 pre-treatment blocked the majority of infection in smCXCR4-transfected cells, 
suggesting that AMD3100 has substantial activity against smCXCR4 in addition to human 
CXCR4.   Alignment of the human and sooty mangabey CXCR4 sequences showed amino acid 
residues previously identified as critical to the interaction between AMD3100 and human CXCR4 
(D171, D262, E288) are conserved between the two species (22, 30, 59).  SIVsmm FJv, FPy, and 
FTv retained the ability to infect cells via smCCR5.  Infection through smCXCR4 appeared to be 
at least as efficient as infection through smCCR5 in vitro. 
 
We then tested the extended panel of sooty mangabey-derived 7TMR molecules with low-CD4-
derived SIVsmm Envs.  Target cells were transfected with 7TMR molecules and smCD4, pre-
treated with AMD3100 to block infection through endogenous huCXCR4 on 293T, and infected 
with Env pseudotyped viruses.  SIVsmm FJv, FPy, and FTv displayed broad and efficient use of 
multiple alternative coreceptors (Figure 2.7).  Like all other SIVsmm studied, these Env used 
smCXCR6 very efficiently and smGPR15 slightly less so.  In addition, while none of the typical 
SIVsmm Env used smCCR3 or smCCR8 (see Figure 2.4, Figure 2.5, and SIVsmm FFv in Figure 
2.7), both of these pathways supported infection by SIVsmm FJv, FPy, and FTv.  Finally, while 
most SIVsmm Envs used smAPJ and smGPR1 to a very limited extent, these 7TMRs supported 
substantially more robust infection by SIVsmm from these CD4-low sooty mangabeys.  Notably, 
neither smCCR2b nor smCCR4 supported infection, nor did infection occur through any 
coreceptors in the absence of smCD4 (data not shown).  Thus, in contrast to typical SIVsmm 
Envs, the SIVsmm Envs derived from rare CD4-depleted sooty mangabeys exhibit expanded use 
of SM alternative coreceptors smCXCR4, smCCR3, and smCCR8 as well as efficient infection 
though smAPJ, smCXCR6, smGPR1, and smGPR15, while retaining the ability to enter cells 
through smCCR5.  This finding is consistent with earlier results using human CXCR4, CCR8 and 
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CXCR6 in fusion assays and extends the breadth of coreceptor use to include sooty mangabey-






Figure 2.1.  Human and sooty mangabey 7-tramsmembrane receptors differ in extracellular 
domains.  Putative alternative coreceptors APJ, CCR2b, CCR3, CCR4, CCR8, CXCR4, CXCR6, 
GPR1 and GPR15 were cloned and sequenced from sooty mangabey (Sm) and predicted amino 
acid sequences were aligned to human (Hu) sequences from GenBank.  Alignments are shown 
between all human and sooty mangabey extracellular domains, including the N-terminal domain 
and extracellular loops. 
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Figure 2.2.  Two alleles of sooty mangabey CD4 support SIVsmm Env-mediated infection 
via CCR5 in vitro.  Target 293T cells were transfected with human CD4 (huCD4) or each of two 
sooty mangabey CD4 alleles (smCD4 2.1 and smCD4 4.3), with or without sooty mangabey 
CCR5 (smCCR5).  Cells were infected with luciferase-expressing pseudotype virions carrying 
Env glycoproteins from two subtype 1 SIVsmm-infected sooty mangabeys using equal amounts 
of each virus based on infectivity in U87/CD4/CCR5 cells (106 RLU of each virus).  SIVsmm FFv 
Env were derived from an infected animal with a CCR5wt/wt genotype (gray) and SIVsmm FNp Env 
were derived from an infected animal with a CCR5∆/∆ genotype (blue).  Virions lacking envelope 
glycoprotein served as negative controls (No Env, black).  Infection was measured by relative 

































Figure 2.3.  Sooty mangabey CXCR4 does not support SIVsmm Env pseudotype infection.  
Target 293T cells were transfected with empty plasmid (None), smCD4 alone, or smCD4 with 
smCCR5 or smCXCR4.  Both smCD4 alleles, (A) smCD4 2.1 and (B) smCD4 4.3, were used for 
transfections.  Target cells were infected with luciferase-expressing SIVsmm FFv (gray) and 
SIVsmm FNp (blue) Env pseudotype virions (5×105 RLU of each virus).  Infection was measured 
























































Figure 2.4.  Alternative coreceptors of sooty mangabey origin support SIVsmm Env 
pseudotype infection.  Target 293T cells were transfected (A) smCD4 2.1 or (B) smCD4 4.3.  
Cells were co-transfected with smCD4 alone (No CoR) or smCD4 with smAPJ, smCCR2b, 
smCCR3, smCCR4, smCCR5, smCCR8, smCXCR6, smGPR1 and smGPR15.  Cells were 
infected with pseudotypes carrying subtype 1 SIVsmm Env cloned from infected CCR5wt/wt (FFv, 
gray) and CCR5∆/∆  (FNp, blue) sooty mangabeys (5×105 RLU of each virus).  Infection was 























































































Figure 2.5.  Alternative coreceptor use by distinct subtypes of SIVsmm.  Target 293T cells 
were transfected with smCD4 4.3 in conjunction with sooty mangabey-derived 7-transmembrane 
receptors as described in Figure 2.4.  Cells were infected with pseudotyped virions (3.5×105 RLU 
of each virus) carrying Env from SIVsmm (A) subtype 2 (FWk), (B) subtype 3 (FBn and FDo), or 
(C) subtype 5 (FNg and FPm).  Infection was measured by relative light units in cell lysates 3 































































































































































































Figure 2.6.  SIVsmm Env from CD4-low sooty mangabeys use sooty mangabey CXCR4.  
Target 293T cells were transfected with or without smCD4 4.3, smCXCR4, and smCCR5 and pre-
treated with or without the CXCR4 antagonist AMD3100 (20µM).  Cells were infected with 
pseudotyped virions carrying No Env (black) or SIVsmm Envs from CD4-low sooty mangabeys 
FJv, FPy, and FTv.  Inocula were equilibrated on the basis of P24 Gag antigen content (2ng P24).  












































Figure 2.7.  SIVsmm Env from CD4-low sooty mangabeys use sooty mangabey alternative 
coreceptors.  Target 293T cells transfected with smCD4 4.3 in conjunction with sooty mangabey 
7-transmembrane receptors (smAPJ, smCCR2b, smCCR3, smCCR4, smCCR5, smCCR8, 
smCXCR4, smCXCR6, smGPR1, smGPR15) were treated with AMD3100 (20µM) to block 
endogenous CXCR4 and then infected with pseudotyped virions.   Pseudotypes carried SIVsmm 
Envs from CD4-low sooty mangabeys FJv , FPy, and FTv (red), or from one animal with typical 
clade 1 infection, FFv (black).  Inocula were equilibrated on the basis of P24 Gag antigen content 
(2ng P24).  Infection was measured by relative light units in cell lysates 3 days post-infection 

















































Table 2.1.  Relatedness of sooty mangabey and human 7TMRs.  
7TMR 
Percent overall amino acid 
identity toa 
Number of residues differing from 
human receptorb 
  Human Rhesus Macaque NTD ECL2 
APJ 98.7 99.7 0 1 
CCR2b 96.7 99.2 1 2 
CCR3 91.3 98.6 6 4 
CCR4 98.6 100.0 0 1 
CCR8 94.4 99.2 8 1 
CXCR4 98.3 99.4 3 2 
CXCR6 94.5 98.3 8 2 
GPR1 97.7 99.7 1 1 
GPR15 97.2 99.4 1 1 
a Alignment between predicted amino acid sequences of sooty mangabey molecules cloned 
herein and homologous human and rhesus macaque sequences from GenBank 
b Number of predicted amino acids differences between sooty mangabey and human molecules 
in the N-terminal domain (NTD) and extracellular loop 2 (ECL2), two regions most relevant to 






Natural SIVsmm infection of sooty mangabeys is typically non-pathogenic despite robust virus 
replication.  Key findings associated with the benign nature of this infection include the absence 
of chronic immune activation and a pattern of infected cells in vivo that shows relative sparing of 
CD4+ central memory T cells (Tcm) (51, 66).  While the relative sparing of sooty mangabey CD4+ 
Tcm from infection is associated with low CCR5 expression, previous studies from our group 
showed that a substantial minority of SIVsmm-infected sooty mangabeys possess CCR5-null 
genotypes (58), indicating that alternative entry coreceptors are used in vivo and will need to be 
defined in order to understand mechanisms underlying viral tropism and targeting in vivo.  In this 
study, we cloned multiple potential alternative coreceptors of sooty mangabey origin and found 
smCXCR6 was used consistently and very efficiently, with infection levels comparable to 
smCCR5, while smGPR15 use was also broad although somewhat less efficient.  Infection 
through smGPR1 and smAPJ was variable and typically low-level; smCXCR4, smCCR3 and 
smCCR8 were used only by SIVsmm from rare sooty mangabeys with profound CD4+ T cell loss 
that previously demonstrated expanded human coreceptor use.  
  
Robust use of the principal sooty mangabey alternative coreceptors CXCR6 and GPR15, along 
with CCR5, was a feature of all SIVsmm studied including pseudotypes from sooty mangabeys 
with CCR5 wild-type as well as CCR5-null genotypes.  While CCR5-null sooty mangabeys display 
high viremia indicative of efficient alternative coreceptor function in vivo (mean >104 copies/ml), a 
modest but significantly higher levels of viremia (~0.5 log difference) was seen in sooty 
mangabeys with CCR5 homozygous wild-type genotypes, and intermediate viral loads in 
heterozygous animals (58).  Those findings suggest that alternative pathways are exclusively 
responsible for SIVsmm replication in animals lacking CCR5, while both CCR5 and alternative 
coreceptors may be used in hosts where both CCR5 and other pathways are available.  It was 
not clear from the amino acid sequences of functional alternative coreceptors what specific 




The sooty mangabey model of SIV infection is of keen interest given the ability of natural hosts to 
avoid disease despite robust viral replication.  Although multiple mechanisms likely contribute to 
this resistance, including distinct immune activation patterns and CD4-negative T helper cell 
function (3, 9, 45, 66, 72), entry coreceptor use by immunodeficiency viruses defines viral target 
cell tropism and can be an important determinant of CD4+ T cell loss.  Acquisition of CXCR4 use 
by HIV-1 parallels rapid CD4+ T cell decline as HIV-1 gains the ability to infect CXCR4-expressing 
naïve T cells (6, 7, 35).  In SIVmac-infected rhesus macaques, depletion of CD4+ Tcm correlates 
with CD4+ T cell loss and disease progression, suggesting a critical role for Tcm in maintaining T 
cell homeostasis (37, 49, 54).  Natural hosts of SIV, including sooty mangabeys, display low 
CCR5 expression on CD4+ T cells relative to non-natural hosts (52, 53, 65, 70, 71).  CCR5 is 
especially restricted on CD4+ Tcm of sooty mangabeys compared with rhesus macaques ex vivo 
and following in vitro stimulation (51).  Tcm of sooty mangabeys are also relatively resistant to SIV 
infection in vitro compared with rhesus macaques, and harbor lower levels of viral DNA in vivo 
(51).  Thus, restricted coreceptor expression may protect critical cells from infection and preserve 
memory CD4+ T cell homeostasis in natural hosts. 
   
Overall levels of viremia in sooty mangabeys are equivalent to or exceed those in rhesus 
macaques (66), indicating no lack of susceptible target cells in sooty mangabeys despite limited 
CCR5 expression.  Therefore, combined with protection of critical target cells mediated by 
restricted CCR5 expression, alternative coreceptors may define populations of more dispensable 
target cells capable of supporting SIV replication in natural hosts without disruption of T cell 
homeostasis.   
 
In human and mouse cells, CXCR6 is found on subsets of CD4+ TH1, TH17 and TREG 
memory/effector cells, as well as NKT cells, but is generally not co-expressed with naïve or 
central memory markers such as CD45RA, CCR7 or L-selectin (28, 34, 41, 63, 69).  If patterns 
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are similar in SIV natural hosts, the exclusion of CXCR6 from less differentiated and self-
renewing naïve or Tcm cells would be consistent with shifting of viral targets away from subsets 
critical for T cell homeostasis into potentially more expendable cell targets.  While GPR15 is 
expressed in human blood CD4+ T cells and in lymphoid tissues (18, 21, 23, 32, 40), its 
distribution on specific subsets has not been defined.  CXCR6 and GPR15 are also both 
expressed in human intestinal tissue (18, 40), which is an important site for viral replication.   
Antibodies to define surface expression of both sooty mangabey molecules are not presently 
available, but we found smCXCR6 and smGPR15 RNA transcripts in sooty mangabey CD4+ T 
cells (unpublished, data not shown) (57).  Thus, it is important to define the patterns of expression 
for these receptors by sooty mangabey CD4+ cell subsets, and their coreceptor function under 
physiological expression conditions in primary cells responsible for replication in vivo.  
 
Coreceptors other than CCR5 and CXCR4 were not thought to be important in human infection 
with HIV-1.  However, a recent report described a transmitter/founder virus from an acutely 
infected person that was impaired in its ability to use CCR5 and CXCR4 but entered efficiently 
through GPR15 (32).  It remains to be determined if alternative coreceptors including CXCR6 or 
GPR15 may also play a role in HIV-1 pathogenesis in rare situations, or more broadly in as-yet 
unrecognized ways.   
 
While the majority of infected sooty mangabeys show neither CD4 loss nor disease, a small 
number of previously-reported animals had extensive CD4+ T cell depletion, which was 
associated with expanded SIVsmm use of human coreceptors including huCXCR4, huCXCR6 
and huCCR8 (46).  We now confirm expanded tropism by Envs from these animals for sooty 
mangabey-derived coreceptor molecules, and identify smCCR3, smGPR1, smGPR15 and 
smAPJ utilization as well.   Acquisition of CXCR4-mediated tropism for naïve CD4+ T cells is 
strongly linked to accelerated CD4+ T cell loss in HIV-infected humans, so it is uncertain if the 
additional coreceptors used by these CXCR4-tropic SIVsmm Envs contribute further to disrupted 
67	  
	  
CD4+ T cell homeostasis.  Unfortunately, we did not have enough Env sequences from either 
CD4-low- or typically-infected sooty mangabeys to form a strong alignment and identify which 
region(s) of gp120 might support this expanded tropism.  We did not see distinct alternative 
coreceptor use or smCXCR4-mediated infection by pseudotypes derived from sooty mangabeys 
naturally infected with subtype 5 SIVsmm, which display more moderate levels of CD4+ T cell loss 
(1).  Thus, CD4+ T cell loss in subtype 5 SIVsmm-infected sooty mangabeys is likely due to 
factors other than expanded tropism by the virus, at least for the coreceptors tested here. 
 
Notably, SIV-infected sooty mangabeys that display widespread CD4+ T cell loss do not progress 
to AIDS (45).  Additionally, uninfected natural host African green monkey T cells were found to 
down-regulate CD4 cell surface expression when entering the memory pool such that African 
green monkeys express a low fraction of CD4+ T cells relative to CD8+ T cells (3, 47, 48).  
Although we hypothesize that typical SIV alternative coreceptor use may protect natural hosts 
from CD4+ T cell loss, it is clear that CD4 loss does not necessarily lead to disease progression.  
Double-negative CD4-CD8- T cells may account for the lack of disease progression in natural 
hosts.  A higher proportion of double-negative T cells are found in uninfected natural host sooty 
mangabeys and African green monkeys relative to uninfected non-natural host rhesus macaques 
(33, 72).  Furthermore, double-negative CD4-CD8- T cells in the blood, lymph nodes, and rectal 
mucosa of sooty mangabeys have effector T cell-like functions (68), and CD4- T cells from African 
green monkeys maintain functions normally attributed to CD4+ T cells (3). Natural host double-
negative cells may be also be protected from bystander killing post-infection as apoptosis occurs 
in fewer double-negative sooty mangabey T cells than double-negative rhesus macaque T cells 
following SIV infection (44).  It is critical to define not only mechanisms leading to CD4+ T cell loss 





Multiple complex and non-exclusive mechanisms are likely involved in protecting sooty 
mangabeys and other natural hosts both from CD4+ T cell loss, as well as from disease in the few 
animals where CD4+ T cell depletion does occur (3, 8, 9, 45, 51, 66, 67, 72).  Thus, both the 
target cells spared from infection and those supporting replication are critical to understanding the 
nature of infection and pathogenesis (29).  Future studies are needed to define CXCR6 and 
GPR15 coreceptor expression patterns on sooty mangabey CD4+ cell subsets, the relationship 
between alternative coreceptor and CCR5 expression, and how alternative coreceptors are 
regulated.  Finally, comparing coreceptor expression patterns between natural and non-natural 
host species may identify more expendable populations of CD4+ cells in the natural host that are 
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Viruses from the SIVsmm/SIVmac lineage generally exhibit robust CD4-dependent infection 
through coreceptor CCR5 and alternative coreceptor CXCR6 expressed on transfected cells in 
vitro.  Other alternative coreceptors also support SIVsmm/SIVmac infection in vitro.  The role of 
CCR5 and alternative coreceptors in SIVsmm/SIVmac infection of primary cells is largely 
undefined.  To later identify if CCR5, CXCR6, or other coreceptors support SIV infection and 
replication in primary sooty mangabey PBMCs and rhesus macaque PBMCs ex vivo, we first 
developed methods to specifically inhibit CCR5-mediated and CXCR6-mediated SIV infection.  
Small-molecule CCR5 antagonists, including Maraviroc, blocked infection via sooty mangabey 
CCR5 (smCCR5) and inhibited the majority of, but not all, infection via rhesus macaque CCR5 
(rmCCR5) in vitro.  There are no known small-molecule inhibitors of CXCR6.  We discovered that 
recombinant human CXCL16, a ligand of CXCR6, attenuated sooty smCXCR6-mediated SIV 
infection at low levels of sooty mangabey CXCR6 expression in vitro.  Neither Maraviroc nor 
CXCL16 had appreciable direct off-target effects on infection mediated by non-ligand 
coreceptors, indicating that Maraviroc and CXCL16 can be used to specifically antagonize CCR5-





Our lab previously demonstrated that natural host sooty mangabey SIVsmm infection and 
replication occur in the absence of functional CCR5, indicating that alternative coreceptors 
support SIVsmm infection and replication in vivo (28).  Furthermore, we defined the genetic and 
functional nature of sooty mangabey coreceptors of SIVsmm in vitro (5) (Chapter 2).  SIVsmm 
Envelopes (Env) cloned from SIVsmm-infected sooty mangabeys display robust use of sooty 
mangabey CCR5 (smCCR5) and sooty mangabey CXCR6 (smCXCR6), as well as moderate to 
low use of smGPR15 and smGPR1 in vitro.  Closely related SIVmac Env derived from pathogenic 
infections of rhesus macaques display a similar pattern of alternative coreceptor use and have 
been found to use rhesus macaque CCR5 (rmCCR5) and rhesus macaque GPR15 (rmGPR15), 
but not rhesus macaque CXCR6 in vitro (15, 27, 45) (also see Chapter 4).  Here, we define 
methods to inhibit SIV infection mediated by the robust alternative coreceptor CCR5 cloned from 
both sooty mangabeys and rhesus macaques, as well as the robust alternative coreceptor 
CXCR6 cloned from sooty mangabeys.   
 
Small-molecule CCR5 antagonists allosterically block HIV-1 infection by binding within the 
transmembrane cavity of human CCR5 and modifying the conformation of extracellular loop 2 
(ECL2), disrupting interactions between the human CCR5 and HIV-1 Env (9, 18, 35).  Each small-
molecule CCR5 antagonist displays unique signaling properties and stabilizes unique 
confirmations of CCR5 (8).  Therefore, we examined which CCR5 antagonists specifically block 
smCCR5- and rmCCR5-mediated SIV infection.  We primarily used Maraviroc, a CCR5 
antagonist clinically approved for the treatment of HIV-1 (4).  We also investigated AD101 (37), 
Aplaviroc (3, 18), CMPD167 (6), and Vicriviroc (33).   
 
Identifying an inhibitor of smCXCR6-mediated infection was more challenging, as there is no 
commercially available small-molecule inhibitor of CXCR6.  Prior studies found that high 
concentrations of CCR5 chemokines RANTES, MIP-1α, and MIP-1β block CCR5-mediated HIV 
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and SIV infection (2).  CXCL16 is a natural chemokine ligand of CXCR6 produced in membrane-
bound and soluble forms in vivo by antigen presenting dendritic cells, monocytes, macrophages, 
and NKT cells (10, 23).  Given the ability of CCR5 ligands to inhibit CCR5-mediated infection, we 
investigated the ability of recombinant human chemokine CXCL16 to block SIV infection 
mediated by smCXCR6.  
 
Notably, SIV infection of natural host sooty mangabeys is non-pathogenic, whereas SIV infection 
of non-natural host rhesus macaques results in rapid progression to AIDS.  Ultimately, we are 
interested in defining the coreceptor use patterns of viruses from both sooty mangabeys and 
rhesus macaques in primary cells.  Therefore, in this this study, we examined the ability of small-
molecule CCR5 antagonists and recombinant human CXCL16 to inhibit entry of SIVsmm from 
naturally infected sooty mangabeys as well as rhesus macaque SIV from the same viral lineage: 
SIVmac 251, SIVmac 239, and SIVsmm E660.  Note that, despite the confounding nomenclature, 
SIVsmm E660 is a rhesus macaque SIV and should not be confused with sooty mangabey 
SIVsmm.  SIVmac 251, SIVmac 239, and SIVsmm E660 are experimental challenge viruses used 
to induce pathogenesis in rhesus macaques.  SIVmac 239/251 and SIVsmm E660 were derived 
by separate experimental cross-species transmissions of SIVsmm from sooty mangabeys into 
rhesus macaques (12) (see Chapter 1, Figure 1.8) and these viruses represent diverse 
pathogenic strains of SIV in rhesus macaques. 
 
We found that small-molecule CCR5 antagonists completely blocked SIV infection via smCCR5.  
These compounds also blocked the majority of, but not all, rmCCR5-mediated SIV infection at 
tolerable concentrations in vitro.  Maraviroc had no appreciable off-target effects on CXCR6- and 
GPR15-mediated SIV infection.  Recombinant human chemokine CXCL16 was a specific and 
significant inhibitor of smCXCR6-mediated SIV infection at low levels of smCXCR6 expression in 
vitro; chemokine CXCL16 blocked the majority of, but not all, SIV infection through smCXCR6. 
Ultimately, these methods to specifically and effectively inhibit CCR5- and CXCR6-mediated SIV 
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infection can be used to define the relative role of CCR5, CXCR6 and other alternative 




CCR5 Antagonists and CXCL16 
Maraviroc (Selzentry, Celsentri) was obtained through the NIH AIDS Reagent Program, Division 
of AIDS, NIAID (Cat #11580) and suspended at 20mg/mL in dimethyl sulfoxide (DMSO).  AD101 
was a gift from J. Strizki (Merck & Co.) and was suspended in DMSO.  AD101 compound was 
verified by liquid chromatography mass spectrometry (LC-MS/MS) in collaboration with R. Kohli at 
the University of Pennsylvania Department of Chemistry Mass Spectrometry Facility.  Aplaviroc, 
CMPD167, and Vicriviroc (Merck & Co.) were a gift from Z. Parker in the laboratory of R. Doms 
(University of Pennsylvania).  Lyophilized recombinant human CXCL16 (R&D Systems #976-CX-
025) was re-suspended at 25µg/mL in phosphate buffered saline and used within 2 days with ≤1 
freeze/thaw cycle. 
 
Viruses and Viral Env Pseudotypes 
SIVsmm FFv 5.1 Env was provided by C. Derdeyn (Emory University) and was cloned from a 
SIVsmm Clade 1infected sooty mangabey with a CCR5wt/wt genotype using single genome 
amplification (SGA) (5, 17, 28, 30).  SIVmac 239 Env was cloned from the full-length provirus 
SIVmac 239 and was a gift from A. Swanstrom in the laboratory of J. Hoxie (University of 
Pennsylvania).  SIVmac 251 Env RZu4-1.1 Day 11 was cloned by C. Derdeyn by SGA from a 
control (non-CD4-depleted) rhesus macaque infected with SIVmac 251 as previously described 
(7).  SIVsmm E660 CP3C-P-A8 and SIVsmm E660 CR54-PK-2A5 Env were cloned by SGA from 
SIVsmm E660 infected rhesus macaques and were a gift from K. Barr, M. Lopker, and G. Shaw 
(University of Pennsylvania) (13, 29).  HIV-1 JR-FL Env was cloned previously from the CCR5-
tropic proviral clone. Proviral infectious molecular clone (IMC) SIVsab 92018ivTF was provided by 
F. Bibollet-Ruche and B. Hahn (University of Pennsylvania) (11).  Sabaeus African Green 
Monkey SIVsab 92018ivTF Env was cloned from this IMC using nested primers designed by 




GAG-CAC-WC-3’); Env SIVsabA-Fwd (5’-CAC-CCC-SCT-CCA-GGC-CTG-TRN-CAA-TA-3’), 
SIVsabB-Rev (5’-CCA-RCC-ATC-SAC-WAT-DCC-CC-3’).  The SIVsab 92018ivTF Env PCR 
product was TA cloned into pcDNA3.1 using a directional TOPO expression kit (Invitrogen).  Env 
pseudotypes were generated by co-transfecting SIV Env plasmids and pNL-Luc-E-R+ into human 
embryonic kidney 293T cells as previously described (5) (Chapter 2).  Vesicular stomatitis virus 
glycoprotein (VSV-G) Env served as a positive control for CD4- and coreceptor-independent 
infection; No Env empty-pcDNA3.1 pseudotyped virions served as negative controls.   
 
Pseudotype Infections 
Infections were performed as described previously (5) (Chapter 2).  Target 293T cells cultured in 
DMEM + 10% FBS + 1% Penicillin-Streptomycin + 1% L-Glutamine were transfected with 1µg 
CD4 and coreceptor using Fugene (Promega).  For Maraviroc titrations, 293T cells were 
transfected with 1µg CD4 and 1µg CCR5 cloned from humans, rhesus macaques, and sooty 
mangabeys.  Cells were washed 24 hours later and re-plated 2×105 cells per well in a 96 well 
plate.  The next day, media was removed and replaced one hour pre-infection with 100µL media 
containing 1.5× vehicle DMSO or Maraviroc 0.1nM, 1nM, 10nM, 100nM, 1µM, 10µM, 100µM, 
1mM.  DNAse-treated Env pseudotype viruses were added 50uL/well for a final volume of 150µL 
and a final concentration of Maraviroc indicated.  Cells were spin-inoculated and luciferase output 
was measured 72 hours post-infection in relative light units (RLU).  Luciferase production in 
vehicle-treated controls was normalized to 100%.  Best-fit sigmoidal curves and EC50 were 
calculated using GraphPad PRISM software (San Diego, CA, USA).  For smCXCR6 transfections 
using lesser amounts of coreceptor plasmid DNA, cells were transfected with 1µg smCD4 plus 
1µg total of smCXCR6 plus empty pcDNA3.1 vector.  Cells transfected with CD4 and 1µg empty 
pcDNA3.1, and cells transfected with 2µg empty pcDNA3.1 served as negative controls.  Cells 
were washed and re-plated as before.  The following day, media was removed and replaced one 
hour pre-infection with 100µL media containing 1.5× CCR5 antagonist, 1.5× CXCL16 with vehicle 
DMSO, or 1.5× vehicle DMSO alone.  DNAse-treated pseudotyped viruses were added 50uL/well 
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for a final volume of 150µL and a final concentration of 10µM Maraviroc, 10µM AD101, 1µM 
Aplaviroc, 6.7µM CMPD167, 10µM Vicriviroc, or 500ng/mL CXCL16 in a final concentration of 




Human PBMCs were isolated by apheresis by the Penn Human Immunology Core.  PBMCs were 
rested for one day and then stimulated 3 days with 10µg/mL Phytohaemagglutinin (PHA) and 
30Unit/mL Interleukin-2 (IL-2) in RPMI + 10% FBS + 1% Penicillin-Streptomycin + 1% L-
Glutamine.  Media was replaced one hour pre-infection with 10µg/mL IL-2 and 10µM Maraviroc or 
other CCR5 antagonist as indicated, 500ng/mL CXCL16 with DMSO, or the corresponding 
volume of vehicle DMSO alone (0.026%).  Approximately 1.5×106 PBMCs in 1mL media were 
plated to 24-well plates. 5ng P24 Gag HIV-1 were added in a total of 100µL per well.  Virus was 
spin-inoculated 2 hours at 1200×g and 25°C.  One day later, cells were washed and re-plated in 
1mL IL-2 media plus drug/chemokine (Day 0).  50µL supernatant was collected periodically for 
P24 Gag ELISA (Perkin-Elmer) performed by S. Bryan and F. Shaheen in the Penn Center for 
AIDS Research (CFAR) Virology Core.   
 
qPCR 
Infections for qPCR were performed in parallel with those for P24 Gag readouts.  Cells were 
washed, lysed in DNA lysis buffer (100mM KCl, 0.1% NP-40, 20mM Tris [pH 8.4], 0.5 mg of 
proteinase K per ml), incubated at 55°C for 2 h, and boiled for 15 min as previously described 
(44).  Primer and probe sets were designed by the Penn CFAR Virology Core to HIV-1 long 
terminal repeat (LTR) strong-stop (forward primer, 5′-GCT AGC TAG GAA ACC CAC TGC TTA-
3′; reverse primer, 5′-GCT AGA GAT TTT CCA CAC TGA CT-3′; probe, FAM-5′-GCG AGT CAC 
ACA ACA GAC GGG CAC ACA CTA CTC GC-3′-DABCYL), Gag as previously described (44), 
and the cellular GAPDH gene (forward primer, 5′-GGT GGT CTC CTC TGA CTT CAA CA-3′; 
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reverse primer, 5′-CCA GCC ACA TAC CAG GAA ATG-3′; probe, FAM-5′-CGC AGC CTG GCA 
TTG CCC TCA ACG ACC ACG CTG CG-3′-DABCYL). PCR was performed on an ABI 7700 real-
time PCR detection system with an initial incubation at 95°C for 10 min followed by 40 cycles of 
95°C for 15 sec and 60°C for 1 min. For quantification, DNA from serial dilutions of ACH2 cells 
over the range of 101 to 105 was amplified in parallel. Data were analyzed using 7000 SDS 
Software (Applied Biosystems). 
 
Flow Cytometry 
For Maraviroc toxicity analysis, human PBMCs were stimulated for 3 days with PHA and IL-2 as 
above.  Media was replaced with IL-2 and cells were plated 1×106 per well in a 6 well plate for 3 
days of treatment with media alone, 100µM Maraviroc, 1mM Maraviroc, or the corresponding 
amounts of vehicle 0.26% DMSO, 2.6% DMSO.  Cells were stained using Aqua LIVE/DEAD 
Fixable Dead Cell Stain Kit (Life Technologies #L34957) and analyzed using a BD LSR flow 
cytometer.  For coreceptor expression analyses, human CD4+ T cells were selectively purified 
following CD14, CD11b, CD16, HLA-DR, CD21 depletion by the Penn Human Immunology Core, 
and stimulated 3 days with PHA and IL-2.  Where noted, media was replaced with IL-2 and 10µM 
Maraviroc, 500ng/mL CXCL16 with DMSO, or DMSO alone for 24 hours.  293T cells were 
transfected with 2µg total plasmid, washed, and read 48 hours post-transfection.  Cells were 
independently stained with antibodies mouse αCCR5 (CD195) 3A9 PE (BD Biosciences), mouse 
αCXCR6 TG3 Alexa Fluor 647 (BioLegend), αCXCR4 (CD184) 12G5 PE (BD Biosciences), 
isotype mouse IgG2a PE, isotype mouse IgG2bκ Alexa Fluor 647.  Cells were imaged using a BD 
FACSCalibur flow cytometer.  Flow cytometry analyses were performed using FlowJo software. 
 
Data Analyses 
Sigmoidal dose response curves were fitted to Maraviroc titration data and statistical analyses of 
EC50 were performed using GraphPad PRISM 6 software (La Jolla, CA, USA).  All statistical 
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comparisons were made by a two-tailed unpaired t-Test with Welch’s correction unless otherwise 
indicated.  Significance was defined as p<0.05. 
 
Ethics statement 
All animal experimentation was conducted following guidelines established by the Animal Welfare 
Act and the NIH for housing and care of laboratory animals and performed in accordance with 
Institutional regulations after review and approval by the Institutional Animal Care and Use 
Committees (IACUC) at the Yerkes National Primate Research Center (YNPRC) and the Tulane 
National Primate Research Center (TNPRC).  Studies were also reviewed and approved by the 






Small-molecule CCR5 antagonists fully block smCCR5- but not rmCCR5-mediated SIV 
pseudotype infection in vitro  
 To address the CCR5-dependence of SIV in nonhuman primate PBMCs, we developed a 
method to inhibit sooty mangabey smCCR5- and rhesus macaque rmCCR5-mediated viral entry.  
We initially tested the CCR5 antagonist Maraviroc, a clinically approved small-molecule 
compound that has been used extensively to block HIV-1 infection in humans.  A prior study 
found that Maraviroc only blocks 80% of SIVmac 239 replication in rhesus macaque peripheral 
blood mononuclear cells (PBMCs) (21) whereas multiple pharmacological studies have found that 
Maraviroc completely blocks CCR5-tropic HIV-1 in human PBMCs (4).  Therefore, we 
hypothesized that Maraviroc may differ in its ability to antagonize CCR5 from different primate 
species. 
 
To determine the species-specific properties of Maraviroc inhibition, we determined the 
concentration of Maraviroc that blocks SIV Env pseudotype infection of 293T cells expressing 
CD4 and CCR5 from humans, rhesus macaques, or sooty mangabeys.  Target 293T cells were 
transfected with human huCD4 and huCCR5, rhesus macaque rmCD4 and rmCCR5, or sooty 
mangabey smCD4 and smCCR5.  The majority of published studies have used 10µM or 15µM 
Maraviroc to block HIV and SIV infection in vitro.  In this experiment, cells were pre-treated with 
vehicle or concentrations of Maraviroc ranging from 100pM to 1mM.  Cells were infected with 
HIV-1 and SIV Env pseudotypes of pNL-Luc-E-R+, a viral backbone that lacks Env and expresses 
luciferase in place of Nef.  Infection was measured by luciferase production in relative light units 
(RLU) and data were normalized to 100% luciferase output in CD4- plus CCR5-transfected cells 





Maraviroc completely blocked CCR5-tropic HIV-1 JR-FL Env-mediated infection via huCCR5 at 
concentrations equal to or above 10µM (Figure 3.1A, 10µM corresponds to 104nM on the 
abscissa x-axis).  Maraviroc 10µM also inhibited almost all SIV Env-mediated infection via 
huCCR5 (Figure 3.1B).  Maraviroc was exceedingly effective in blocking smCCR5-mediated SIV 
pseudotype infection; 1µM Maraviroc inhibited nearly all smCCR5-mediated infection in vitro 
(Figure 3.1C).  By contrast, Maraviroc was a relatively poor inhibitor of rmCCR5-medaited 
infection and did not completely block SIV pseudotype infection via rmCCR5 at concentrations 
below 100µM (Figure 3.1D).  Between 16% and 27% (mean 21 ± 4.9% standard deviation SD) of 
rmCCR5-mediated SIV pseudotype infection remained in the presence of 10µM Maraviroc, which 
was significantly higher than the percentage of smCCR5-mediated SIV pseudotype infection 
(mean 3 ± 2.7% SD) in the presence of 10µM Maraviroc (p<0.0005).  CCR5 antagonist Maraviroc 
is a poor inhibitor of rmCCR5-mediated SIV pseudotype infection in vitro relative to huCCR5- and 
smCCR5-mediated infection. 
 
The ability of Maraviroc to inhibit SIV infection was primarily host-CCR5 dependent as there was 
little variation between viral Env at inhibitory concentrations of Maraviroc (Table 3.1).  The SIV 
log10EC50 concentrations were not significantly different between Env pseudotypes in huCD4 plus 
huCCR5 (p=0.75, NS) or rmCD4 plus rmCCR5 (p=0.95, NS) transfected cells based on the 
sigmoidal best fit.  The SIV log10EC50 were significantly different between Env pseudotypes in 
cells transfected with smCD4 plus smCCR5 (p=0.012), indicating that there may be some viral 
Env-specific Maraviroc blocking in transfected cells expressing sooty mangabey receptors.  
However, 10µM Maraviroc equally and fully blocked all SIV Env pseudotypes in smCD4- plus 
smCCR5-transfected cells regardless of variation between EC50 values. 
 
Our data suggested that Maraviroc concentrations at or above 100µM block rmCCR5-mediated 
SIV infection in vitro.  However, 100µM Maraviroc demonstrated off-target and likely toxic effects 
on coreceptor-independent VSV-G pseudotype positive control infections in 293T cells (data not 
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shown).  Concentrations of Maraviroc above 100µM that appear to block SIV infection may 
actually induce target 293T cell death.  Because we ultimately planned to use Maraviroc to block 
SIV infection in PBMCs, we measured the toxicity of 100µM and 1mM Maraviroc in readily 
available human PBMCs.  Human PBMCs were stimulated with PHA and IL-2 and treated three 
days with 100µM or 1mM Maraviroc, or the corresponding amounts of 0.26% or 2.6% vehicle, 
DMSO.  PBMCs were stained with Aqua Live/Dead stain, a reactive dye that permeates 
membranes of necrotic cells and reacts with free amines in the cytoplasm, resulting in intense 
fluorescent staining of dead cells.  Stained cells were analyzed by flow cytometry. 
 
At the lower 100µM concentration, neither Maraviroc nor the comparable amount of vehicle had a 
large effect on the percentage of Aqua-negative live cells relative to untreated controls and 
roughly 90% of cells remained intact (Figure 3.2).  Higher concentrations of vehicle induced a 
modest 15% drop in the percentage of live cells relative to untreated controls.  A high 
concentration of the Maraviroc compound itself caused a precipitous drop in the percentage of 
live cells.  1mM Maraviroc also caused visible changes in the number of intact cells (data not 
shown).  These findings caution that concentrations of Maraviroc above 100µM that appear block 
SIV in vitro likely induce widespread cell death.  In full abundance of caution because we had 
seen off-target effects of 100µM Maraviroc on VSV-G Env-mediated infection in 293T cells, we 
opted to use the standard 10µM concentration of Maraviroc for future experiments. 
 
We next determined if other small-molecule CCR5 antagonists block smCCR5- and rmCCR5-
mediated SIV infection.  Specifically, we searched for a small molecule inhibitor that, unlike 
Maraviroc, could fully block SIV infection via rmCCR5.  Target 293T cells were transfected with 
rmCD4 and rmCCR5, or smCD4 and smCCR5.  We pre-treated cells with CCR5 antagonists at 
concentrations historically used to block HIV-1 infection in vitro: AD101 10µM, Aplaviroc 1µM, 
CMPD167 6.7µM, and Vicriviroc 10µM.  Cells were infected with SIV Env pseudotypes of pNL-
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Luc-E-R+ and luciferase output was expressed as the percentage of luciferase expression in 
antagonist-treated cells relative to vehicle-treated controls. 
 
All CCR5 antagonists we examined failed to completely block rmCCR5-mediated SIV pseudotype 
infection (Figure 3.3A), while the majority of CCR5 antagonists efficiently blocked smCCR5-
mediated SIV pseudotype infection (Figure 3.3B) in vitro.  This finding was particularly surprising 
given that AD101 was previously shown to block SIVmac 251 replication in rhesus macaque 
PBMCs (1).  Inhibition of rmCCR5-mediated SIVmac 239 and SIVmac 251 infection ranged from 
only 52% (Vicriviroc) to 85% (AD101).  CMPD167 was a notably poor inhibitor of SIV infection 
through smCCR5. TAK779 also failed to completely block rmCCR5-mediated SIV infection in vitro 
(data not shown).  None of the small-molecule CCR5 antagonists exhibited clearly superior 
rmCCR5 antagonism relative to Maraviroc.  Rhesus macaque rmCCR5-mediated SIV pseudotype 
infection was not fully inhibited by small-molecule CCR5 antagonists. 
 
Maraviroc lacks direct off-target effects on CXCR6- or GPR15-mediated infection 
To verify the coreceptor specificity of Maraviroc, we determined if Maraviroc showed 
direct off-target effects on infection mediated by alternative coreceptors CXCR6 and GPR15 in 
vitro.  Target 293T cells expressing sooty mangabey CD4 and coreceptors, or rhesus macaque 
CD4 and coreceptors, were pre-treated with vehicle or 10µM Maraviroc.  Cells were infected with 
SIV pNL-Luc-E-R+ Env pseudotypes and infection was measured by luciferase output three days 
post-infection. 
 
As we had observed previously, Maraviroc blocked SIV Env-mediated infection through smCCR5 
and the majority of, but not all, infection through rmCCR5 (Figure 3.4).  All SIVsmm and SIVmac 
Env pseudotypes infected target cells via smCCR5, smCXCR6, and smGPR15 (Figure 3.4A).  
These SIV pseudotypes also infected cells expressing rmCCR5 and rmGPR15 whereas 
rmCXCR6 was a weak alternative coreceptor of SIV (discussed further in Chapter 4) (Figure 
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3.4B).  Importantly, with all but one of the SIV Env pseudotypes, Maraviroc did not cause a 
significant decrease in either CXCR6- or GPR15-mediated pseudotype infection relative to 
vehicle-treated controls.   
 
To determine if Maraviroc had broad off-target effects on cells or post-entry infection steps, we 
examined the effect of Maraviroc on infection by a positive control VSV-G Env, which mediates 
infection of 293T cells independent of both CD4 and coreceptor.  Maraviroc induced a slight 
decrease in VSV-G Env-mediated infection in 293T cells relative to vehicle-treated controls, but 
the difference did not reach significance (p=0.069, NS) (Figure 3.4C).  The trend toward 
significance may indicate the toxic effects of Maraviroc we had observed earlier with high 
concentrations in human PBMCs.  Therefore, again, we opted to use the published concentration 
of Maraviroc, 10µM, in future experiments.  We concluded that Maraviroc was a specific inhibitor 
of CCR5-mediated infection and had no marked off target effects on infection mediated by 
alternative coreceptors CXCR6 or GPR15 in vitro. 
 
Chemokine CXCL16 attenuates SIV pseudotype infection at low levels of smCXCR6 
expression in vitro 
 We designed a method to block infection mediated by smCXCR6, the most robust 
alternative coreceptor of sooty mangabey SIVsmm in vitro (5).  Because there are no available 
small-molecule CXCR6 antagonists, we determined if recombinant human chemokine CXCL16 
inhibits smCXCR6-mediated SIV Env pseudotype infection in vitro.  Prior experiments found that 
CXCL16 blocked very little smCXCR6-mediated SIV pseudotype infection in 293T cells 
(unpublished, data not shown).  The alternative coreceptor smCXCR6 was likely expressed at 
very high levels in these transfected cells.  Therefore, we titrated the expression of smCXCR6 in 
293T cells by transfecting these cells with decreasing amounts of smCXCR6 plasmid to see if 
there was a limit where SIV Env pseudotypes exhibited robust infection and where chemokine 
CXCL16 significantly blocked that infection.  Target 293T cells were transfected with 1µg of 
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smCD4 plasmid and smCXCR6 plasmid ranging from 1µg down to 0.01µg (10ng).  Cells were 
pre-treated one hour with 500ng/mL recombinant human CXCL16 and infected with pNL-Luc-E-
R+ Env pseudotypes of SIVsmm FFv and SIVsab 92018ivTF, a virus cloned from natural host 
Sabaeus African Green Monkeys that also uses alternative coreceptor CXCR6 (11). 
 
The inhibitory effects of CXCL16 were moderate and did not vary between 1µg and 0.1µg of 
transfected smCXCR6 plasmid DNA (Figure 3.5A).  At high levels of transfected smCXCR6 
plasmid DNA and consequent high levels of smCXCR6 expression, CXCL16 blocked only 55% to 
65% of smCXCR6-mediated SIV pseudotype infection.  Importantly, when we transfected 293T 
cells with only 0.01µg of smCXCR6 plasmid DNA, SIV pseudotype infection remained robust and 
CXCL16 blocked 85% to 90% of smCXCR6-mediated SIV infection.  Thus, CXCL16 attenuates 
smCXCR6-mediated SIV Env pseudotype infection best when smCXCR6 is expressed at low 
levels in 293T cells.  Chemokine CXCL16 was not a complete inhibitor of smCXCR6-mediated 
pseudotype infection in vitro.  A small amount of SIVsmm FFv and SIVsab 92018ivTF Env-
mediated infection remained even in CXCL16-treated cells transfected with 0.01µg of smCXCR6 
(Figure 3.5B); luciferase expression in CXCL16-treated cells transfected with 0.01µg of 
smCXCR6 was significantly above that in cells lacking a coreceptor (p<0.002) and above that in 
cells infected with a pseudotype negative control virus lacking Env (p<0.003). 
 
Given recombinant human CXCL16 is an effective inhibitor of smCXCR6-mediated SIV infection 
only at low levels (0.01µg plasmid DNA) of smCXCR6 transfection in vitro, we compared CXCR6 
expression in transfected 293T cells to more physiologically relevant expression in cultured CD4+ 
T cells.  We discovered that none of the commercially available flow cytometry-compatible 
antibodies to human CXCR6 (huCXCR6) bind nonhuman primate smCXCR6 (data not shown).  
Therefore, we performed this experiment using huCXCR6 plasmid DNA and human CD4+ T cells.  
293T cells were transfected with huCXCR6 plasmid DNA from 1µg down to 0.001µg (1ng).  In 
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parallel, CD4+ T cells were purified from human PBMCs and stimulated with PHA and IL-2.  Cells 
were stained with anti-human CXCR6 antibody and expression was analyzed by flow cytometry. 
 
Fewer than 2% of stimulated human CD4+ T cells expressed huCXCR6 and huCXCR6 was not 
detected in resting CD4+ T cells (Figure 3.6).  Notably, 293T cells transfected with 0.01µg of 
huCXCR6 had a frequency of CXCR6 positive cells (1.2%) below the frequency of expression on 
peripheral CD4+ T cells.  We did not directly compare median fluorescence intensity between 
groups because of the large cell size differential between 293T cells and CD4+ T cells.  Based 
roughly upon the frequency of target cells expressing CXCR6, it is conceivable that CXCL16 may 
inhibit a significant amount of CXCR6-mediated SIV infection in primary PBMCs.  
 
Chemokine CXCL16 lacks direct off-target effects on CCR5- or GPR15-mediated infection 
 Before using CXCL16 to block CXCR6-mediated SIV infection in primary cells, we 
ensured that CXCL16 had not direct off-target effects on infection mediated by coreceptors other 
than CXCR6.  To determine if CXCL16 has any direct off-target effects on SIV infection mediated 
by other CCR5 and GPR15 in vitro, target 293T cells were transfected with smCD4 and 0.01µg of 
smCCR5, smCXCR6, or smGPR15 plasmid DNA.  Cells were pre-treated with recombinant 
human CXCL16 and infected with pNL-Luc-E-R+ SIV Env pseudotypes.  Luciferase expression 
was measured three days post-infection. 
 
Once again, we observed that recombinant human CXCL16 blocks over 80% of CXCR6-
mediated SIV Env pseudotype infection relative to untreated controls at low levels of smCXCR6 
expression.  Crucially, CXCL16 had no significant effect on smCCR5-mediated or smGPR15-
mediated SIV infection in vitro (Figure 3.7A).  Chemokine CXCL16 also had no significant effect 
on VSV-G Env pseudotype infection (p=0.93, NS) (Figure 3.7B), indicating that the chemokine 




Chemokine CXCL16 is an effector chemokine found at sites of inflammation and could potentially 
drive activation of T cells or enhance PBMC permissively to infection.  Therefore, we further 
investigated the effects of chemokine CXCL16 on CCR5-tropic and CXCR4-tropic HIV-1 infection 
and replication in human PBMCs with the hypothesis that CXCL16 does not impact infection and 
replication of a CXCR6-independent virus ex vivo.  Human PBMCs were stimulated with PHA and 
IL-2 and pre-treated with or without CXCL16, followed by infection with CCR5-tropic HIV-1 BaL or 
CXCR4-tropic HIV-1 NL4-3, HIV-1 3B, and HIV-1 TYBE.  Human PBMCs were collected three 
days post-infection for quantitative real-time PCR (qPCR) measuring HIV-1 LTR and Gag viral 
DNA.  We also collected and measured supernatant P24 Gag production over time.  Data 
represent peak viral production at Day 8 post-infection. 
 
Chemokine CXCL16 did not attenuate CCR5-tropic or CXCR4-tropic HIV-1 infection, indicating 
that CXCL16 has no negative off-target effects on CCR5- or CXCR4-mediated infection (Figure 
3.8).  Viral supernatant P24 Gag production at the peak of HIV-1 infection was slightly but 
consistently enhanced by CXCL16 (range 4%, HIV-1 NL4-3, to 37%, HIV-1 TYBE relative to 
untreated controls) (Figure 3.8A).  This finding was consistent in a repeated experiment (data not 
shown).  Chemokine CXCL16 enhanced early HIV-1 reverse transcription as the relative level of 
LTR strong-stop DNA was 14% (HIV-1 3B) to 44% (HIV-1 BaL) higher in cells treated with 
CXCL16 than in cells without CXCL16 (Figure 3.8B).  However, CXCL16 did not consistently 
enhance HIV-1 Gag DNA expression relative to untreated controls (Figure 3.8C).  Additional 
experiments are needed to determine the full effect of chemokine CXCL16 in primary PBMCs.  
These limited data provide preliminary evidence that CXCL16 may enhance infection in PBMCs.  
Therefore, any blocking effects of CXCL16 in primary PBMCs may slightly underestimate the true 
contribution of CXCR6 to SIV infection. 
 
Maraviroc and CXCL16 lack off-target effects on coreceptor cell surface expression 
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Through Maraviroc and CXCL16 had no direct off-target effects on coreceptor function in 
transfected 293T cells, we ensured that neither the small-molecule antagonist nor the chemokine 
had marked off-target effects on coreceptor expression in primary cells.  Because there is no 
antibody to nonhuman primate CXCR6, we again performed this experiment in human primary 
cells.  Peripheral human CD4+ T cells were stimulated with PHA and IL-2 and treated one day 
with vehicle, 10µM Maraviroc, or 500ng/mL CXCL16.  One day later, cells were stained with 
antibodies to CCR5 and human CXCR6 and imaged by flow cytometry.  Although CXCR4 is not a 
coreceptor of SIV, we also assayed the expression of CXCR4 as another marker of potential off-
target effects of CXCL16 on coreceptor expression. 
 
Overall, neither Maraviroc nor CXCL16 induced an obvious change in the expression of non-
ligand coreceptors in primary human CD4+ T cells (Figure 3.9, Table 3.2).  As we expected from 
numerous prior studies, human CD4+ T cells expressed high levels of CXCR4.  Neither Maraviroc 
nor CXCL16 had a large effect on CXCR4 expression in peripheral CD4+ T cells.  The stimulated 
human CD4+ T cells expressed very low levels of CCR5, perhaps reflecting poor activation, and it 
was difficult to determine if Maraviroc or CXCL16 impacted CCR5 expression.  The median 
fluorescence intensity of CCR5 increased slightly following Maraviroc treatment, lending very 
limited support to prior evidence that Maraviroc stabilizes cell-surface expression of CCR5 and 
increases the percentage of CD3+CCR5+ PBMCs in vivo (20).   
 
Many chemokines induce internalization and lower the surface expression of their natural 
receptors.  While Maraviroc had no clear effect on CXCR6 expression, we observed that 
chemokine CXCL16 induced a drop in both the frequency of CD4+ T cells expressing surface 
CXCR6 and the CXCR6 median fluorescence intensity (Figure 3.9, Table 3.2).  Further 
experiments with additional PBMC donors and additional time points are needed to definitively 
measure the effect of Maraviroc and CXCL16 on chemokine receptor cell surface expression, 
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Figure 3.1. CCR5 antagonist Maraviroc does not entirely block rmCCR5-mediated SIV Env 
pseudotype infection in transfected target cells in vitro.  Target 293T cells were transfected 
with (A and B) human CD4 and CCR5, (C) sooty mangabey CD4 and CCR5, or (D) rhesus 
macaque CD4 and CCR5.  Cells were pre-treated 1 hour with vehicle (No Drug) or Maraviroc at 
final concentrations in log10 increments from 0.1nM to 1mM.  Cells were infected with luciferase-
expressing pNL-Luc-E-R+ Env pseudotypes of HIV-1 JR-FL (gray), SIVsmm FFv2.1 (blue), 
SIVsmm E660 CP3C (green), SIVmac 239 (red triangle), and SIVmac 251 (red diamond).  
Infection was measured by luciferase output 3 days post-infection and normalized to 100% entry 
in the presence of vehicle alone.  Data were fitted to a sigmoidal dose response curve.  (N=3, 





Figure 3.2. Maraviroc is toxic to human PBMCs at concentrations above 100µM.  Primary 
human PBMCs were simulated 3 days with PHA and IL-2.  Cells were then treated 3 days with IL-
2 media alone (untreated), with 100µM Maraviroc, or with 1mM Maraviroc.  Cells were also 
treated with the corresponding amounts of vehicle DMSO alone.  PBMCs were stained with Aqua 
Live/Dead dye and analyzed by flow cytometry.  Gates roughly represent Aqua-negative live cell 
populations as a fraction of the total cell population. 
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Figure 3.3. CCR5 antagonists do not completely block rmCCR5-mediated SIV Env 
pseudotype infection in vitro.  Target 293T cells were transfected with (A) rhesus macaque 
rmCD4 and rmCCR5, or (B) sooty mangabey smCD4 and smCCR5.  Cells were pre-treated with 
CCR5 antagonists AD101 (10µM), Aplaviroc (1µM), CMPD167 (6.7µM), Maraviroc (10µM), or 
Vicriviroc (10µM) and infected with pNL-Luc-E-R+ Env pseudotypes of SIVsmm FFv2.1 (black), 
SIVmac 239 (light gray), or SIVmac 251(dark gray).  Infection was measured by luciferase output 
3 days post-infection.  Data for each viral Env is expressed as the percentage of infection in 























































































































Figure 3.4. Maraviroc has no off-target effects on CXCR6- or GPR15-mediated SIV Env 
pseudotype infection in vitro. Target 293T cells were transfected with (A) sooty mangabey 
smCD4 and coreceptors, or (B) rhesus macaque rmCD4 and coreceptors.  Cells were pre-treated 
one hour with 10µM Maraviroc (MVC) or vehicle and infected with luciferase-expressing pNL-Luc-
E-R+ Env pseudotypes of SIVsmm FFv, SIVmac 239, SIVmac 251, and SIVsmm E660.  Infection 
was measured by luciferase output three days post-infection in relative light units (RLU). (N=3, 
mean ± SD.)  (C) 293T cells were pre-treated one hour with vehicle or 10µM Maraviroc and 
infected with positive control CD4- and coreceptor-independent VSV-G Env pseudotypes.  



































































Figure 3.5. Chemokine CXCL16 attenuates SIV pseudotype infection at low levels of 
smCXCR6 expression in vitro.  (A) Target 293T cells were transfected with 1ug of sooty 
mangabey smCD4 plasmid DNA and decreasing amounts of smCXCR6 plasmid DNA ranging 
from 1µg to 0.01µg.  Cells were pre-treated with 500ng/mL recombinant human chemokine 
CXCL16 and infected with luciferase-expressing pNL-Luc-E-R+ Env pseudotypes of SIVsmm FFv 
(dark gray) and SIVsab (another natural host SIV known to use smCXCR6, light gray).  Data is 
expressed as the percent of luciferase expression in CXCL16-treated cells relative to untreated 
cells.  (B) Another representation of the same data set: Target 293T cells were transfected, pre-
treated, and infected as in (A).  Data is expressed as absolute luciferase production (RLU).  
Control cells transfected with smCD4 alone without coreceptor (None), and negative control 
infection with a pseudotype virus lacking Env (No Envelope, black) are included for comparison.  




















































Figure 3.6.  Expression of human CXCR6 on peripheral CD4+ T cells and transfected 293T 
cells.  Human CD4+ T cells were purified from PBMCs and simulated with PHA/IL-2.  293T cells 
were transfected with decreasing amounts of human CXCR6 ranging from 1µg to 0.001µg of 
plasmid DNA.  Cells were stained with an isotype control (Isotype), or stained with antibody to 
human CXCR6 and analyzed by flow cytometry. 
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Figure 3.7.  CXCL16 blocks CXCR6- but does not block CCR5- or GPR15-mediated SIV 
infection.  (A) Target 293T cells were transfected with 1µg of smCD4 and 0.01µg of coreceptors 
smCCR5, smCXCR6 or smGPR15.  Cells were pre-treated 1 hour with vehicle or 500ng/mL 
CXCL16 and infected with luciferase-expressing pNL-Luc-E-R+ Env pseudotypes of SIVsmm FFv, 
SIVmac and SIVsab.  (N=3, mean ± SD.)  (B) 293T cells were treated one hour with vehicle 
(None) or CXCL16 and infected with pNL-Luc-E-R+ Env pseudotypes of VSV-G.  Infection was 










































Figure 3.8. CXCL16 does not attenuate CCR5- or CXCR4-tropic HIV-1 infection and 
replication.  Human PBMCs were stimulated with PHA and IL-2.  Stimulated cells were pre-
treated with or without 500ng/mL CXCL16.  Cells were infected with replication-competent HIV-1 
viruses: CCR5-tropic HIV-1 BaL and CXCR4-tropic HIV-1 NL4-3, HIV-1 3B, and HIV-1 TYBE.  (A) 
Supernatant was collected at the peak of infection (Day 8) and viral P24 Gag was measured by 
ELISA.  (B,C) Three days post-infection, PBMCs were lysed and assayed by qPCR for HIV-1 
LTR strong-stop and HIV-1 Gag viral DNA copies relative to housekeeping gene GAPDH.  








































































Figure 3.9.  Maraviroc and CXCL16 do not affect expression of non-ligand alternative 
coreceptors.  Human peripheral blood CD4+ T cells were purified and stimulated with PHA and 
IL-2.  Following stimulation, cells were treated for one day with vehicle (black line), 10µM 
Maraviroc (red line), or 500ng/mL CXCL16 (blue line) and stained with antibodies to CCR5, 
CXCR6, and CXCR4.  Cells were also stained with isotype controls (gray).  Analysis was 
performed by flow cytometry. 
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Table 3.1. Maraviroc EC50 values in transfected 293T cells. 
SIV Enva EC50 (log10, nM) 
 Human Rhesus Macaque Sooty Mangabey 
SIVsmm FFv2.1 2.3 2.0 1.0 
SIVmac 239 2.6 2.7 1.5 
SIVmac 251 2.7 1.9 1.2 
SIVsmm E660 2.1 1.7 0.9 
a Luciferase-expressing pNL-Luc-E-R+  Env pseudotypes of SIVsmm FFv2.1, SIVmac 239, 
SIVmac 251, and SIVsmm E660 CP3C were used to infect Maraviroc-treated transfected cells 
expressing human CD4 and CCR5, rhesus macaque CD4 and CCR5, or sooty mangabey CD4 





Table 3.2.  Maraviroc and CXCL16 do not affect expression of non-ligand alternative 
coreceptors.   
  Treatmenta Antibodyb Expressionc 
   % MFI 
  No Drug 
CXCR4 
53.6 26.4 
  Maraviroc 53.9 27.1 
  CXCL16 48.4 25.5 
 (Isotype) -- 18.3 
  No Drug 
CCR5 
2.14 19.3 
  Maraviroc 3.33 23.3 
  CXCL16 1.56 18.8 
 (Isotype) -- 18.3 
 No Drug 
CXCR6 
21.7 57.3 
 Maraviroc 21.4 55.2 
 CXCL16 11.3 34.0 
 (Isotype) -- 27.1 
a Peripheral CD4+ T cells were stimulated with PHA and IL-2.  Following stimulation, cells were 
treated for one day with vehicle DMSO (No Drug), 10µM Maraviroc (MVC), or 500ng/mL 
CXCL16.  
b Cells were stained with antibodies to receptor CXCR4, CCR5, and CXCR6, or with isotype 
control antibodies. 
c Data is expressed as the percentage of live cells expressing each coreceptor (%) relative to 






We designed and defined methods that can be used to block or attenuate CCR5-mediated and 
alternative coreceptor CXCR6-mediated SIV infection in vitro.  Specifically, we will use these 
methods to determine the role of CCR5, CXCR6, and other alternative coreceptors in SIV 
infection of non-natural host rhesus macaque PBMCs and natural host sooty mangabey PBMCs 
(Chapter 4). 
 
For the first time, we demonstrate that CXCL16 can be used to attenuate CXCR6-mediated SIV 
infection in vitro.  Recombinant human CXCL16 significantly lowered SIV Env-mediated infection 
via smCXCR6 in cells transfected with small amounts of smCXCR6 plasmid DNA.  The exact 
mechanism of CXCL16 inhibition of CXCR6-tropic SIV infection is not clear.  We observed that 
CXCL16 induced a modest drop in CXCR6 expression on human peripheral CD4+ T cells, which 
suggests homologous desensitization via receptor endocytosis as one mechanism preventing SIV 
infection.  Notably, human CXCL16 only blocked smCXCR6-mediated 293T cell infection at low 
levels of smCXCR6 plasmid DNA transfection.  We observed that 293T cells transfected with 
0.01µg of human CXCR6 plasmid DNA and CD4+ T cells stimulated with PHA and IL-2 display 
similar frequencies of CXCR6+ cells.  The comparison between a cell line and primary PBMCs is 
rough, but this may indicate that CXCL16 can attenuate a significant amount of CXCR6-mediated 
SIV infection in primary cells. 
 
Further studies could define more potent inhibitors of smCXCR6-medaited SIV infection.  It is 
possible that species-matched recombinant sooty mangabey CXCL16 would be a more potent 
inhibitor of smCXCR6-mediated SIV infection.  We did not investigate the ability of human 
CXCL16 to block SIV infection via human CXCR6 and compare results to our data from 
smCXCR6.  A prior study described a potent chemotactic CXCR6 antagonist formed by adding 
an N-terminal extension to CXCL16 (26).  This CXCL16 construct may also be a more potent 
inhibitor of CXCR6-mediatead SIV infection than wild-type human CXCL16.  
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Maraviroc inhibition is host CCR5-dependent.  Maraviroc was a potent antagonist of smCCR5 
and inhibited smCCR5-mediated SIV infection in transfected 293T cells.  By contrast, at 
concentrations tolerable to cultured cells, Maraviroc only inhibited 80% of SIV infection through 
rmCCR5 in transfected 293T cells.  Therefore, we anticipate that Maraviroc may block more 
smCCR5-mediated SIV infection in sooty mangabey PBMCs than rmCCR5-mediatead SIV 
infection in rhesus macaque PBMCs.   
 
Notably, viruses from sooty mangabeys and rhesus macaques were equally sensitive to 
Maraviroc; Maraviroc blocked smCCR5-mediated infection by sooty mangabey SIVsmm and 
rhesus macaque SIVmac 239, SIVmac 251, and SIVsmm Env pseudotypes.  None of the SIV 
Env we studied appeared to be Maraviroc-resistant.  All SIV Env pseudotypes we tested were 
fully sensitive to Maraviroc in cells expressing human CD4 and CCR5 or sooty mangabey CD4 
and CCR5.  Maraviroc-resistant HIV-1 have been observed before (19, 22, 25, 32, 34-36, 38, 42), 
however, this drug resistance typically evolves only after extensive passage in antagonist-treated 
culture or after long-term antagonist treatment in vivo. 
 
Inhibiting CCR5-mediated entry in a transfected 293T cell assay in vitro is likely more challenging 
than blocking infection under more physiological conditions with primary viral isolates containing 
less Env in primary PBMCs with less CCR5 ex vivo (31).  SIV Env was likely expressed at high 
levels on the surface of Env-pseudotyped virions relative to primary SIV isolates.  Receptor CD4 
and coreceptor CCR5 were clearly expressed at very high levels in transfected 293T cells.  
Previous studies found that the amount of CCR5 expressed on the cell surface has a major 
influence on the IC50 and efficacy of Maraviroc inhibition in vitro (9, 14, 43).  The amount of Env 
on the surface of the virion may also affect Maraviroc inhibition.  Nonetheless, our finding that 
Maraviroc blocks only 80% of rmCCR5-mediated SIV pseudotype infection in transfected 293T 
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cells closely recapitulates prior studies where Maraviroc blocked only 80% of provirus SIVmac 
239 replication in rhesus macaque PBMCs (21).   
 
Prior studies found that while amino acid sequence discrepancies between huCCR5 and 
rmCCR5 do not affect the binding of natural chemokine ligands of CCR5, these species-specific 
amino acid substitutions do affect the binding of small molecule antagonists.  Previous data 
indicate that the relatively poor antagonism of Maraviroc against rmCCR5-mediated SIV infection 
is due to faster dissociation kinetics of Maraviroc and rmCCR5 than Maraviroc and huCCR5 (24).  
Presumably this pattern would also hold between rmCCR5 and smCCR5.  We aligned the amino 
acid sequences of huCCR5, smCCR5, and rmCCR5 and found a single amino acid residue 
I198M unique to rmCCR5 that likely defines the poor interaction between Maraviroc and rmCCR5 
relative to Maraviroc and smCCR5/huCCR5.  Accordingly, a prior site-directed mutagenesis study 
found that an I198A substitution in the fifth transmembrane region of huCCR5 increased the 
dissociation constant KD and decreased the binding efficiency of Maraviroc (8).  I198V and I198L 
mutations in huCCR5 also impaired the ability of CCR5 antagonists AD101, SCH-C, and TAK779 
to block SIV infection (1).  Furthermore, introducing M198I in rmCCR5 restores the ability of 
CCR5 antagonist SCH-C to fully inhibit rmCCR5-mediated infection (1).  Therefore, CCR5 amino 
acid residue 198 likely plays a critical role in the discrepant Maraviroc antagonism between 
smCCR5 and rmCCR5.  Prior studies determined that amino acid residue I198 was less critical to 
Aplaviroc and Vicriviroc binding (16), however, we found that neither Aplaviroc nor Vicriviroc fully 
block SIV infection via rmCCR5.  Perhaps attributes in addition to the CCR5 amino acid 
sequence mediate the relatively poor antagonism of Maraviroc against rmCCR5-medaited SIV 
infection. 
 
Others have used CCR5 antagonists to decrease the plasma viral load in SIVmac-infected rhesus 
macaques in vivo (40) and to block infection by CCR5-tropic SHIV SF162 (20, 39, 41).  In these 
studies, viral loads only slightly decreased and protection was only transient.  These results could 
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be due to the poor activity of CCR5 antagonists against rmCCR5, but could also be explained by 
pharmacokinetics of these compounds in nonhuman primates, the level of CCR5 on cells at the 
challenge site, or perhaps alternative coreceptor use.  Further studies are needed to define the 
ability of Maraviroc to block rmCCR5-mediated SIV infection in rhesus macaque primary cells 
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RHESUS MACAQUE SIV INFECTION IS CCR5-DEPENDENT WHILE SOOTY 
MANGABEY SIV INFECTION IS PARTIALLY CCR5-INDEPENDENT AND CAN BE 
MEDIATED BY CXCR6 
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Natural host sooty mangabeys infected with simian immunodeficiency virus (SIV) exhibit high 
plasma viral loads without widespread CD4+ T cell loss.  By contrast, non-natural host rhesus 
macaques experimentally infected with related SIV exhibit high plasma viral loads with 
subsequent CD4+ T cell loss and progression to AIDS.  Here, we identified host-dependent 
patterns of SIV coreceptor use that distinguish viral entry in sooty mangabeys from viral entry in 
rhesus macaques.  We confirmed sooty mangabey CCR5, CXCR6, and GPR15 as coreceptors of 
SIV in vitro.  Rhesus macaque CCR5 and GPR15 supported SIV infection in vitro, but rhesus 
macaque CXCR6 was a poor coreceptor of SIV relative to sooty mangabey CXCR6.  Using 
CCR5 inhibitor Maraviroc, we determined that SIV was highly CCR5-dependent in rhesus 
macaque peripheral blood mononuclear cells (PBMCs), whereas SIV was partially CCR5-
independent in sooty mangabey PBMCs.  CXCL16, a chemokine ligand of CXCR6, partially 
attenuated SIV infection of sooty mangabey PBMCs, indicating that sooty mangabey CXCR6 was 
a functional alternative coreceptor of some SIV isolates in primary sooty mangabey cells.  
Importantly, SIV from sooty mangabeys and SIV from rhesus macaques exhibited similar patterns 
of alternative coreceptor use on equivalent coreceptors in vitro, and SIVmac 239 was highly 
CCR5-dependent in rhesus macaque PBMCs but largely CCR5-indepenent in sooty mangabey 
PBMCs.  These data indicate that alternative coreceptor-mediated SIV infection was host-
dependent.  The expression patterns of CXCR6 and other alterative coreceptor(s) of SIV in sooty 
mangabey CD4+ cell subsets may classify host target cells that can maintain high levels of SIV 





Simian immunodeficiency virus (SIV) infections of primate natural hosts, including SIVsmm 
infection of sooty mangabeys, result in high viral loads without widespread CD4+ T cell loss or 
progression to AIDS.  By contrast, SIV infection of primate non-natural hosts, like SIVmac 239, 
SIVmac 251, and SIVsmm E660 infections of rhesus macaques, typically result in high viral 
loads, widespread loss of CD4+ T cells, and rapid progression to AIDS.  Rhesus macaques 
infected with SIVmac 239, SIVmac 251, and SIVsmm E660 are often used as animal models of 
human HIV-1 infection and pathogenesis.   
 
Whereas SIVsmm viruses are endemic to wild sooty mangabeys in West Africa and remained so 
when animals were transferred to captive sites in the United States (2, 18, 20), pathogenic rhesus 
macaque SIV, including SIVmac 239, SIVmac 251, and SIVsmm E660, arose only after co-
captive and experimental SIVsmm cross-species transmissions to Asian non-natural host rhesus 
macaques (Chapter 1, Introduction, Figure 1.8) (12).  The three viruses SIVmac 239, SIVmac 
251, and SIVsmm E660 are often used in rhesus macaque challenge studies as animal models 
ofHIV-1 infection and pathogenesis. 
 
Note that, despite the confounding name, SIVsmm E660 is a virus used to infect rhesus 
macaques and induces pathogenesis in these non-natural hosts (12, 13).  The laboratory isolate 
SIVsmm E660 is distinct from SIVsmm primary isolates from natural infections that occur in sooty 
mangabeys. 
 
The focus of the field has been on the question of how rhesus macaque SIV viruses can be boldly 
pathogenic in their rhesus macaque hosts, while very closely related parental sooty mangabey 
SIVsmm infections do not cause disease progression in their sooty mangabey hosts.  There are 
many possible explanations as to why non-natural host rhesus macaques succumb to SIV 
infection whereas natural host sooty mangabeys do not progress to AIDS despite ongoing SIV 
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replication (1, 23, 34).  In this study, we reveal differential coreceptor use by SIV in primary cells 
from natural host sooty mangabeys versus primary cells from non-natural host rhesus macaques 
as one possible mechanism explaining the dichotomy between disease outcomes in primate 
hosts. 
 
Though all SIVsmm and SIVmac were previously presumed to be coreceptor CCR5-dependent, 
we discovered that alternative, non-CCR5 coreceptors support sooty mangabey SIVsmm 
infection in vitro and in vivo (6, 29) (Chapter 2).  All sooty mangabey SIVsmm Envelope proteins 
(Env) we examined to date mediate infection of transfected target cells expressing sooty 
mangabey CD4 (smCD4) and sooty mangabey CCR5 (smCCR5).  Crucially, alternative 
coreceptor sooty mangabey CXCR6 (smCXCR6) supports equally robust SIVsmm Env-mediated 
infection in vitro (6).  Sooty mangabey smGPR15 and smGPR1 also support moderate to low 
SIVsmm Env-mediated infection. 
 
Because cross-species transmissions of SIVsmm gave rise to rhesus macaque challenge viruses 
SIVmac 239, SIVmac 251, and SIVsmm E660, we hypothesized that these rhesus macaque SIV 
exhibit the general ability to use alternative coreceptors very similar to that of SIVsmm.  SIVmac 
239 and SIVmac 251 can use alternative coreceptors of human origin as these viruses replicate 
to varying degrees in CCR5Δ/Δ human PBMCs that lack functional CCR5 (3, 5, 14, 32, 39).  
Human CCR5, CXCR6, and GPR15 were found to support SIVmac 239 in cell lines in vitro (17).  
Thus, it appears that SIVmac 239 and other pathogenic rhesus macaque SIV in this viral family 
are generally CCR5-, CXCR6-, and GPR15-tropic in vitro much like sooty mangabey SIVsmm, 
not accounting for species-matched coreceptors. 
 
Importantly, previous studies found that species-matched rhesus macaque CCR5 (rmCCR5) and 
rhesus macaque GPR15 (rmGPR15) are coreceptors of rhesus macaque SIV, but that rmCXCR6 
is a poor coreceptor of SIVmac 239 and SIVmac 17E/F relative to human CXCR6 (26, 27).  We 
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hypothesized that rmCXCR6 is also a poor coreceptor of other rhesus macaque SIV, including 
SIVmac 251 (which was co-derived with SIVmac 239 and SIVmac 17E/F) and independently-
derived SIVsmm E660 (12) (Chapter 1, Introduction, Figure 1.8).  In addition, we determined if 
rmCXCR6 is a poor coreceptor of SIV relative to smCXCR6.  We investigated which coreceptors 
of both rhesus macaque and sooty mangabey origin support SIVsmm, SIVmac 239, SIVmac 251, 
and SIVsmm E660 Env-mediated infection.  We discovered that SIVsmm and rhesus macaque 
SIV use the same coreceptors in vitro, and confirmed that rmCXCR6 is a poor coreceptor of all 
these SIV Env relative to smCXCR6. 
 
Having defined the species-specific coreceptors that support sooty mangabey SIVsmm and 
rhesus macaque SIVmac 239, SIVmac 251, and SIVsmm E660 Env-mediated infection in vitro, 
we also sought to define the relative role of CCR5 and alternative coreceptors in infection of sooty 
mangabey and rhesus macaque peripheral blood mononuclear cells (PBMCs) ex vivo.  SIV 
coreceptor use in vitro may not mimic SIV coreceptor use in primary cells ex vivo, or coreceptor 
use in vivo.  This is especially relevant because there is no antibody to primate CXCR6 and we 
had not previously confirmed that CXCR6 is expressed on primate CD4+ cells.  We hypothesized 
that SIVsmm and rhesus macaque SIV exhibit distinct patterns of host-dependent coreceptor use 
in primary cells from sooty mangabeys and rhesus macaques.  Implicit in this, we hypothesized 
that SIVsmm infection and replication in sooty mangabey PBMCs (smPBMCs) are highly 
dependent upon alternative coreceptors, including smCXCR6.  We also hypothesized that 
SIVmac infection and replication in rhesus macaques are almost exclusively CCR5-dependent.  
 
Prior evidence suggests that SIVsmm infection and replication in the majority of sooty mangabeys 
are highly CCR5-independent and alternative coreceptor-dependent.  SIVsmm infection and 
robust viral loads within a small population of CCR5Δ/Δ sooty mangabeys offers the most striking 
proof of SIV alternative coreceptor use in sooty mangabeys (29).  We also found that SIVsmm 
from both CCR5wt/wt and CCR5Δ/Δ sooty mangabeys use alternative coreceptors and, thus, the 
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virus likely retains the ability to use alternative coreceptors even in sooty mangabeys expressing 
functional CCR5 (6) (Chapter 2).  Collectively, natural host sooty mangabeys express 
exceedingly low levels of wild-type CCR5 on peripheral and lymph node CD4+ T cells (22, 24, 33, 
35, 37).  Because short-lived CD4+ T cells support the majority of SIVsmm infection and 
replication in vivo (11), the low level of CCR5 on CD4+ T cells from sooty mangabeys led us to 
hypothesize that alternative coreceptors support a portion of the exceedingly robust SIVsmm 
replication in sooty mangabeys.   
 
In contrast to SIVsmm infection of sooty mangabeys, prior studies suggest SIVmac infection of 
rhesus macaques is highly CCR5-dependent. Peripheral and lymph-node CD4+ T cells from 
rhesus macaques and other non-natural hosts express high levels of CCR5 relative to those 
observed in natural hosts (24), indicating that these hosts may easily support CCR5-mediated 
viral replication in vivo.  When CCR5 antagonist CMPD167 was injected into chronically SIVmac 
251-infected rhesus macaques, plasma viral loads decreased over 4-fold (36), indicating that 
CCR5 supports some SIVmac 251 infection and replication in vivo.  High concentrations of CCR5 
antagonist TAK-779 completely blocked SIVmac 239 and SIVmac 251 infection and replication in 
rhesus macaque PBMCs (39), demonstrating that rhesus macaque SIV are highly CCR5-
dependent in primary rhesus macaque PBMCs (rmPBMCs) ex vivo.  Although SIVmac 239 
utilizes alternative coreceptor rmGPR15 in vitro, a single amino acid substitution in SIVmac 239 
Env that specifically abrogated rmGPR15 use (but not rmCCR5 use) resulted in rhesus macaque 
plasma viral loads in vivo comparable to those achieved with a wild-type SIVmac 239 (27).  
Furthermore, when SIVmac 239 was used to infect human CCR5Δ/Δ PBMCs, viral protein 
products were not found in CD4+ cells expressing GPR15 (17).  These data suggest that 
rmGPR15 use is not a major replicative advantage to SIVmac 239 in vivo (27).  Collectively, 





We defined the coreceptor use patterns of SIVsmm and SIVmac in sooty mangabey and rhesus 
macaque PBMCs side-by-side.  Because CCR5 expression is exceedingly low in natural host 
sooty mangabeys (22, 24), alternative coreceptors may dictate the bulk of SIV tropism in vivo.  
Identifying divergent SIV coreceptor use patterns between host sooty mangabeys and host 
rhesus macaques will assist classification of dispensable natural host sooty mangabey immune 
target cells that maintain viral replication without precipitating widespread CD4+ T cell loss.  In 
addition, characterizing rhesus macaque SIVmac 239, SIVmac 251, and SIVsmm E660 as a 
primarily CCR5-topic viruses in rhesus macaques would lend credibility to rhesus macaque SIV 
infection as a model of human HIV-1 infection and pathogenesis (12), as HIV-1 is highly CCR5-
dependent (especially in early stages of infection).    
 
Herein, we define the coreceptors of sooty mangabey and rhesus macaque origin that support 
SIV infection in transfected cells in vitro.  We also use selective inhibitors to determine if CCR5, 
CXCR6, and/or other coreceptors support SIVsmm and rhesus macaque SIV infection in sooty 






Maraviroc and CXCL16 
Maraviroc (Selzentry, Celsentri) was obtained through the NIH AIDS Reagent Program, Division 
of AIDS, NIAID (Cat #11580) and suspended at 20mg/mL in dimethyl sulfoxide (DMSO). 
Lyophilized recombinant human CXCL16 (R&D Systems #976-CX-025) was suspended at 
25µg/mL in phosphate buffered saline and used within 2 days with ≤1 freeze/thaw cycle.  Cells 
were treated pre-infection with vehicle DMSO alone, Maraviroc, CXCL16 plus DMSO, or 
Maraviroc plus CXCL16.  Final concentrations at the time of infection were 10µM Maraviroc 
and/or 500ng/mL CXCL16 in less than 0.03% vehicle DMSO. 
 
Viruses and viral Env 
SIVsmm FFv 2.1 and SIVsmm FFv4.1 Env were cloned by C. Derdeyn and B. Li (Emory 
University) from a CCR5wt/wt Clade 1 SIVsmm-infected sooty mangabey (animal FFv, Yerkes 
National Primate Research Center nomenclature) using single genome amplification (SGA) (6, 
19, 29, 31).  SIVmac 239 Env was cloned from the full-length provirus SIVmac 239.  SIVmac 251 
Env RZu4-1.1 Day 11 was cloned by C. Derdeyn by SGA from a control (non-CD4-depleted) 
rhesus macaque infected with SIVmac 251 as previously described (10, 21).  SIVsmm E660 
CP3C-P-A8 and SIVsmm E660 CR54-PK-2A5 Env were cloned by SGA from acutely SIVsmm 
E660-infected rhesus macaques and were a gift from K. Barr and G. Shaw (University of 
Pennsylvania) (16, 30).  The HIV-1 pNL-Luc-E-R+ backbone and Env pseudotype formation 
protocol were described previously (4, 6, 29) (Chapter 2).  Replication-competent proviral clone 
SIVmac 239 was a gift from the laboratory of J. Hoxie (University of Pennsylvania).  A replication-
competent proviral SIVmac 251 Env clone was formed by N. Francella (University of 
Pennsylvania) by replacing SIVmac 239 Env with the SIVmac 251 RZu4-1.1 Day 11 Env, 
generating a proviral clone with a SIVmac 239 backbone and Env from a single SIVmac 251 virus 
(9, 10).  These proviral clones were transfected into 293T cells using Fugene (Promega) and viral 
supernatant was harvested 3-4 days later and quantified by P27 Gag ELISA.  SIVsmm E660 
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primary isolate was obtained through the NIH AIDS Reagent Program, Division of AIDS, NIAID, 
NIH from V. Hirsch and P. Johnson (Catalog #3288) (13).  Primary isolates SIVsmm M935 and 
SIVsmm D215 were generated from SIVsmm-infected CCR5wt/wt sooty mangabeys M935 and 
D215 (Tulane National Primate Research Center nomenclature) and were a gift from P. Marx.  
 
Cell lines and PBMCs 
Adherent human embryonic kidney 293T cells were maintained in DMEM + 10% FBS + 1% 
Penicillin-Streptomycin + 1% L-Glutamine.  Adherent canine thymocyte Cf2Th.Luc cells carry a 
stable HIV-1 LTR-driven luciferase gene activated by HIV-1 Tat (7) and were a gift from H. 
Barbian and F. Bibollet-Ruche in the laboratory of B. Hahn (University of Pennsylvania).  These 
cells were maintained in DMEM + 3.5% FBS + 1% Penicillin-Streptomycin + 1% L-Glutamine.  
Uninfected sooty mangabey PBMCs from CCR5wt/wt animals FBa1, FRz, FUu, FYz, FIa1, and FIz 
were collected and Ficoll purified at the Yerkes National Primate Research Center with 
assistance from the laboratory of F. Villinger.  Rhesus macaque PBMCs were a gift from B. 
Ferraro in the laboratory of D. Weiner (University of Pennsylvania).  We PCR amplified and 
sequenced rmCXCR6 from seven rhesus macaques using primers previously described (6) 
(Chapter 2) and verified that 7 out of 7 rhesus macaques carried the rmCXCR6R30/R30 genotype. 
Primate PBMCs were thawed and cultured in RPMI + 10% FBS + 1% Penicillin-Streptomycin + 
1% L-Glutamine overnight prior to stimulation. 
 
Pseudotype Infections 
Rhesus macaque rmCCR5, rmCXCR6, and rmGPR15 were independently cloned from rhesus 
macaque PBMC genomic DNA using primers discussed previously (6) (Chapter 2).  The 
sequences of these clones matched those published in GenBank.  Two alleles of rmGPR15 
encoding two proteins with a single amino acid difference were described previously (28, 38).  All 
experiments were performed with the rmGPR15 M279 allele.  Sooty mangabey smCCR5, 
smCXCR6, and smGPR15 were also cloned as previously described (6) (Chapter 2).  Primate 
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CD4 plasmids were a gift from T. Vanderford (Emory University).  Target 293T cell infections 
were performed as described previously (6) (Chapter 2).  Briefly, cells were transfected with 1µg 
CD4 and 1µg coreceptor plasmid DNA using Fugene.  Cells transfected with CD4 alone served 
as negative controls. Transfected cells were washed 24 hours post-transfection and re-plated 
2×105 cells per well in a 96 well plate.  The next day, DNAse-treated pNL-Luc-E-R+ Env 
pseudotype viruses were added 50uL/well.  VSV-G pseudotyped viruses served as positive 
controls and Env-negative pseudotypes served as negative controls.  Cells were spin-inoculated 
and luciferase output was measured 72 hours post-infection in relative light units (RLU) after 
500mg integration.  Luciferase production in CD4 + CCR5 cells was normalized to 100% by 
species such that: 
Percent entry = 100% × [(RLU in species CD4 + alternative coreceptor) ÷ (RLU in 
species CD4 + CCR5)]  
 
Cf2Th.Luc cells were transfected with 1µg CD4 and 1µg coreceptor plasmid DNA using Fugene 
and were washed and re-plated 1×105 cells per well in a 96 well plate.  Cells transfected with 
empty plasmid and with CD4 alone served as negative controls.  Cf2Th.Luc cells were infected 
with 5ng P27 Gag SIVmac 239 provirus, 5ng P27 Gag SIVmac 251 Env provirus, 5ng SIVsmm 
E660 primary isolate, or a max volume 50µL SIVsmm M935 and D215 primary isolates (we had 
limited stock of primary isolates and did not know the P27 Gag concentration or TCID50 before-
hand).  Uninfected cells served as negative controls for the relatively high baseline expression of 
luciferase in this cell line.  Cells were spin-inoculated 2 hours at 1200×g and 25°C.  Infection was 
measured 48 hours post-infection by luciferase production (Luciferase Assay System; Promega) 
with 500ms integration using a Luminoskan Ascent Microplate Luminometer (Thermo Scientific).  
 
Infection and Replication Experiments 
Rhesus macaque and sooty mangabey PBMCs were stimulated 3-5 days with 5µg/mL 
Concanavalin A (ConA) and 30Units/mL Interleukin-2 (IL-2).  Media was replaced one hour pre-
infection with IL-2 media containing vehicle, Maraviroc, CXCL16, or Maraviroc plus CXCL16.  
Cells were plated 1×106 cells/well in 1.5mL to 2mL total volume in a 24-well plate.  Viral 
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supernatants were added as following: 5ng P27 SIVmac 239, 5ng P27 SIVmac 251, 5ng P27 
SIVsmm E660, 100µL SIVsmm M935, 100µL SIVsmm D215.  Cells were spin-inoculated 2 hours 
at 1200xg and 25°C.  Media was collected one day post-infection (Day -1) followed by washing 
and replacing with IL-2 media containing fresh drug or chemokine (Day 0).  50µL of supernatant 
was collected every 2-3 days for P27 Gag ELISA performed by S. Bryan and F. Shaheen in the 
Penn Center for AIDS Research Virology Core. 
 
Statistics 
All statistical comparisons were made by a two-tailed unpaired t-Test using Welch’s correction 
unless otherwise indicated.  Significance was defined as p<0.05.  Statistical analyses were 
performed using GraphPad PRISM 6 software (La Jolla, CA, USA).  
 
Ethics statement 
All animal experimentation was conducted following guidelines established by the Animal Welfare 
Act and the NIH for housing and care of laboratory animals and performed in accordance with 
Institutional regulations after review and approval by the Institutional Animal Care and Use 
Committees (IACUC) at the Yerkes National Primate Research Center (YNPRC) and the Tulane 
National Primate Research Center (TNPRC).  Studies were also reviewed and approved by the 





The same coreceptors support SIVsmm and rhesus macaque SIV in vitro 
Natural host SIVsmm Env use coreceptor smCCR5 but also exhibit robust infection 
through alternative coreceptor smCXCR6 and moderate entry through alternative coreceptor 
smGPR15 in transfected cells in vitro (6).  We hypothesized that pathogenic SIV from rhesus 
macaques would exhibit a similar pattern of alternative coreceptor use with these sooty 
mangabey coreceptors in vitro because rhesus macaque SIV were developed from SIVsmm.  We 
examined coreceptor use patterns of three SIV frequently used to induce pathogenesis in rhesus 
macaques: SIVmac 239, SIVmac 251, and SIVsmm E660.  Importantly, SIVmac 239/251 and 
SIVsmm E660 viruses were derived from independent SIVsmm cross-species transmissions into 
rhesus macaques and these viruses represent diverse sub-species of pathogenic rhesus 
macaque SIV (12) (Chapter 1, Introduction, Figure 1.8).  Infection with SIVmac 239, SIVmac 251, 
or SIVsmm E660 leads to AIDS in non-natural host rhesus macaques. 
 
To determine if sooty mangabey SIVsmm and rhesus macaque SIVmac 239, SIVmac 251, and 
SIVsmm E660 exhibit similar use of sooty mangabey coreceptors, we transfected 293T cells with 
sooty mangabey CD4 (smCD4) in combination with smCCR5, smCXCR6, and smGPR15.  Cells 
transfected with smCD4 alone served as a negative control.  Transfected cells were infected with 
Env pseudotypes of pNL-Luc-E-R+ that express luciferase in place of Nef upon infection (4).  
Luciferase output was measured three days post-infection in relative light units (RLU).  We used 
absolute luciferase RLU values to assign significance.  Data are expressed as a percentage of 
entry through smCD4 and smCCR5 (Figure 4.1A). 
 
We examined multiple Env from the SIVsmm/SIVmac viral lineage.  Sooty mangabey SIVsmm 
FFv2.1 Env was previously cloned by single genome amplification (SGA) from a Clade 1 viral 
isolate collected from a CCR5wt/wt sooty mangabey (6, 29).  The SIVmac 239 Env was cloned 
from the infectious molecular clone SIVmac 239.  The SIVmac 251 Env was cloned by SGA from 
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a SIVmac 251-infected rhesus macaque as previously described (10, 21).  Two SIVsmm E660 
transmitter/founder Env clones, SIVsmm E660 CP3C and SIVsmm E660 CR54, were cloned by 
SGA from an acutely infected rhesus macaque challenged with SIVsmm E660 as previously 
described (15, 30).  
 
SIVmac 239, SIVmac 251, and SIVsmm E660 Env exhibited a pattern of alternative coreceptor 
use in vitro similar to that of SIVsmm from sooty mangabeys.  As we observed previously (6) 
(Chapter 2), alternative coreceptor smCXCR6 supported robust SIVsmm FFv2.1 Env-mediated 
infection at 90% of the level of infection mediated by smCCR5 (Figure 4.1A).  Alternative 
coreceptor smGPR15 also supported moderate SIVsmm FFv2.1 Env-mediated infection in vitro at 
65% of the level of infection through smCCR5 (Figure 4.1A).   
 
Notably, smCXCR6 was a robust alternative coreceptor of rhesus macaque SIV Env.  SIVsmm 
E660 CP3C, SIVsmm E660 CR54, and SIVmac 251 Env mediated infection through smCXCR6 
significantly above infection through smCCR5 (p=0.003, p=0.007, p=0.002 respectively) (Figure 
4.1A).  SIVmac 239 infection through smCXCR6 occurred at 78% of the level of infection through 
smCCR5.  Alternative coreceptor smGPR15 supported SIVmac 239, SIVmac 251, and SIVsmm 
E660 CP3C infection at levels from 13% (SIVsmm E660 CR54) to 110% (SIVmac 251) of 
infection through smCCR5 (p=NS).  SIVsmm E660 CR54 exhibited very low infection through 
smGPR15 relative to smCCR5.   
 
In summary, we found that smCXCR6 was a robust alternative coreceptor of both SIVsmm and 
rhesus macaque SIV in vitro.  Viral Env from rhesus macaque viruses SIVmac 251 and SIVsmm 
E660 exhibited infection through smCXCR6 significantly above infection through smCCR5.  Sooty 
mangabey smGPR15 was a strong coreceptor of SIVmac 239, SIVmac 251, and SIVsmm E660 
CP3C Env; a moderate coreceptor of SIVsmm FFv2.1 Env; and a poor coreceptor of SIVsmm 
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E660 CR54 Env in transfected cells in vitro.  Collectively, SIVsmm Env and rhesus macaque SIV 
Env exhibited similar patterns of sooty mangabey coreceptor use. 
 
Rhesus macaque CXCR6 is a weak coreceptor of SIV in vitro 
Viruses SIVmac 239, SIVmac 251, and SIVsmm E660 are frequently used to infect 
rhesus macaques, not sooty mangabeys.  Thus, we next sought to answer a more relevant 
question: which coreceptors of rhesus macaque origin support SIVmac 239, SIVmac 251, and 
SIVsmm E660 infection in vitro?  Previous studies found that rmCCR5 and rmGPR15 support 
SIVmac infection in vitro; crucially, these studies also observed that rhesus macaque rmCXCR6 
was a poor coreceptor of SIVmac 239/251-related rhesus macaque SIV relative to human 
CXCR6 (26, 27).  We were interested to determine if SIVsmm E660 CP3C and SIVsmm E660 
CR54 Env, which represent a different sub-family of rhesus macaque SIV, also exhibit poor 
infection through rmCXCR6.  We also determined if infection through non-natural host rmCXCR6 
was low relative to infection through natural host smCXCR6. 
 
To define the coreceptors of rhesus macaque origin that support SIVmac 239, SIVmac 251, and 
SIVsmm E660 Env-mediated infection in vitro, we cloned CD4 and putative coreceptors rmCCR5, 
rmCXCR6, and rmGPR15 from rhesus macaque genomic DNA using methods previously 
described (6) (Chapter 2).  The DNA sequences of rmCD4, rmCCR5, rmCXCR6, and rmGPR15 
matched rhesus macaque sequences published previously (8, 26, 38) (data not shown).  Target 
293T cells were transfected with rmCD4 and rmCCR5, rmCXCR6, or rmGPR15.  Transfected 
cells were infected with pNL-Luc-E-R+ Env pseudotypes as before.  Luciferase expression was 
measured three days post-infection, we used absolute luciferase RLU values to assign 
significance, and data are displayed as the percentage of entry through rmCD4 plus rmCCR5 




Absolute levels of luciferase expression following infection of 293T cells expressing rmCD4 plus 
rmCCR5 were comparable to levels of luciferase expression following infection of 293T cells 
expressing smCD4 plus smCCR5 (data not shown).  Rhesus macaque rmCXCR6 was a poor 
coreceptor of SIVsmm FFv2.1 Env, as infection through rmCXCR6 was only 43% of that through 
rmCCR5 (p=0.02) (Figure 4.1B).  Consistent with previous findings (26), rmCXCR6 was a 
remarkably poor coreceptor of SIVmac and SIVsmm E660 Env pseudotypes with rmCXCR6-
mediated infection ranging from only 3% (SIVsmm E660 CR54) to 11% (SIVmac 251) of infection 
through rmCCR5 (p≤0.03) (Figure 4.1B).  Indeed, rmCXCR6-mediated SIVsmm E660 CP3C and 
SIVsmm E660 CR54 infections were not significantly above infection in control cells transfected 
with rmCD4 alone.  Thus, relative to SIVmac 239/251 Env, SIVsmm E660 Env exhibited 
exceedingly poor infection through rmCXCR6.  The inability of rmCXCR6 to support SIVsmm 
E660 infection was a particularly sharp contrast to smCXCR6, which supported SIVsmm E660 
infection significantly above the levels of rmCCR5-mediated infection (compare Figure 4.1A and 
Figure 4.1B).   
 
All SIV Env exhibited significantly lower levels of infection through rmCD4 plus rmCXCR6 than 
those through smCD4 plus smCXCR6 (SIVsmm FFv 2.1 p=0.02, SIVmac 239 p=0.005, SIVmac 
251 p=0.003, SIVsmm E660 CP3C and SIVsmm E660 CR54 p<0.001).  Therefore, we concluded 
that non-natural host rhesus macaque rmCXCR6 is a poor coreceptor of SIV relative to natural 
host sooty mangabey smCXCR6 in vitro.  These data add to prior findings that rmCXCR6 is a 
weak coreceptor of SIV relative to human CXCR6 (26). 
 
Rhesus macaque rmGPR15 supported SIVsmm FFv2.1 Env-mediated infection at levels 74% of 
that through rmCCR5 (Figure 4.1B).  Rhesus macaque SIV Env also exhibited lower infection 
through rmGPR15 than rmCCR5.  Rhesus macaque GPR15 supported rhesus macaque SIV 
infection at 15% (SIVsmm E660 CR54) to 78% (SIVmac 251) of infection through rmCCR5.  
Coreceptors rmGPR15 and smGPR15 supported similar absoluate levels of infection.  Thus, 
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although rmCXCR6 is a poor coreceptor of SIV relative to smCXCR6, rmGPR15 and smGPR15 
are comparable in vitro. 
 
To confirm that rmCXCR6 is a weak coreceptor in other cell lines in vitro, and to define rmCXCR6 
as a weak coreceptor of replication competent SIV, we performed a similar experiment using 
transfected canine cells in vitro.  Canine thymus Cf2Th.Luc cells were previously engineered with 
a stable HIV-1 LTR-luciferase reporter; these cells express luciferase following infection by 
viruses carrying Tat (7).  Target Cf2Th.Luc cells were transfected with CD4 and CCR5, CXCR6, 
and GPR15 derived from sooty mangabeys and rhesus macaques.  We infected target Cf2Th.Luc 
cells with replication-competent provirus SIVmac 239, chimeric provirus SIVmac 239 with a 
SIVmac 251 Env (hereafter referred to as SIVmac 251 Env chimera to distinguish it from the 
SIVmac 251 swarm), and primary isolate SIVsmm E660.  Luciferase output was measured two 
days post-infection and normalized to luciferase production in target cells with species-matched 
CD4 plus CCR5 as before.   
 
We confirmed that rmCXCR6 is a poor coreceptor of replication competent SIV relative to 
smCXCR6 (Figure 4.2).  Entry through smCD4 plus smCCR5 was comparable to entry through 
rmCD4 plus rmCCR5 (data not shown).  Alternative coreceptor smCXCR6 supported robust 
infection by SIVmac 239, SIVmac 251 Env chimera, and SIVsmm E660 (Figure 4.2A).  Notably, 
SIVsmm E660 infection through smCXCR6 was significantly higher than infection through 
smCCR5 (p=0.003) as we observed previously with individual SIVsmm E660 Env pseudotypes 
(Figure 4.1A).  In contrast to smCXCR6, rmCXCR6 supported only 4% (SIVsmm E660) to 22% 
(SIVmac 251 Env chimera) of infection compared to infection through rmCCR5 (SIVmac 239 and 
SIVmac 251 Env chimera p≤0.02) (Figure 4.2B).  SIVmac 239 and SIVmac 251 Env chimera 
infection via smCD4 plus smCXCR6 was significantly (5-fold to 6-fold) higher than infection via 
rmCD4 plus rmCXCR6 (p=0.003, p=0.03 respectively).  SIVsmm E660 infection was also much 
more robust in cells expressing smCD4 plus smCXCR6 than in cells expressing rmCD4 plus 
133	  
	  
rmCXCR6, although we did not perform enough replicates of SIVsmm E660 infection to asses 
significance. 
 
Alternative coreceptors smGPR15 and rmGPR15 supported Cf2Th.Luc cell infection by 
replication competent SIVmac 239, SIVmac 251 Env chimera, and SIVsmm E660 (Figure 4.2).  
The pattern of rmGPR15 use varied amongst viruses.  SIVmac 239 infection through rmGPR15 
was 30% higher than through rmCCR5 (p=0.052, trend toward significance).  SIVmac 251 Env 
chimera infection was 20% lower through rmGPR15 than rmCCR5.  SIVsmm E660 also exhibited 
moderate use of alternative coreceptor GPR15 in vitro. 
 
The Cf2Th.Luc assay also confirmed that individual SIV Env are indicative of coreceptor 
utilization patterns of the swarms from which they were isolated.  Notably, replication competent 
SIVsmm E660 had a pattern of sooty mangabey coreceptor use similar to that of individual 
SIVsmm E660 CP3C and SIVsmm E660 CR54 Env, marked by robust infection through 
smCXCR6 above the level of infection through smCCR5 and moderate infection through 
smGPR15 (compare Figure 4.1A and Figure 4.2A).  We also found that primary isolate SIVsmm 
D215 from an infected sooty mangabey exhibited a pattern of robust smCCR5, robust smCXCR6, 
and moderate smGPR15 coreceptor use trending toward that of the individual SIVsmm FFv2.1 
Env in vitro (data not shown). 
 
In summary, infections in transfected Cf2Th.Luc cells further demonstrated that rmCXCR6 was a 
very poor coreceptor of SIV Env in vitro relative to smCXCR6.  Notably, rhesus macaque 
rmCXCR6 was a particularly poor coreceptor of rhesus macaque SIV typically used to infect non-
natural hosts, including SIVmac 239, SIVmac 251, and SIVsmm E660.  We also confirmed that 
alternative coreceptor rmGPR15 is a coreceptor of SIV in vitro and supports infection comparable 




SIVmac in rmPBMCs is primarily CCR5-dependent, whereas SIVsmm in smPBMCs is 
partially CCR5-independent  
We next set out to define SIV alternative coreceptor use in primary sooty mangabey and 
rhesus macaque PBMCs.  A coreceptor that supports infection in transfected cells in vitro may 
not support infection and replication in PBMCs ex vivo.  Transfected 293T and Cf2Th.Luc cells 
express artificially high levels of CD4 and coreceptor and are permissive to infection.  It is 
possible that a functional coreceptor in vitro is not co-expressed with requisite receptor CD4 on 
the surface of primary cells ex vivo, or that cells expressing CD4 and coreceptor also co-express 
viral restriction factors, or that cells expressing CD4 and coreceptor lack expression of host genes 
required for productive infection.  Therefore, it is critical to define the coreceptors that support SIV 
infection and replication in primary cells, as these are likely coreceptors that support SIV infection 
and replication in vivo.  Initially, we defined the relative role of CCR5 in SIV infection and 
replication using the CCR5 antagonist Maraviroc, which specifically blocks CCR5-mediated but 
not CXCR6-medaited or GPR15-medaited SIV infection in vitro (Chapter 3, Figure 3.4). 
 
Sooty mangabey smCXCR6 is a very robust alternative coreceptor of SIV in vitro and supports 
infection at levels similar to those supported by smCCR5 (6) (Chapter 2, Figure 4.1, Figure 4.2).  
Therefore, we hypothesized that SIVsmm infection and replication can occur independent of 
smCCR5 in smPBMCs.  Because rmCXCR6 supports little to no SIV infection in vitro (26) (Figure 
4.1, Figure 4.2) and because rmGPR15 appears to be dispensable both ex vivo and in vivo (17, 
27), we also hypothesized that SIVmac infection and replication in rmPBMCs is highly CCR5-
dependent.  To address these hypotheses, we stimulated smPBMCs and rmPBMCs with ConA 
plus IL-2 and pre-treated cells one hour prior to infection with vehicle (DMSO) or 10µM Maraviroc.  
Sooty mangabey PBMCs from two uninfected CCR5wt/wt animals (FBa1 and FUu) were infected 
with SIVsmm primary isolates SIVsmm D215 and SIVsmm M935 derived from two infected 
CCR5wt/wt animals.  Rhesus macaque PBMCs from three animals (Rm1, Rm2, and Rm3) were 
infected with SIVmac 239 and SIVmac 251 Env chimera.  Culture supernatants were collected 24 
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hours post-infection (Day -1), after washing off the inocula (Day 0), and periodically over the 
course of infection.  We performed SIV P27 Gag ELISA to measure SIV viral production and 
accumulation at each time point.  
 
SIVsmm infection and replication in natural host smPBMCs occurred in the presence of CCR5 
antagonist Maraviroc (Figure 4.3A).  Both SIVsmm D215 and SIVsmm M935 exhibited robust 
infection in vehicle-treated smPBMCs and 14% (SIVsmm D215 in sooty mangabey FBa1) to 40% 
(SIVsmm M935 in sooty mangabey FUu) of infection remained in the presence of Maraviroc at 
the peak of viral production (mean 28.4 ± 11.4% standard deviation SD).  There was no 
difference in sensitivity to Maraviroc between viruses SIVsmm D215 and SIVsmm M935 (p=0.66, 
NS, Mann Whitney U test) or between animals FBa1 and FUu (p=0.33, NS, Mann Whitney U 
test), but a much larger data set is needed to fully conclude that there is no variation between 
these parameters.  Maraviroc is a potent inhibitor of smCCR5-mediated SIV Env pseudotype 
infection at concentrations greater than or equal to 1µM in vitro (Chapter 3, Figure 3.1C).  
Therefore, SIVsmm D215 and SIVsmm M935 infection and replication in smPBMCs treated with 
10µM Maraviroc likely demonstrate that one or more alternative, non-CCR5 coreceptors support 
infection and replication in natural host smPBMCs.  
 
In contrast to the partially CCR5-independent SIVsmm D215 and SIVsmm M935 infection of 
smPBMCs, SIVmac 239 and SIVmac 251 infection and replication in rmPBMCs were almost 
entirely dependent on CCR5 (Figure 4.3B).  SIVmac 239 and SIVmac 251 Env chimera exhibited 
very robust infection of vehicle-treated rmPBMCs.  In the presence of Maraviroc, SIVmac 239 and 
SIVmac 251 Env chimera were more than 90% blocked (mean 95.6 ± 3.9% SD).  At the peak of 
infection, only 0.6% (SIVmac 251 Env chimera in rhesus macaque Rm3) to 10% (SIVmac 239 in 
rhesus macaque Rm1) of SIVmac 239 and SIVmac 251 replication remained in Maraviroc-treated 
rmPBMCs (mean 4.4 ± 3.9% SD).  This result is especially remarkable given that Maraviroc is an 
incomplete inhibitor of rmCCR5-mediated SIV pseudotype infection in 293T cells in vitro (Chapter 
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3, Figure 3.1D); we predict that a full antagonist of rmCCR5 may further inhibit SIVmac infection 
in rmPBMCs.  The marked attenuation of SIVmac infection and replication in the presence of 
Maraviroc indicated that SIVmac 239 and SIVmac 251 Env chimera infection of non-natural host 
rmPBMCs was highly CCR5-dependent. 
 
rmPBMCs support CCR5-dependent SIV infection, whereas smPBMCs support CCR5- and 
CXCR6-mediated SIV infection 
 To further define coreceptors that support SIV infection and replication in sooty 
mangabeys and rhesus macaques, we pre-treated nonhuman primate PBMCs with CCR5 
antagonist Maraviroc and/or recombinant human chemokine CXCL16.  Chemokine CXCL16 is a 
natural ligand of CXCR6.  We previously demonstrated that CXCL16 significantly blocks the 
majority of SIVsmm infection when smCXCR6 is expressed at low levels in vitro (Chapter 3, 
Figure 3.5).  Additionally, we demonstrated that CXCL16 has no direct off-target effects on SIV 
infection mediated by smCCR5 or smGPR15 in vitro (Chapter 3, Figure 3.7).  In PBMCs, 
infections that are CCR5-dependent will be almost entirely blocked by Maraviroc (see Figure 
4.3B); infections that are CCR5- and alternative-coreceptor dependent will not be entirely blocked 
by Maraviroc and residual infection and replication will remain (see Figure 4.3A); infections that 
are highly dependent on CXCR6 may be significantly blocked by CXCL16 alone; and notably, 
infections that are significantly blocked by the combination of Maraviroc plus CXCL16 relative to 
Maraviroc alone also indicate that some SIV infection is supported by CXCR6. 
 
ConA and IL-2 stimulated rmPBMCs and smPBMCs were pre-treated with vehicle, 10µM 
Maraviroc, 500ng/mL CXCL16, or a combination of both Maraviroc and CXCL16.  Rhesus 
macaque rmPBMCs from one animal (Rm4) were infected with SIVmac 239 and SIVmac 251 Env 
chimera.  Sooty mangabey smPBMCs from five CCR5wt/wt animals (FRz, FUu, FYz, FIa1, FIz) 
were infected with SIVsmm M935, SIVsmm D215, SIVsmm E660, and SIVmac 239.  Supernatant 




As we observed previously, SIVmac 239 and SIVmac 251 Env chimera infections in rmPBMCs 
were almost completely CCR5-dependent.  Maraviroc blocked 85% to 90% of peak SIVmac P27 
Gag production in rmPBMCs from animal Rm4 (Figure 4.4, Table 4.1).  When data for Rm4 were 
combined with the above data from Rm1, Rm2, and Rm3 (Figure 4.3B), we found that SIVmac 
239 (mean 95 ± 4.2% SD) and SIVmac 251 (mean 92 ± 6.5% SD) were almost entirely blocked 
by Maraviroc in rmPBMCs (Figure 4.4A and Figure 4.4B respectively).  Chemokine CXCL16 did 
not block SIVmac 239 infection of Rm4 rmPBMCs.  Unexpectedly, chemokine CXCL16 did block 
42% of SIVmac 251 Env chimera infection of Rm4 rmPBMCs.  This could indicate that rmCXCR6 
supports some SIVmac 251 infection in rmPBMCs despite being a poor coreceptor of SIVmac 
251 Env pseudotypes in vitro.  However, the blocking of SIVmac 251 infection in Rm4 rmPBMCs 
was not enhanced by the combination of Maraviroc and CXCL16 relative to Maraviroc alone, 
indicating that rmCXCR6 did not support SIVmac 251 Env chimera infection on top of rmCCR5-
mediated infection.  Further experiments are needed to address whether or not rmCXCR6 
supports any SIV infection and replication in rmPBMCs.  However, given the ability of Maraviroc 
to block over 90% of infection in these rmPBMCs, it is apparent that rmCCR5 is the dominant 
coreceptor in rmPBMCs. 
 
As we observed previously, sooty mangabey viruses SIVsmm D215 and SIVsmm M935 were 
partially CCR5-independent in smPBMCs (Figure 4.5A and Figure 4.5B, Table 4.2).  At the peak 
of infection, Maraviroc blocked between 21% and 61% (mean 43.7 ± 14.8% SD) of peak SIVsmm 
D215 and SIVsmm M935 viral production relative to vehicle treated controls (p≤0.01 for both 
viruses).  Interestingly, pathogenic rhesus macaque virus SIVsmm E660 was also partially CCR5-
independent in smPBMCs (Figure 4.5C).  Maraviroc failed to block any SIVsmm E660 viral 
production in smPBMCs from animals FIa1 or FIz and blocked only 23% (FRz) to 32% (FYz) of 
SIVsmm E660 viral production in smPBMCs from remaining animals (Figure 4.5C, Table 4.2).  
Furthermore, SIVsmm E660 was significantly less sensitive to Maraviroc than either SIVsmm 
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D215 (p=0.046) or SIVsmm M935 (p=0.02).  This recapitulates the finding that individual SIVsmm 
E660 CP3C and SIVsmm E660 CR54 Env display significantly higher infection in transfected 
293T cells expressing smCD4 plus smCXCR6 than in transfected 293T cells expressing smCD4 
plus smCCR5 in vitro (see Figure 4.1A), as well as the finding that SIVsmm E660 primary isolate 
infects Cf2Th.Luc cells expressing smCD4 and smCXCR6 at levels significantly above infection in 
Cf2Th.Luc cells expressing smCD4 and smCCR5 (see Figure 4.2A). 
 
Crucially, we observed the first direct evidence that smCXCR6 is expressed on smPBMCs and 
can support SIV infection in smPBMCs.  Both SIVsmm D215 and SIVsmm E660 exhibited use of 
alternative coreceptor smCXCR6 in primary smPBMCs.  Chemokine CXCL16 blocked a 
significant percentage of SIVsmm D215 infection relative to vehicle-treated controls (p=0.01) and 
the combination of Maraviroc and chemokine CXCL16 significantly lowered SIVsmm D215 
infection relative to infection in smPBMCs treated with Maraviroc alone (p=0.02) (Figure 4.5A).  
Chemokine CXCL16 alone had no significant effect on SIVsmm E660 infection.  However, 
SIVsmm E660 infection was significantly attenuated by the combination of Maraviroc and 
CXCL16 relative to Maraviroc alone (p = 0.02) (Figure 4.5C).  The combination of Maraviroc and 
CXCL16 did not entirely block either SIVsmm D215 or SIVsmm E660 infection.  Therefore, we 
concluded that SIVsmm D215 and SIVsmm E660 use alternative coreceptor smCXCR6 in 
addition to smCCR5, and may exhibit infection through additional non-CCR5 alternative 
coreceptors as well. 
 
SIVsmm M935 did not exhibit clear use of smCXCR6.  Chemokine CXCL16 did not block a 
significant amount of SIVsmm M935 infection relative to vehicle-treated controls (p=0.17, NS) and 
the combination of CXCL16 and Maraviroc did not enhance blocking of SIVsmm M935 infection 
relative to Maraviroc alone (Figure 4.5B).  (This was true even when SIVsmm M935 infection of 
FIa1 smPBMCs pre-treated with both Maraviroc and CXCL16 was temporarily discarded as an 
outlier.)  Thus, it appears that not all SIV exhibit clear use of smCXCR6 in smPBMCs.  The 
139	  
	  
combination of Maraviroc and CXCL16 blocked only 32% of SIVsmm M935 infection in 
smPBMCs.  On average, there was more residual SIVsmm M935 infection than residual SIVsmm 
D215 or SIVsmm E660 in the presence of Maraviroc plus CXCL16, although the trend did not 
reach statistical significance (p≥0.19, NS relative to both SIVsmm D215 and SIVsmm E660).  It is 
possible that alternative coreceptors other than smCXCR6 support the majority of SIVsmm M935 
CCR5-independent infection in smPBMCs. 
 
To specifically investigate the host role in CCR5-dependent versus CCR5-independent SIV 
infection, we measured SIVmac 239 infection and replication in smPBMCs from two sooty 
mangabeys (FIa1, FIz) and directly compared the results to SIVmac 239 infection and replication 
in rmPBMCs.  Strikingly, Maraviroc only blocked 4% and 15% of SIVmac 239 viral production in 
FIa1 and FIz smPBMCs respectively (Figure 4.5D and Table 4.2).  By contrast, we previously 
found that Maraviroc blocks over 90% of SIVmac 239 infection in rmPBMCs (see Figure 4.4A, 
Table 4.1).  Therefore, SIVmac 239 is primarily CCR5-independent in smPBMCs whereas 
SIVmac 239 is primarily CCR5-dependent in rmPBMCs.   
 
The role of smCXCR6 in SIVmac 239 infection of smPBMCs was not clear given the small 
sample size but we saw a trend in support of smCXCR6-mediated infection in both sets of 
smPBMCs.  Chemokine CXCL16 blocked 68% of SIVmac 239 viral production in smPBMCs from 
sooty mangabey FIz.  Although neither Maraviroc nor CXCL16 alone inhibited SIVmac 239 
infection in smPBMCs from animal FIa1, the effect of Maraviroc and CXCL16 together was clearly 
additive and the combination of both drugs blocked 75% of SIVmac 239 viral production in these 
smPBMCs.  Additional experiments are needed to address the role of smCXCR6 in SIVmac 239 
infection of smPBMCs.  However, it is clear that SIVmac 239 is partially to mostly CCR5-
independent in natural host sooty mangabey smPBMCs and primarily CCR5-dependent in non-
natural host rhesus macaque rmPBMCs.  Furthermore, these findings clearly demonstrate that 




In summary, our data provided the first evidence that smCXCR6 supports partially CCR5-
independent SIV infection and replication in smPBMCs.  SIVsmm D215 and SIVsmm E660 
clearly utilized alternative coreceptor smCXCR6 for some portion of infection and replication in 
sooty mangabey PBMCs.  Other alternative coreceptors, such as smGPR15, may have also 
supported SIV infection and replication in smPBMCs.  Ultimately, the relative CCR5-dependence 
of SIV in sooty mangabey smPBMCs and rhesus macaque rmPBMCs is dictated by the host 






	    
Figure 4.1.  Species-specific coreceptor use by SIV Env pseudotypes in vitro. Target 293T 
cells were transfected with (A) sooty mangabey smCD4 and sooty mangabey 
smCCR5/CXCR6/GPR15, or with (B) rhesus macaque rmCD4 and rhesus macaque 
rmCCR5/CXCR6/GPR15.  Target cells transfected with CD4 alone (None) served as negative 
controls.  Cells were infected with luciferase-expressing Env-pseudotypes.  Natural host sooty 
mangabey SIVsmm FFv2.1 Env was cloned from an infected sooty mangabey that did not 
progress to AIDS (gray, hashed bars).  Remaining SIVmac 239, SIVmac 251, SIVsmm E660 
CP3C, and SIVsmm CR54 Env were derived from viruses that are typically used to infect and 
induce pathogenesis in rhesus macaques (blue and violet, solid bars).  Infection was measured 3 
days post-infection by luciferase expression and data were normalized to 100% entry through 






































































	    
Figure 4.2.  Rhesus macaque CXCR6 is a weak coreceptor of replication-competent 
SIVmac and SIVsmm E660 in vitro.  Target Cf2Th.Luc cells were transfected with (A) smCD4 
and smCCR5/CXCR6/GPR15, or with (B) rmCD4 with and rmCCR5/CXCR6/GPR15.  Cells 
transfected with CD4 alone served as negative controls.  Target cells were infected with viruses 
produced from infectious molecular clone SIVmac 239, and a chimeric infectious molecular clone 
of SIVmac 239 carrying SIVmac 251 Env.  Target cells were also infected with SIVsmm E660 
primary isolate.  Infection was measured 3 days post-infection via luciferase expression and data 
were normalized to 100% entry through species-matched CD4 and CCR5.  (N=3 for all viruses in 
































































Figure 4.3.  SIVmac infection and replication are highly dependent on CCR5 in rhesus 
macaque PBMCs, whereas SIVsmm infection and replication are partially CCR5-
independent in sooty mangabey PBMCs.   PBMCs from (A) two sooty mangabeys (FBa1, 
FUu) and (B) three rhesus macaques (Rm1, Rm2, Rm3) were stimulated with ConA/IL-2 and pre-
treated with vehicle (No Drug) or 10µM Maraviroc.  Sooty mangabey PBMCs were then infected 
with primary isolates SIVsmm D215 and SIVsmm M935.  Rhesus macaque PBMCs were infected 
with SIVmac 239 and a SIVmac 251 Env chimera.  Pre-wash supernatant was collected 24 hours 
post-infection (P.I.) (Day -1), cells were washed with fresh media (Day 0), and viral production 





Figure 4.4.  SIVmac infection and replication in rhesus macaque PBMCs is CCR5-
dependent.  Rhesus macaque PBMCs from four animals (Rm1, Rm2, Rm3, Rm4) were 
stimulated with ConA/IL-2 and pre-treated with vehicle (No Drug) or 10µM Maraviroc.  PBMCs 
from rhesus macaque Rm4 were also pre-treated with 500ng/mL CXCL16 or both Maraviroc and 
CXCL16.  Cells were infected with (A) SIVmac 239 or (B) SIVmac 251 Env chimera.  Culture 
supernatants were collected at multiple time points.  Data represent Day 8 peak supernatant P27 





Figure 4.5.  Alternative coreceptors, including smCXCR6, support SIV infection and 
replication in smPBMCs.  Sooty mangabey PBMCs from five animals (FRz, FUu, FYz, FIa1, 
FIz) were stimulated with ConA/IL-2 and pre-treated one hour with vehicle, 10µM Maraviroc, 
500ng/mL CXCL16, or both Maraviroc and CXCL16 as shown.  Cells were infected with sooty 
mangabey primary isolates (A) SIVsmm D215 and (B) SIVsmm M935, with primary isolate (C) 
SIVsmm E660, or with provirus (D) SIVmac 239.  Culture supernatants were collected at multiple 
time points post-infection.  Data represent Day 8 peak infection supernatant P27 Gag production 




Table 4.1.  Maraviroc and CXCL16 blocking in primary rhesus macaque PBMCs 
Virus Treatmenta Blocked (%)b Averagec 




















95 ± 4.2 
-- 
-- 
















92 ± 6.5 
-- 
-- 
a Cells were treated one hour pre-infection and continuously thereafter with 10µM Maraviroc, 
500ng/mL CXCL16, or a combination of 10µM Maraviroc and 500ng/mL CXCL16. 
 
b Percentage of entry blocked by the addition of drug/chemokine relative to controls treated with 
vehicle alone.  [100% - 100 × (P27 Gag in treated) ÷ (P27 Gag in vehicle control)].  Maraivorc-
blocking data from Figure 3 (Rm1, Rm2, Rm3) are also combined into this data set. 
 





Table 4.2.  Maraviroc and CXCL16 blocking in primary sooty mangabey PBMCs. 
Virus Treatmenta Blocked (%)b Averagec 























44 ± 15.2 
26 ± 21.0 
43 ± 35.0 



















43 ± 16.8 
57 ± 20.7 
78 ± 14.7 



















17 ± 15.7 
42 ± 39.1 
71 ± 17.3 






















a Cells were treated one hour pre-infection and continuously thereafter with10µM Maraviroc, 
500ng/mL CXCL16, or a combination of 10µM Maraviroc and 500ng/mL CXCL16. 
 
b Percentage of entry blocked by the addition of drug/chemokine relative to controls treated with 
vehicle alone.  ND represents infection not done given a limited number of cells or limited viral 
stock. [100% - 100 × (P27 Gag in treated) ÷ (P27 Gag in vehicle control)].  All negative values 
representing infections above vehicle controls were converted to zero for this table but not for in-
text statistics or graphical analyses. 
 






We determined that SIVmac infection and replication in rhesus macaque rmPBMCs is highly 
CCR5-dependent whereas SIV infection and replication in sooty mangabey smPBMCs is partially 
CCR5-independent.  Averaging all experiments, Maraviroc blocked 93.5% (± 5.2% SD) of 
SIVmac 239 and SIVmac 251 peak viral production in rhesus macaque rmPBMCs.  The CCR5-
dependence in this study is consistent with that observed previously where high concentrations of 
CCR5 antagonist TAK779 blocked SIVmac 239 and SIVmac 251 infection and replication in 
rhesus macaque PBMCs from multiple donors (39).  These data indicate that rmCCR5 is the 
primary coreceptor of these pathogenic SIVmac in these non-natural host primary cells.  By 
contrast, Maraviroc blocked only 44% (± 14.8% SD) of primary sooty mangabey SIVsmm D215 
and SIVsmm M935 viral production smPBMCs.  Therefore, coreceptors other than smCCR5 
support robust natural SIVsmm infection in these natural host primary cells. 
 
The relative CCR5-dependence of SIV infection in rhesus macaque and sooty mangabey PBMCs 
ex vivo is dictated primarily by the primate host cells and not by the virus itself.  Of note, the only 
virus-dependent factor that dictated coreceptor use in each species in vitro was the general ability 
to use CCR5/CXCR6/GPR15, and this ability was conserved between all viruses from the 
SIVsmm/SIVmac lineage we studied.  Pathogenic rhesus macaque SIV were capable of being 
highly CCR5-independent.  Maraviroc blocked only 17% (±15.7% SD) of SIVsmm E660 infection 
of smPBMCs and this inhibition did not reach statistical significance.  Furthermore, the blocking 
effect of Maraviroc against SIVsmm E660 was significantly less than that against sooty 
mangabey viruses SIVsmm D215 and SIVsmm M935.  Clearly, the SIVsmm E660 virus from 
rhesus macaques is capable of using sooty mangabey alternative coreceptors for infection and 
replication in smPBMCs.  SIVmac 239, a virus also used to induce pathogenesis in rhesus 
macaques, showed a trend toward alternative coreceptor use in smPBMCs much like SIVsmm 
E660.  Maraviroc blocked only 10% (range 4% to 15%) of SIVmac 239 infection and replication in 
smPBMCs, indicating that SIVmac 239 utilizes non-CCR5 alternative coreceptors for infection 
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and replication in smPBMCs.  The CCR5-independent SIVmac 239 infection in smPBMCs is in 
stark contrast to CCR5-dependent SIVmac 239 infection rmPBMCs where Maraviroc blocked 
92% (±6.4% standard deviation) of SIVmac 239 infection. 
 
Host-dependent coreceptor use was also apparent from SIV Env pseudotype infections of CD4- 
plus coreceptor-transfected 293T cells in vitro.  Sooty mangabey smCCR5, smCXCR6, and 
smGPR15 supported pseudotype infection mediated by SIVsmm Env and rhesus macaque 
SIVmac 239, SIVmac 251, and SIVsmm E660 Env.  SIVsmm E660 and SIVmac 251 Env actually 
exhibited significantly more infection in cells expressing alterative coreceptor smCXCR6 than in 
cells expressing smCCR5.  Rhesus macaque rmCXCR6 was a remarkably poor coreceptor of 
SIV relative to smCXCR6.  The same panel of SIV Env pseudotypes utilized rmCCR5 and 
rmGPR15, but showed little infection of cells expressing rmCXCR6.  Strikingly, SIVsmm E660 
Env that had very robust infection through smCXCR6 did not utilize rmCXCR6 at all.  For all Env 
pseudotypes, infection in cells expressing rmCD4 plus rmCXCR6 was significantly lower than 
infection in cells rmCD4 plus rmCCR5 as well as infection in cells expressing smCD4 plus 
smCXCR6.  Sooty mangabey primary PBMCs likely express robust alternative coreceptor 
smCXCR6 whereas rhesus macaque primary PBMCs likely express weak rmCXCR6, which does 
not mediate robust SIV infection.  
 
We identified sooty mangabey smCXCR6 as an alternative coreceptor of SIVsmm infection and 
replication in primary smPBMCs.  Chemokine CXCL16 significantly blocked SIVsmm D215 viral 
production in smPBMCs relative to vehicle-treated controls, indicating that smCXCR6 supports 
SIVsmm D215 infection ex vivo.  If observing SIV that use both smCCR5 and smCXCR6 
efficiently, pre-treatment with Maraviroc alone or CXCL16 alone may have little effect because 
the virus can use the alternate uninhibited coreceptor.  In such cases, the combination of 
Maraviroc and CXCL16 may be needed to generate an effect.  Accordingly, when CXCL16 was 
used in combination with Maraviroc, SIVsmm E660 viral production was significantly lower than in 
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cells treated with Maraviroc alone.  Like SIVsmm D215, SIVsmm E660 can use smCXCR6 to 
infect primary smPBMCs.  The combination of Maraviroc and CXCL16 did not fully block SIV 
infection in smPBMCs, making it impossible to rule out alternative coreceptors in addition to 
smCXCR6.  These experiments indicate that smCXCR6 supports SIVsmm D215 and SIVsmm 
E660 infection in addition to smCCR5, and perhaps in addition to other alternative coreceptors.  
No one has defined the expression of smCXCR6 in smPBMCs, so these experiments also 
secondarily confirmed, by virtue of smCXCR6-mediated infection, that smCXCR6 is expressed on 
the surface of smPBMCs. 
 
The discovery that Maraviroc blocks a portion of SIVsmm infection and replication in smPBMCs 
was somewhat surprising.  Maraviroc blocked an average of 44% (± 14.8% SD) of primary sooty 
mangabey SIVsmm D215 and SIVsmm M935 infection and replication in smPBMCs ex vivo.  
Previous experiments found that Maraviroc had no effect on SIVsmm infection and replication in 
smPBMCs (29).  While contradictory, our findings are consistent with the observed relationship 
between SIVsmm CCR5 genotype and plasma viral loads in vivo.  Sooty mangabeys with a 
CCR5wt/wt. genotype display higher viral loads (mean log10 4.83 ± 0.10 SEM) than sooty 
mangabeys with a CCR5Δ/Δ genotype that lack functional CCR5 expression (mean log10 4.65 ± 
0.10 SEM) (29).  Thus, sooty mangabeys lacking functional CCR5 have 34% lower plasma viral 
loads than animals with functional CCR5.  This number is remarkably consistent with our 
observation here: Maraviroc blocked 44% of SIVsmm infection and replication in smPBMCs.  
Therefore, it is far from inconceivable that Maraviroc blocks some SIVsmm infection ex vivo or 
that smCCR5 supports some SIVsmm infection and replication in smPBMCs.   
 
While, of the coreceptors tested, sooty mangabey smCXCR6 is the most robust alternative 
coreceptor of SIV Env pseudotypes in transfected cells in vitro (Chapter 2, Figure 4.1A, Figure 
4.2A), it may not be the only alternative coreceptor of SIV in smPBMCs.  Chemokine CXCL16 
treatment had no significant effect on sooty mangabey SIVsmm M935 infection and replication in 
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smPBMCs either by itself or in combination with Maraviroc, indicating that SIVsmm M935 may 
rely on other alternative coreceptors for CCR5-independent infection and replication.  In addition, 
neither SIVsmm D215 nor SIVsmm E660 were fully inhibited by the combination of CXCL16 and 
Maraviroc, again implying that additional alternative coreceptors could play a role in SIVsmm 
infection of smPBMCs.  We were not able to pharmacologically block smGPR15-mediated 
infection in smPBMCs; there is no known small-molecule inhibitor or chemokine ligand for 
GPR15.  Experiments directly addressing the role of smGPR15 are needed.  Sooty mangabey 
smGPR15 supports SIV Env pseudotype infection in vitro and may support some SIV replication 
in smPBMCs ex vivo.  
 
Some SIVsmm infection in the presence of CXCL16 is also likely due to incomplete inhibition of 
smCXCR6-mediated infection.  Chemokine CXCL16 is not a complete inhibitor of smCXCR6-
mediated infection and CXCL16 significantly lowers smCXCR6-mediated infection only when 
used in transfected cells expressing low levels of smCXCR6 (Chapter 3, Figure 3.5).  The level of 
CXCR6 expressed in these transfected cells may approximate the level of CXCR6 expressed in 
primary CD4+ T cells (Chapter 3, Figure 3.6), but we were not able to confirm that directly with 
smCXCR6 and sooty mangabey primary CD4+ target cells.  Despite significantly lowering 
smCXCR6-mediated SIV Env pseudotype infection in smCD4- plus smCXCR6 transfected cells 
relative to untreated controls in vitro, a significant amount of infection occurs above background 
negative controls (Chapter 3, Figure 3.5B).  A more potent small-molecule inhibitor of CXCR6-
mediated infection, sooty mangabey species-specific CXCL16, or an efficient way to knockdown 
smCXCR6 expression in PBMCs would be helpful in assigning the relative role of smCXCR6 and 
other alternative coreceptors in SIV infection of smPBMCs. 
 
The relative inability of rmCXCR6 to support SIV infection in vitro and perhaps ex vivo can likely 
be attributed to amino acid 31 in the N-terminal domain of CXCR6 (26).  Sooty mangabey 
smCXCR6 carries amino acid serine S31 whereas rhesus macaque rmCXCR6 carries arginine 
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R31.  Importantly, reversion of rmCXCR6 R31 to S31 restores the function of rmCXCR6 in vitro 
(26), indicating that this residue alone could be responsible for the poor coreceptor activity of 
rmCXCR6.  The rhesus macaque rmCXCR6 R31 is the only allele of rmCXCR6 identified to date.  
We sequenced rmCXCR6 from seven rhesus macaques, including Rm1 through Rm4 used in this 
study, and only found the R31 allele of rmCXCR6 (data not shown).  Additionally, in a survey of 
36 rhesus macaques at the Wisconsin National Primate Research Center, only the rmCXCR6 
R31 allele was identified (38).  We did not sequence smCXCR6 from all sooty mangabeys in this 
study, but to date no one has described allelic variation in smCXCR6 (6, 26).  It is not known how 
the single amino acid substitution S31R between sooty mangabeys and rhesus macaques affects 
SIV Env binding, CXCR6 signaling, or other attributes necessary for SIV entry and infection.  It is 
conceivable this S31R charge difference proximal to the first trans-membrane domain of CXCR6 
may affect folding and membrane trafficking of the receptor.  Prior studies found that transfected 
cells express AU1-tagged rmCXCR6 and human CXCR6 at similar levels, but perhaps the AU1 
tag itself could stabilize surface expression.  In humans, an E3Q substitution and charge change 
in the N-terminal domain of human CXCR6 results in intracellular accumulation of CXCR6 and 
defective trafficking due to the loss of negative charge (25).  
 
Rhesus macaque rmGPR15 supported moderate SIVmac 239 and SIVmac 251 infection in vitro, 
but did not support obvious SIVmac 239 or SIVmac 251 infection in rmPBMCs ex vivo, as CCR5 
antagonist Maraviroc blocked almost all SIVmac infection in PBMCs. Prior evidence suggests 
GPR15 may be essential to SIV replication in vitro in cells lines lacking CCR5 because SIVmac 
239 and SIVmac 251 replicate well in human CEMx174 cells that express high levels of human 
GPR15 but do not express CCR5 (3, 17).  It is not clear why SIVmac 239 and SIVmac 251 did not 
utilize rmGPR15 in Maraviroc-treated rmPBMCs, but Maraviroc alone blocked the vast majority of 
SIVmac 239 and SIVmac 251 peak infection as well as infection over a period up to 19 days in 
rmPBMCs.  SIVmac 239 and SIVmac 251 did replicate at low levels in rmPBMCs from one 
animal starting at Day 6 post-infection, perhaps indicating some adaptation to use of rmGPR15 in 
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a single set of rmPBMCs.  However, it is also possible the SIVmac adapted to use Maraviroc-
bound receptor or that Maraviroc activity decayed over time in culture.  Perhaps rmGPR15 is not 
expressed at high enough levels on peripheral CD4+ target rmPBMCs to support significant SIV 
infection and replication, but a comprehensive study of rmGPR15 expression in rmPBMCs and 
CD4+ cell subsets has not been done.  Previous experiments demonstrate that SIVmac 239 that 
can not infect cells via rmGPR15 in vitro do infect and replicate to the same degree as wild-type 
SIVmac 239 in rhesus macaques in vivo (27).  A prior study also found that SIVmac 239 does not 
infect CD4+GPR15+ human PBMCs, even in cells from a CCR5Δ/Δ donor (17).  Together with our 
findings, it appears that rmGPR15 is not a robust coreceptor of SIVmac 239 and SIVmac 251 
infection and replication in rmPBMCs. 
 
We observed variation between individual animal hosts following infection of PBMCs.  For 
example, Maraviroc had no effect on SIVsmm E660 infection in smPBMCs from FIa1 and FIz, 
whereas Maraviroc blocked 23% to 32% of SIVsmm E660 infection in smPBMCs from other sooty 
mangabeys.  In smPBMCs from FIa1, neither Maraviroc nor CXCL16 had an effect on SIVsmm 
E660 or SIVmac 239 infection, whereas both Maraviroc and CXCL16 individually blocked some 
SIVsmm M935 and SIVsmm D215 infection.  This variation could reflect differences in alternative 
coreceptor expression between sooty mangabey hosts.  The variation in Maraviroc, CXCL16, and 
combined blocking between sooty mangabeys in this study was neither consistent nor significant 
(p=NS, ANOVA).  The measure of P27 Gag production and accumulation over time may be one 
source of experimental variation.  In the future, we may repeat experiments using an assay to 
measure the role of individual coreceptors closer to the point of SIV entry, or after a single round 
of viral replication, to control for confounding data that may arise by measuring combined viral 
production and accumulation/decay in supernatant over several days.  We attempted to measure 
SIV Gag and SIV LTR strong-stop DNA in infected PBMCs using an existing qPCR protocol 




Future experiments of rmPBMCs infected with SIVsmm E660 and SIVsmm primary isolates will 
further demonstrate that SIV infection and replication in rhesus macaque rmPBMCs are highly 
CCR5-dependent, and demonstrate that SIVsmm/SIVmac alternative coreceptor use is host-
dependent, not virus-dependent.  In this experiment, rmPBMC infections were performed with 
clonal viruses whereas most smPBMC infections were performed with viral swarms.  In order to 
address this, we also plan to infect rmPBMCs with SIVmac 251 swarm, and to infect smPBMCs 
with clonal Env chimeras of SIVsmm.  Additional experiments are needed to measure SIVsmm 
infection and replication in CCR5Δ/Δ  smPBMCs treated with CXCL16 to further define the 
contributions of smCXCR6 and other alternative coreceptors in smPBMCs. 
 
In summary, we determined that SIVsmm infection is partially CCR5-independent and that 
alternative coreceptor smCXCR6 can support SIVsmm infection in smPBMCs from natural host 
sooty mangabeys.  By contrast, SIVmac infection and replication in non-natural host rmPBMCs is 
highly dependent upon coreceptor rmCCR5.  This substantiates SIVmac infection of rhesus 
macaques as a model of HIV-1 infection of humans because both infections are highly CCR5-
restricted in their cognate hosts.  However, the mechanisms underlying CCR5 restriction in 
rhesus macaques and humans are is quite different.  CCR5-restriction in rhesus macaque 
SIVmac infection is host-dependent whereas CCR5-restriction in human HIV-1 infection is virus-
dependent.  Strikingly, these two different mechanisms leading to CCR5-restricted infection lead 
to similar disease outcomes including CD4+ T cell loss and progression to AIDS in both rhesus 
macaque and human hosts.  Notably, both of these hosts express high levels of CCR5 on CD4+ T 
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Nonhuman primate models greatly enhance our understanding of HIV-1 pathogenesis.  Natural 
hosts of simian immunodeficiency virus (SIV) do not progress to AIDS following infection while 
more recent non-natural hosts of SIV do progress to AIDS.  Understanding mechanisms that 
underlie this dichotomy between infection of natural and non-natural hosts may lead to a better 
understanding of mechanisms of disease progression and AIDS in HIV-1-infected patients.  There 
are many features of natural host SIV infections that possibly underlie the lack of disease 
progression in these primates (see Chapter 1, Introduction, Table 1.1).  These features include, 
but are not limited to, intact mucosal immunity (36, 65, 75), lack of chronic immune activation (63, 
68, 84), tempered innate and adaptive immune responses in the chronic phase of infection (6, 24, 
45), maintenance of primary lymphoid architecture (68), and sparing of critical cell subsets from 
direct infection (9, 15, 72). 
 
Natural host sooty mangabeys (Cercocebus atys) and non-natural host rhesus macaques 
(Macaca mulatta) exhibit divergent responses to SIV infection.  SIVsmm-infected sooty 
mangabeys exhibit high viral loads without widespread CD4+ T cell loss or progression to AIDS.  
By contrast, SIV-infected rhesus macaques exhibit high viral loads with widespread CD4+ T cell 
loss and rapid progression to AIDS.  Strikingly, even sooty mangabeys and rhesus macaques 
concomitantly challenged with the same primary isolate of SIVsmm display these very different 
outcomes following infection (83).  These data clearly indicate that host factors, not properties of 
the virus alone, mediate discrepant outcomes in sooty mangabeys and rhesus macaques.   
 
In this thesis, I identified SIV alternative coreceptor use as a host-dependent factor that 
distinguishes natural host sooty mangabey SIV infection from non-natural host rhesus macaque 
SIV infection ex vivo.  I discovered SIV infection of sooty mangabey peripheral blood 
mononuclear cells (smPBMCs) is partially CCR5-independent.  Alternative, non-CCR5 coreceptor 
sooty mangabey CXCR6 (smCXCR6) supported robust SIV infection in transfected cells in vitro 
and also supported some SIV infection in primary PBMCs ex vivo.  Other alternative coreceptors, 
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notably smGPR15, supported moderate SIV infection in vitro and may support SIV infection in 
sooty mangabey smPBMCs ex vivo.  In stark contrast to SIV infection of sooty mangabey 
smPBMCs, I discovered that SIV infection of rhesus macaque PBMCs (rmPBMCs) was almost 
entirely CCR5-dependent.  Rhesus macaque CXCR6 (rmCXCR6) was an exceedingly weak 
coreceptor of SIV in transfected cells in vitro.  Rhesus macaque rmGPR15 supported SIV 
infection in vitro, but did not support robust SIV infection of rmPBMCs ex vivo as rmCCR5 was by 
far the dominant coreceptor in these cells. 
 
The relative CCR5-dependence of SIV infection was host-dependent.  SIV isolates from 
nonpathogenic infection of sooty mangabeys and pathogenic SIV from rhesus macaques 
exhibited similar patterns of CCR5 and alternative coreceptor use in vitro.  Additionally, a 
pathogenic rhesus macaque virus, SIVmac 239, was CCR5-dependent in rmPBMCs but largely 
CCR5-independent in smPBMCs.  Thus, SIV alternative coreceptor use in sooty mangabey 
infection is a host-determinant that distinguishes partially CCR5-independent sooty mangabey 
SIV infections from highly CCR5-dependent rhesus macaque SIV infections. 
 
Conserved patterns of coreceptor use in other hosts of SIV  
In this thesis, I examined SIV infection in a single natural host primate species and a 
single non-natural host primate species.  Defining alternative coreceptor-mediated SIV infection 
as a feature distinguishing additional natural host species from CCR5-dependent SIV infection in 
additional non-natural host species will provide further evidence of CCR5-independent coreceptor 
use as a possible determinant of CD4+ T cell homeostasis in the presence of high-level viral 
replication.  We hypothesize that alternative coreceptor-mediated SIV infection is a conserved 
feature in natural hosts whereas CCR5-restricted SIV infection is a conserved feature in non-




There is evidence of CCR5-independent and alternative coreceptor-dependent SIV infection in 
other natural hosts.  African primate red-capped mangabeys (Cercocebus torquatus) are 
presumed not to progress to AIDS following endemic SIVrcm infection (5, 33).  SIVrcm infected 
CD4+ cell lines engineered to express human CCR2 or human CXCR6 but not human CCR5 in 
vitro (5, 16).  After SIVrcm was passaged in macaque cells, SIVrcm gained the ability to infect 
CD4+ cell lines expressing human CCR4 but still lacked the ability to infect CD4+ cell lines 
expressing CCR5 (32).  Similar experiments were not performed with coreceptors of red-capped 
mangabey origin and further studies of SIVrcm infection and replication in primary cells ex vivo 
are needed.  However, these data suggest that SIVrcm infection in red-capped mangabeys may 
be entirely CCR5-independent and alternative coreceptor-dependent. 
 
SIVagm infections of African green monkeys (Chlorocebus) also exhibit evidence of CCR5-
independence and alternative coreceptor use.  African green monkeys are clearly natural hosts of 
SIVagm and infection results in high viral loads without chronic immune activation, CD4+ T cell 
loss, or progression to AIDS (44, 55, 63, 69, 70, 73).  Prior experiments found that SIVagm 
infected CD4+ transfected cell lines via alternative coreceptors CCR5, CXCR6, and GPR15 of 
human origin (35, 55, 56) and that Maraviroc blocked only a fraction of SIVagm infection in TZM-
bl cells (27, 35).  We recently observed that African green monkey sub-species sabaeus CXCR6 
(agmCXCR6) was a robust alternative coreceptor of a sabaeus SIVagm.sab Env in transfected 
293T cells (Figure 5.1, unpublished, data courtesy of K. Sheehan-Wetzel).  Alternative 
coreceptors sabGPR15 and sabGPR1 also supported moderate to low SIVagm Env-mediated 
infection in vitro.  Thus, the overall pattern of alternative coreceptor use by SIVagm appears 
similar to that of SIVsmm/SIVmac in vitro.  Additional in vitro experiments with a diverse panel of 
primary sabaeus SIVagm Env are needed; unfortunately, many available SIVagm isolates were 
passaged extensively in human cell lines and may no longer resemble coreceptor use by wild 
SIVagm viruses (1, 35, 47).  Further studies of SIVagm infection and replication in primary cells 




Human HIV-1 infection is clearly pathogenic.  In the majority of untreated cases, HIV-1 leads to 
CD4+ T cell loss and progress to AIDS marked by increased susceptibility to opportunistic 
infections.  The HIV-1 virus itself is CCR5-tropic and, like SIVsmm/SIVmac infection of rhesus 
macaques, human HIV-1 infection is highly CCR5-dependent both at the point of infection and 
throughout early stages of infection.  In a subset of cases, HIV-1 can acquire the use of CXCR4.  
However, CXCR4 use is clearly not required for pathogenesis and progression to AIDS. 
 
SIVcpz-infected chimpanzees exhibit signs of pathogenesis including loss of CD4+ T cells in the 
spleen and lymph node, as well as an increased death hazard relative to uninfected chimpanzees 
(48).  Pathogenic SIVcpz infection of chimpanzees (Pan troglodytes) may also be CCR5-
dependent.  Preliminary data suggest SIVcpz Env display robust infection through chimpanzee 
CCR5 and little to no infection through CXCR6, GPR15, or other putative coreceptors in vitro (K. 
Sheehan-Wetzel, unpublished, data not shown).  Further experiments will be needed to fully 
define SIVcpz coreceptor utilization in vitro and ex vivo.  SIVcpz is of special interest because the 
two SIV from which it arose are presumed to be non-pathogenic in their respective African hosts 
(3,	  19,	  33), whereas transmission of SIVcpz to humans led to the pathogenic HIV-1 Group M 
pandemic (80) (see Chapter 1, Introduction, Figure 1.1).  It not known if African greater spot-
nosed monkey (Cercopithecus nictitans) SIVgsn Env, the precursor to SIVcpz Env, use CCR5 or 
alternative coreceptors for infection and replication in vitro or ex vivo.  We hypothesize that 
SIVgsn infection is at least partially CCR5-independent.  Further evidence that greater spot-
nosed monkeys do not progress to AIDS as well as identification of SIVgsn alternative 
coreceptors may define a bottleneck leading to CCR5-tropism, CCR5-dependence, and 
pathogenesis during transmission of SIVgsn to chimpanzees. 
 
It is intriguing that multiple convergent mechanisms may lead to CCR5-dependence in non-
natural hosts and CCR5-independence in natural hosts of SIV and HIV-1.  Notably, the 
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mechanisms leading to highly CCR5-dependent human HIV-1 infection and highly CCR5-
dependent rhesus macaque SIV infection are very different.  Whereas host factors dictate CCR5-
dependence of multi-tropic SIV in rhesus macaques, the CCR5-tropic HIV-1 virus itself dictates 
CCR5-dependence in humans.  Similarly, divergent mechanisms may lead to CCR5-
independence in hosts that do not progress to AIDS.  SIVrcm CCR5-independence is likely 
mediated by the SIVrcm virus, which appears not use CCR5 at all, whereas SIVsmm and SIVagm 
CCR5-independence are a function of the multi-tropic SIV (26, 35, 79), the exceedingly low 
expression of CCR5 on CD4+ T cells (72, 74), and the expression of functional CXCR6 in sooty 
mangabeys and African green monkeys.  
 
Lack of CXCR6-mediated SIV infection may be a common feature in non-natural 
host primates 
The relative CCR5-dependence of SIV infection of other non-natural hosts has not been studied.  
I found that rhesus macaque rmCXCR6 was a very poor coreceptor of SIV in vitro relative to 
rmCCR5 (as had been shown previously (77)) and relative to smCXCR6.  A lack of rmCXCR6-
mediated infection in rmPBMCs could explain why SIV infection and replication are almost 
entirely rmCCR5-dependent in rmPBMCs.  The poor SIV coreceptor activity of rmCXCR6 relative 
to human CXCR6 in vitro was previously attributed to a S31R amino acid substitution in the N-
terminal domain of rmCXCR6 (Figure 5.2) (77).  Human CXCR6 and sooty mangabey CXCR6 
carry S31 and both support robust CXCR6-tropic SIV infection in vitro.  Rhesus macaque CXCR6 
carries R31 and supports negligible SIV infection in vitro (77) (Chapter 4).  Importantly, previous 
studies observed that the reversion of R31 to S31 in rhesus macaque CXCR6 restored its robust 
function as a coreceptor of SIV in vitro, indicating that this residue is solely responsible for the 
poor coreceptor activity of wild-type rmCXCR6 (77).  We can infer some attributes of 





Asian pig-tailed macaques (Macaca nemestrina) exhibit high levels of baseline immune activation 
and rapidly succumb to AIDS following infection with SIV isolated from natural hosts (4, 32, 43).  
SIVmac 239 infection of pig-tailed macaques also leads to CD4+ T cell loss and exceedingly rapid 
progression to AIDS (53).  Asian cynomolgus macaques (Macaca fascicularis) also succumb to 
AIDS following infection with viruses from the SIVsmm/SIVmac lineage (58, 89).  The role of 
CCR5 in pig-tailed macaque and cynomolgus macaque SIV infection has not been defined.  
However, like rhesus macaques, both pig-tailed macaques and cynomolgus macaques carry the 
R31 amino acid in CXCR6 and it is likely that both pig-tailed macaque CXCR6 and cynomolgus 
macaque CXCR6 are poor coreceptors of SIV from the SIVmac/SIVsmm lineage.  Further studies 
are needed to define the allelic frequency leading to the R31 CXCR6 protein, the prevalence of 
CXCR6 genotypes, and CXCR6 function in a large number of non-natural host primates that 
exhibit CD4+ T cell loss and progression to AIDS.  
 
The conserved nature of amino acid R31 between non-natural host experimental primate models 
of pathogenic infection is intriguing.  Notably, the functional S31 CXCR6 is conserved between 
natural host sooty mangabeys, natural host African green monkeys, and presumed natural host 
red-capped mangabeys.  This pattern in CXCR6 amino acid sequences provides further evidence 
that alternative coreceptor CXCR6 is an important host factor that may dictate differential 
outcomes of infection in natural and non-natural hosts. 
 
Model: Alternative coreceptor expression limited to expendable cells maintains 
SIV replication without leading to CD4+ T cell loss in natural hosts  
Importantly, not all CD4+ T cell loss in pathogenic HIV-1 and SIV infection is due to direct viral 
infection and cytotoxicity (2, 29, 37, 38, 85).  Direct infection of CD4+ T cell subsets critical to 
maintaining immune homeostasis is one likely mechanism of chronic immune activation, leading 
to bystander CD4+ T cell exhaustion and precipitous widespread CD4+ T cell loss.  In this model, 
critical CD4+ T cell subsets are defined as permissive cells that maintain healthy immune 
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homeostasis by replenishing CD4+ T cells lost to infection and chronic immune activation.  Critical 
cells can also be defined as cells that maintain healthy immune tissue architecture.  Expendable 
CD4+ T cell subsets are defined as permissive terminally differentiated cells that are frequently 
replaced by proliferation of critical CD4+ T cells.  Both the target cells spared from infection and 
those supporting replication are critical to understanding the nature of infection and pathogenesis 
(39) (Figure 5.3). 
 
Non-natural hosts of SIV and human hosts of HIV-1 express high levels of CCR5 on CD4+ T cells 
(74).  CCR5 is expressed at high levels on critical and expendable CD4+ T cell subsets in non-
natural hosts and in human hosts that progress to AIDS.  In this model, CCR5-dependent SIV 
and CCR5-dependent HIV-1 infection occurs in both critical and expendable CD4+ T cell subsets.  
Cells lost to direct infection and chronic immune activation would not be replenished due to the 
loss of critical replenishing cells.  Healthy immune architecture would be lost, precipitating chronic 
immune activation, widespread CD4+ T cell loss and disease progression.  
 
In contrast to non-natural hosts and humans, natural hosts exhibit broadly low levels of CCR5 on 
CD4+ T cells (74).  Alternative coreceptors of SIV likely mediate the bulk of viral replication in this 
environment of limited CCR5 expression.  In this model, alternative coreceptors, such as CXCR6, 
are expressed at high levels on expendable CD4+ T cell subsets while they are expressed at low 
to negligible levels on critical CD4+ T cell subsets.  SIV infection of expendable CD4+ T cell 
subsets maintains high levels of viral replication made evident by the high plasma viral loads in 
natural hosts.  In parallel, critical CD4+ T cell subsets protected from direct SIV infection replenish 
expendable CD4+ T cells lost to infection.  Thus, SIV-infected natural hosts exhibit healthy 
immune architecture and immune homeostasis without widespread loss of CD4+ T cells despite 




Many subsets of cells fit this model.  Effector CD4+ T cells and effector memory (Tem) CD4+ T 
cells are a front line of defense against HIV and SIV infection.  These cells are clearly essential to 
the immune response to SIV as some of the most successful vaccines against SIVmac 239 and 
SIVmac 251 in rhesus macaques specifically elicit potent CD4+ Tem cell responses (41, 42).  
These cells are also early targets of HIV-1 and SIV infection in both natural and non-natural 
hosts; gastrointestinal CD4+ Tem are rapidly depleted in the acute phase of infection (7).  Effector 
CD4+ T cells and CD4+ Tem cells are expendable in the sense that they are terminally 
differentiated and may be replenished by CD4+ central memory T cells (Tcm) (39, 40, 71).  CD4+ 
effector T cells and CD4+ Tem cells from humans, rhesus macaques, and sooty mangabeys are 
infected in vivo (72, 87).  Importantly, sooty mangabey CD4+ Tem cells and rhesus macaque 
CD4+ Tem cells are infected at similar levels, despite low CCR5 expression on sooty mangabey 
CD4+ Tem cells (72).  This likely indicates that high levels of SIV alternative coreceptor expression 
support high levels of SIV infection in sooty mangabey CD4+ Tem cells. 
 
Central memory CD4+ Tcm cells are antigen-experienced cells found in the blood and lymphoid 
tissues that may replenish CD4+ Tem and effector CD4+ T cells lost to infection (39, 40, 71).  
These cells are critical to immune homeostasis because they maintain effector cell functions in 
the face of rampant viral replication and cell death (66).  Preserved CD4+ Tcm cells were 
associated with survival in vaccine challenge studies in macaques (57).  Human CD4+ Tcm cells 
harbor high levels of HIV-1 (8, 18).  The rate of CD4+ Tcm decline is 20-fold greater in SIV-infected 
rhesus macaques than in SIV-infected sooty mangabeys (67) and rhesus macaque CD4+ Tcm 
harbor significantly more SIV viral DNA than sooty mangabey CD4+ Tcm in vivo (72).  Accordingly, 
rhesus macaque CD4+ Tcm cells express high levels of CCR5 whereas sooty mangabey CD4+ Tcm 
cells express exceedingly low levels of CCR5.  Given the observed protection of sooty mangabey 
CD4+ Tcm cells, we hypothesize that SIV alternative coreceptor expression is negligible in sooty 




Central memory stem CD4+ T cells (Tscm) are a more recently defined subset of long-lived cells in 
blood and secondary lymphoid tissues that are uniquely able to self-renew as well as differentiate 
into CD4+ Tcm, Tem, and other memory T cell subsets (31, 61, 62), making these cells critical to 
immune homeostasis.  HIV-1 DNA is found in CD4+ Tscm cells from infected patients both on and 
off therapy (13).  HIV-1-infected patients that maintain normal CD4+ T cell counts despite 
persistently high viremia (i.e. viremic non-progressors), exhibit low levels of CD4+ Tscm cell 
infection relative to patients that eventually progress to CD4+ T cell loss (52).  SIV-infected rhesus 
macaques display high levels of direct infection of CD4+CCR5+ Tscm cells whereas the majority of 
SIV-infected sooty mangabeys have no detectable infection in the CD4+ Tscm subset (14).  We 
hypothesize that SIV alternative coreceptor expression is negligible in sooty mangabey CD4+ Tcm 
cells.  
 
Critical T-helper 17 (Th17) CD4+ T cells maintain immune homeostasis, support gastrointestinal 
mucosa-associated lymphoid tissue (GALT), and stabilize the gastrointestinal epithelial barrier to 
microbial translocation.  Th17 cells are rapidly depleted in human HIV-1 and rhesus macaque 
SIVmac 239 infections whereas Th17 cells are not lost in sooty mangabey SIVsmm infection (9, 
15).  Human peripheral blood Th17 cells express CCR5 and CXCR6 (60).  We hypothesize that 
SIV alternative coreceptor expression on sooty mangabey Th17 cells is negligible. 
 
CD4+ T follicular helper cells (Tfh) reside in the germinal center of lymph nodes.  They provide T 
cell help for adaptive B cells responses and maintain lymph node architecture.  Lymph node 
pathology is observed in non-natural hosts but not in natural hosts of SIV (10, 20, 84).  Notably, 
germinal center Tfh cells are infected at higher frequencies in non-natural host macaques and 
humans than in sooty mangabeys (11, 64, 90).  We hypothesize that SIV alternative coreceptor 




Currently, little is known about the expression of CXCR6 or GPR15 in primary natural host CD4+ 
T cell subsets.  The limited data we have comes from prior expression studies in human cells.  
There currently is no antibody to primate CXCR6 molecules, and, therefore, we did not assay 
CXCR6 expression in sooty mangabey immune subsets.  Quantitative real-time PCR revealed 
that CXCR6 mRNA was expressed at similar levels in sooty mangabey CD4+ PBMCs and rhesus 
macaque CD4+ PBMCs.  Expression levels generally increased in CD4+ PBMCs from both 
species following stimulation with PHA and IL-2 (unpublished, data not shown) (78).  We are in 
search of an antibody to define alternative coreceptor CXCR6 expression in sooty mangabey 
CD4+ T cells relative to CCR5 expression in rhesus macaque CD4+ T cells. 
  
In humans, CXCR6 is found on CD4+ effector T cells and on subsets of CD4+ T helper cells.  
CXCR6 is generally associated with inflamed tissue sites, consistent with our hypothesis that 
sooty mangabey effector cells express high levels alternative coreceptor.  CXCR6 is generally not 
co-expressed with Tcm cell markers such as CCR7 or L-selectin in human PBMCs (34, 51, 54, 60, 
81, 86).  GPR15 is expressed in human CD4+ T cells from blood and lymphoid tissues (21, 25, 
28, 46, 59) and has been found at variable levels on peripheral human CD4+ Tcm and Tem cells 
(49, 50).  Notably, CXCR6 and GPR15 are both expressed in human intestinal tissue (21, 59), an 
important tissue effector site of viral replication in both natural and non-natural hosts. 
 
Future studies are needed to define the expression of CXCR6 and other alternative coreceptors 
on sooty mangabey CD4+ cell subsets.  These studies will ideally focus on CD4+ T cell subsets 
from tissue sites as well as peripheral blood.  Various cellular activation protocols ex vivo can 
result in unique coreceptor expression, as has been observed with CXCR6, and must be 
considered in future studies (54).  It is also important to determine if natural host CD4+ cells that 
express alternative coreceptors are infected in vivo.  Notably, a recent study discovered that even 
abortive infections of CD4+ T cells may lead to pyroptosis, a highly inflammatory form of cell 




Alternative coreceptors and acute viral reservoir formation 
 Patients on long-term antiretroviral therapy (ART) with undetectable plasma viral loads 
typically experience viral recrudescence only weeks after therapy is terminated, indicating that 
long-lasting reservoirs of HIV-1 persist in the absence of easily detectable viral replication.  
Persistent reservoirs of HIV-1 infection are formed very early in the acute phase of infection.  In 
2013, there was hope that very early ART treatment would “cure” HIV-1-infected infants; an infant 
received ART within hours of HIV-1 exposure and remained free of plasma HIV-1 over two years 
after therapy was stopped (76).  Unfortunately, this patient and other infants treated similarly have 
since experienced viral rebound following ART cessation (12, 82), indicating that persistent 
reservoirs of HIV-1 are formed very early following exposure.  Viral rebound also occurs in non-
natural host rhesus macaques receiving ART during the eclipse phase of SIV infection.  SIVmac 
251-infected rhesus macaques were treated with ART three days post-infection, before viral RNA 
or proviral DNA were detected in the blood.  Viral rebound occurred in these animals shortly after 
ART cessation, demonstrating that a persistent SIV reservoir was seeded rapidly in these non-
natural hosts (88).   
 
The field lacks full understanding of mechanisms supporting acute viral reservoir formation.  
Efforts are needed to identify specific CD4+ T cell subsets that mediate persistent reservoir 
formation.  Resting memory CD4+ T cells harbor latent virus in patients on therapy (30).  Some 
studies propose that CD4+ Tcm may represent one of the largest reservoirs of HIV-1 infected cells 
in patients treated with ART (17).  Intriguingly, in the study of SIVmac 251-infected rhesus 
macaques receiving ART three days post-infection, proviral DNA was primarily found in CD4+ Tcm 
and CD4+ T transitional memory cells in the three days before ART was initiated.  Therefore, 
infection of these specific CD4+ T cell subsets may drive persistent reservoir formation and result 




Because CD4+ Tcm from natural host sooty mangabeys are protected from direct SIV infection 
relative to CD4+ Tcm from non-natural host rhesus macaques (67, 72), future studies are 
warranted to determine if persistent viral reservoir formation is slower in natural hosts than in non-
natural host rhesus macaques and humans.  (Of note, it would be difficult to perform such an 
experiment in sooty mangabeys because regulations forbid SIV challenge studies in these 
protected animals.)  The exceedingly low CCR5 expression on sooty mangabey CD4+ Tcm is 
associated with low SIV infection in this subset (72), and, accordingly, we hypothesize that low 
alternative coreceptor expression in CD4+ Tcm of natural hosts is also generally associated with 
protection.  If persistent reservoir formation occurs slowly in natural hosts, the expression 
patterns of SIV coreceptors in natural and non-natural host CD4+ cells may help identify cell 
subsets that mediate rapid and persistent viral reservoir formation. 
 
 
In summary, I determined that non-natural host rhesus macaque SIV infection is highly CCR5-
dependent whereas natural host sooty mangabey SIV infection is partially CCR5-independent 
and can be mediated by alterative coreceptors, including sooty mangabey CXCR6.  The 
discovery that SIVmac 239 and SIVmac 251 infections in rhesus macaque PBMCs are highly 
CCR5-dependent substantiates the rhesus macaque as a model of CCR5-tropic HIV-1 infection 
in humans.  Because CCR5 expression is ubiquitously low on the surface of natural host CD4+ T 
cells, alternative coreceptors likely support SIVsmm infection and replication in vivo.  Defining the 
expression of CXCR6 and other alternative coreceptors on the surface of CD4+ T cell subsets 
from sooty mangabeys may add to our current understanding of critical and expendable CD4+ T 
cell subsets, and could possibly identify novel CD4+ T cell subsets capable of maintaining viral 
replication without leading to widespread CD4+ T cell loss in natural hosts of SIV.  Further studies 
of acute natural host SIV infection and alternative coreceptor-mediated CD4+ T cell subset 






Figure 5.1.  African green monkey alternative coreceptors support SIVagm infection in 
vitro.  African green monkey sabaeus SIVagm.sab 92018ivTF Env was cloned from an infectious 
molecular clone of SIVagm.sab 92018ivTF derived by others following passage of SIVagm.sab in 
sabeaus animals (22, 35).  Luciferase-expressing pNL-Luc-E-R+ Env pseudotypes were used to 
infect target 293T cells transfected with sabaeus agmCD4 and sabaeus putative coreceptors.  
Infection was measured three days post-infection by luciferase expression in relative light units 
(RLU).  (N=3, error bars represent standard deviation.)  Data courtesy of Katie Sheehan-Wetzel, 






































Figure 5.2. Amino acid alignment of primate CXCR6 N-terminal domains.  The amino acid 
sequences of CXCR6 N-termini from natural host African green monkey and sooty mangabey are 
aligned to those from non-natural host rhesus macaque, pig-tailed macaque, and cynomolgus 
macaque.  The arrow highlights the S31/R31 in natural hosts and non-natural hosts.  Human 
CXCR6 is included for comparison; however, note that HIV-1 does not use CXCR6 as a 
coreceptor. (*, conserved residue between all species.) 
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Figure 5.3.  Model of SIV cellular tropism and outcomes in natural and non-natural hosts.  
A hypothetical model of SIV tropism in natural (left) and non-natural (right) primate hosts and 
subsequent impacts on disease progression.  Natural host SIV infection, including SIVsmm 
infection in sooty mangabeys, occurs primarily in dispensable CD4+ cell subsets leading to 
sustained viremia without loss of immune homeostasis.  By contrast, non-natural host SIV 
infection, including SIV infection in rhesus macaques, occurs in both critical and dispensable cell 
subsets leading to sustained viremia with loss of immune homeostasis.  Tcm, T central memory 
cells; Tscm, T stem central memory cells; Th17, T-helper 17 cells; Tfh, T follicular helper cells; Tem, 
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